6	LUMIZYME.xml:S1:4:1	O
ADVERSE	LUMIZYME.xml:S1:6:7	O
REACTIONS	LUMIZYME.xml:S1:14:9	O

EXCERPT	LUMIZYME.xml:S1:28:7	O
:	LUMIZYME.xml:S1:35:1	O
The	LUMIZYME.xml:S1:43:3	O
most	LUMIZYME.xml:S1:47:4	O
frequently	LUMIZYME.xml:S1:52:10	O
reported	LUMIZYME.xml:S1:63:8	O
adverse	LUMIZYME.xml:S1:72:7	O
reactions	LUMIZYME.xml:S1:80:9	O
(	LUMIZYME.xml:S1:90:1	O
5%	LUMIZYME.xml:S1:94:2	O
)	LUMIZYME.xml:S1:96:1	O
in	LUMIZYME.xml:S1:98:2	O
clinical	LUMIZYME.xml:S1:101:8	O
trials	LUMIZYME.xml:S1:110:6	O
were	LUMIZYME.xml:S1:117:4	O
hypersensitivity	LUMIZYME.xml:S1:122:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:139:9	I-AdverseReaction
and	LUMIZYME.xml:S1:149:3	O
included	LUMIZYME.xml:S1:153:8	O
:	LUMIZYME.xml:S1:161:1	O
anaphylaxis	LUMIZYME.xml:S1:163:11	B-AdverseReaction
,	LUMIZYME.xml:S1:174:1	O
rash	LUMIZYME.xml:S1:176:4	B-AdverseReaction
,	LUMIZYME.xml:S1:180:1	O
pyrexia	LUMIZYME.xml:S1:182:7	B-AdverseReaction
,	LUMIZYME.xml:S1:189:1	O
flushing	LUMIZYME.xml:S1:191:8	B-AdverseReaction
feeling	LUMIZYME.xml:S1:200:7	B-AdverseReaction
hot	LUMIZYME.xml:S1:208:3	I-AdverseReaction
,	LUMIZYME.xml:S1:211:1	O
urticaria	LUMIZYME.xml:S1:213:9	B-AdverseReaction
,	LUMIZYME.xml:S1:222:1	O
headache	LUMIZYME.xml:S1:224:8	B-AdverseReaction
,	LUMIZYME.xml:S1:232:1	O
hyperhidrosis	LUMIZYME.xml:S1:234:13	B-AdverseReaction
,	LUMIZYME.xml:S1:247:1	O
nausea	LUMIZYME.xml:S1:249:6	B-AdverseReaction
,	LUMIZYME.xml:S1:255:1	O
cough	LUMIZYME.xml:S1:257:5	B-AdverseReaction
,	LUMIZYME.xml:S1:262:1	O
decreased	LUMIZYME.xml:S1:264:9	B-AdverseReaction
oxygen	LUMIZYME.xml:S1:274:6	I-AdverseReaction
saturation	LUMIZYME.xml:S1:281:10	I-AdverseReaction
,	LUMIZYME.xml:S1:291:1	O
tachycardia	LUMIZYME.xml:S1:293:11	B-AdverseReaction
,	LUMIZYME.xml:S1:304:1	O
tachypnea	LUMIZYME.xml:S1:306:9	B-AdverseReaction
,	LUMIZYME.xml:S1:315:1	O
chest	LUMIZYME.xml:S1:317:5	B-AdverseReaction
discomfort	LUMIZYME.xml:S1:323:10	I-AdverseReaction
,	LUMIZYME.xml:S1:333:1	O
dizziness	LUMIZYME.xml:S1:335:9	B-AdverseReaction
,	LUMIZYME.xml:S1:344:1	O
muscle	LUMIZYME.xml:S1:346:6	B-AdverseReaction
twitching	LUMIZYME.xml:S1:353:9	I-AdverseReaction
,	LUMIZYME.xml:S1:362:1	O
agitation	LUMIZYME.xml:S1:364:9	B-AdverseReaction
,	LUMIZYME.xml:S1:373:1	O
cyanosis	LUMIZYME.xml:S1:375:8	B-AdverseReaction
,	LUMIZYME.xml:S1:383:1	O
erythema	LUMIZYME.xml:S1:385:8	B-AdverseReaction
,	LUMIZYME.xml:S1:393:1	O
hypertension	LUMIZYME.xml:S1:395:12	B-AdverseReaction
increased	LUMIZYME.xml:S1:408:9	B-AdverseReaction
blood	LUMIZYME.xml:S1:418:5	I-AdverseReaction
pressure	LUMIZYME.xml:S1:424:8	I-AdverseReaction
,	LUMIZYME.xml:S1:432:1	O
pallor	LUMIZYME.xml:S1:434:6	B-AdverseReaction
,	LUMIZYME.xml:S1:440:1	O
rigors	LUMIZYME.xml:S1:442:6	B-AdverseReaction
,	LUMIZYME.xml:S1:448:1	O
tremor	LUMIZYME.xml:S1:450:6	B-AdverseReaction
,	LUMIZYME.xml:S1:456:1	O
vomiting	LUMIZYME.xml:S1:458:8	B-AdverseReaction
,	LUMIZYME.xml:S1:466:1	O
fatigue	LUMIZYME.xml:S1:468:7	B-AdverseReaction
,	LUMIZYME.xml:S1:475:1	O
and	LUMIZYME.xml:S1:477:3	O
myalgia	LUMIZYME.xml:S1:481:7	B-AdverseReaction
(	LUMIZYME.xml:S1:489:1	O
6.1	LUMIZYME.xml:S1:490:3	O
)	LUMIZYME.xml:S1:493:1	O
.	LUMIZYME.xml:S1:494:1	O

To	LUMIZYME.xml:S1:503:2	O
report	LUMIZYME.xml:S1:506:6	O
SUSPECTED	LUMIZYME.xml:S1:513:9	O
ADVERSE	LUMIZYME.xml:S1:523:7	O
REACTIONS	LUMIZYME.xml:S1:531:9	O
,	LUMIZYME.xml:S1:540:1	O
contact	LUMIZYME.xml:S1:542:7	O
Genzyme	LUMIZYME.xml:S1:550:7	O
at	LUMIZYME.xml:S1:558:2	O
1	LUMIZYME.xml:S1:561:1	O
-	LUMIZYME.xml:S1:562:1	O
800	LUMIZYME.xml:S1:563:3	O
-	LUMIZYME.xml:S1:566:1	O
745	LUMIZYME.xml:S1:567:3	O
-	LUMIZYME.xml:S1:570:1	O
4447	LUMIZYME.xml:S1:571:4	O
or	LUMIZYME.xml:S1:576:2	O
FDA	LUMIZYME.xml:S1:579:3	O
at	LUMIZYME.xml:S1:583:2	O
1	LUMIZYME.xml:S1:586:1	O
-	LUMIZYME.xml:S1:587:1	O
800	LUMIZYME.xml:S1:588:3	O
-	LUMIZYME.xml:S1:591:1	O
FDA	LUMIZYME.xml:S1:592:3	O
-	LUMIZYME.xml:S1:595:1	O
1088	LUMIZYME.xml:S1:596:4	O
or	LUMIZYME.xml:S1:601:2	O
www	LUMIZYME.xml:S1:604:3	O
.	LUMIZYME.xml:S1:607:1	O
fda	LUMIZYME.xml:S1:608:3	O
.	LUMIZYME.xml:S1:611:1	O
gov	LUMIZYME.xml:S1:612:3	O
medwatch	LUMIZYME.xml:S1:616:8	O

6.1	LUMIZYME.xml:S1:635:3	O

Clinical	LUMIZYME.xml:S1:639:8	O

Trials	LUMIZYME.xml:S1:648:6	O
Experience	LUMIZYME.xml:S1:655:10	O

Because	LUMIZYME.xml:S1:669:7	O
clinical	LUMIZYME.xml:S1:677:8	O
trials	LUMIZYME.xml:S1:686:6	O
are	LUMIZYME.xml:S1:693:3	O
conducted	LUMIZYME.xml:S1:697:9	O
under	LUMIZYME.xml:S1:707:5	O
widely	LUMIZYME.xml:S1:713:6	O
varying	LUMIZYME.xml:S1:720:7	O
conditions	LUMIZYME.xml:S1:728:10	O
,	LUMIZYME.xml:S1:738:1	O
adverse	LUMIZYME.xml:S1:740:7	O
reaction	LUMIZYME.xml:S1:748:8	O
rates	LUMIZYME.xml:S1:757:5	O
observed	LUMIZYME.xml:S1:763:8	O
in	LUMIZYME.xml:S1:772:2	O
the	LUMIZYME.xml:S1:775:3	O
clinical	LUMIZYME.xml:S1:779:8	O
trials	LUMIZYME.xml:S1:788:6	O
of	LUMIZYME.xml:S1:795:2	O
a	LUMIZYME.xml:S1:798:1	O
drug	LUMIZYME.xml:S1:800:4	O
cannot	LUMIZYME.xml:S1:805:6	O
be	LUMIZYME.xml:S1:812:2	O
directly	LUMIZYME.xml:S1:815:8	O
compared	LUMIZYME.xml:S1:824:8	O
to	LUMIZYME.xml:S1:833:2	O
rates	LUMIZYME.xml:S1:836:5	O
in	LUMIZYME.xml:S1:842:2	O
the	LUMIZYME.xml:S1:845:3	O
clinical	LUMIZYME.xml:S1:849:8	O
trials	LUMIZYME.xml:S1:858:6	O
of	LUMIZYME.xml:S1:865:2	O
another	LUMIZYME.xml:S1:868:7	O
drug	LUMIZYME.xml:S1:876:4	O
and	LUMIZYME.xml:S1:881:3	O
may	LUMIZYME.xml:S1:885:3	O
not	LUMIZYME.xml:S1:889:3	O
reflect	LUMIZYME.xml:S1:893:7	O
the	LUMIZYME.xml:S1:901:3	O
rates	LUMIZYME.xml:S1:905:5	O
observed	LUMIZYME.xml:S1:911:8	O
in	LUMIZYME.xml:S1:920:2	O
clinical	LUMIZYME.xml:S1:923:8	O
practice	LUMIZYME.xml:S1:932:8	O
.	LUMIZYME.xml:S1:940:1	O

The	LUMIZYME.xml:S1:946:3	O
following	LUMIZYME.xml:S1:950:9	O
serious	LUMIZYME.xml:S1:960:7	O
adverse	LUMIZYME.xml:S1:968:7	O
reactions	LUMIZYME.xml:S1:976:9	O
are	LUMIZYME.xml:S1:986:3	O
described	LUMIZYME.xml:S1:990:9	O
below	LUMIZYME.xml:S1:1000:5	O
and	LUMIZYME.xml:S1:1006:3	O
elsewhere	LUMIZYME.xml:S1:1010:9	O
in	LUMIZYME.xml:S1:1020:2	O
the	LUMIZYME.xml:S1:1023:3	O
labeling	LUMIZYME.xml:S1:1027:8	O
:	LUMIZYME.xml:S1:1035:1	O

Anaphylaxis	LUMIZYME.xml:S1:1044:11	O
and	LUMIZYME.xml:S1:1056:3	O
hypersensitivity	LUMIZYME.xml:S1:1060:16	O
reactions	LUMIZYME.xml:S1:1077:9	O
[	LUMIZYME.xml:S1:1087:1	O
seeWarnings	LUMIZYME.xml:S1:1088:11	O
and	LUMIZYME.xml:S1:1100:3	O
Precautions	LUMIZYME.xml:S1:1104:11	O
(	LUMIZYME.xml:S1:1116:1	O
5.1	LUMIZYME.xml:S1:1117:3	O
)]	LUMIZYME.xml:S1:1120:2	O
.	LUMIZYME.xml:S1:1123:1	O

In	LUMIZYME.xml:S1:1130:2	O
clinical	LUMIZYME.xml:S1:1133:8	O
trials	LUMIZYME.xml:S1:1142:6	O
,	LUMIZYME.xml:S1:1148:1	O
the	LUMIZYME.xml:S1:1150:3	O
most	LUMIZYME.xml:S1:1154:4	O
common	LUMIZYME.xml:S1:1159:6	O
adverse	LUMIZYME.xml:S1:1166:7	O
reactions	LUMIZYME.xml:S1:1174:9	O
(	LUMIZYME.xml:S1:1184:1	O
5%	LUMIZYME.xml:S1:1188:2	O
)	LUMIZYME.xml:S1:1190:1	O
following	LUMIZYME.xml:S1:1192:9	O
alglucosidase	LUMIZYME.xml:S1:1202:13	O
alfa	LUMIZYME.xml:S1:1216:4	O
treatment	LUMIZYME.xml:S1:1221:9	O
were	LUMIZYME.xml:S1:1231:4	O
hypersensitivity	LUMIZYME.xml:S1:1236:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:1253:9	I-AdverseReaction
,	LUMIZYME.xml:S1:1262:1	O
and	LUMIZYME.xml:S1:1264:3	O
included	LUMIZYME.xml:S1:1268:8	O
anaphylaxis	LUMIZYME.xml:S1:1277:11	B-AdverseReaction
,	LUMIZYME.xml:S1:1288:1	O
rash	LUMIZYME.xml:S1:1290:4	B-AdverseReaction
,	LUMIZYME.xml:S1:1294:1	O
pyrexia	LUMIZYME.xml:S1:1296:7	B-AdverseReaction
,	LUMIZYME.xml:S1:1303:1	O
flushing	LUMIZYME.xml:S1:1305:8	B-AdverseReaction
feeling	LUMIZYME.xml:S1:1314:7	B-AdverseReaction
hot	LUMIZYME.xml:S1:1322:3	I-AdverseReaction
,	LUMIZYME.xml:S1:1325:1	O
urticaria	LUMIZYME.xml:S1:1327:9	B-AdverseReaction
,	LUMIZYME.xml:S1:1336:1	O
headache	LUMIZYME.xml:S1:1338:8	B-AdverseReaction
,	LUMIZYME.xml:S1:1346:1	O
hyperhidrosis	LUMIZYME.xml:S1:1348:13	B-AdverseReaction
,	LUMIZYME.xml:S1:1361:1	O
nausea	LUMIZYME.xml:S1:1363:6	B-AdverseReaction
,	LUMIZYME.xml:S1:1369:1	O
cough	LUMIZYME.xml:S1:1371:5	B-AdverseReaction
,	LUMIZYME.xml:S1:1376:1	O
decreased	LUMIZYME.xml:S1:1378:9	B-AdverseReaction
oxygen	LUMIZYME.xml:S1:1388:6	I-AdverseReaction
saturation	LUMIZYME.xml:S1:1395:10	I-AdverseReaction
,	LUMIZYME.xml:S1:1405:1	O
tachycardia	LUMIZYME.xml:S1:1407:11	B-AdverseReaction
,	LUMIZYME.xml:S1:1418:1	O
tachypnea	LUMIZYME.xml:S1:1420:9	B-AdverseReaction
,	LUMIZYME.xml:S1:1429:1	O
chest	LUMIZYME.xml:S1:1431:5	B-AdverseReaction
discomfort	LUMIZYME.xml:S1:1437:10	I-AdverseReaction
,	LUMIZYME.xml:S1:1447:1	O
dizziness	LUMIZYME.xml:S1:1449:9	B-AdverseReaction
,	LUMIZYME.xml:S1:1458:1	O
muscle	LUMIZYME.xml:S1:1460:6	B-AdverseReaction
twitching	LUMIZYME.xml:S1:1467:9	I-AdverseReaction
,	LUMIZYME.xml:S1:1476:1	O
agitation	LUMIZYME.xml:S1:1478:9	B-AdverseReaction
,	LUMIZYME.xml:S1:1487:1	O
cyanosis	LUMIZYME.xml:S1:1489:8	B-AdverseReaction
,	LUMIZYME.xml:S1:1497:1	O
erythema	LUMIZYME.xml:S1:1499:8	B-AdverseReaction
,	LUMIZYME.xml:S1:1507:1	O
hypertension	LUMIZYME.xml:S1:1509:12	B-AdverseReaction
increased	LUMIZYME.xml:S1:1522:9	B-AdverseReaction
blood	LUMIZYME.xml:S1:1532:5	I-AdverseReaction
pressure	LUMIZYME.xml:S1:1538:8	I-AdverseReaction
,	LUMIZYME.xml:S1:1546:1	O
pallor	LUMIZYME.xml:S1:1548:6	B-AdverseReaction
,	LUMIZYME.xml:S1:1554:1	O
rigors	LUMIZYME.xml:S1:1556:6	B-AdverseReaction
,	LUMIZYME.xml:S1:1562:1	O
tremor	LUMIZYME.xml:S1:1564:6	B-AdverseReaction
,	LUMIZYME.xml:S1:1570:1	O
vomiting	LUMIZYME.xml:S1:1572:8	B-AdverseReaction
,	LUMIZYME.xml:S1:1580:1	O
fatigue	LUMIZYME.xml:S1:1582:7	B-AdverseReaction
,	LUMIZYME.xml:S1:1589:1	O
and	LUMIZYME.xml:S1:1591:3	O
myalgia	LUMIZYME.xml:S1:1595:7	B-AdverseReaction
.	LUMIZYME.xml:S1:1602:1	O

Clinical	LUMIZYME.xml:S1:1612:8	O

Trials	LUMIZYME.xml:S1:1621:6	O
in	LUMIZYME.xml:S1:1628:2	O
Infantile	LUMIZYME.xml:S1:1631:9	O
-	LUMIZYME.xml:S1:1640:1	O
Onset	LUMIZYME.xml:S1:1641:5	O
and	LUMIZYME.xml:S1:1647:3	O
Juvenile	LUMIZYME.xml:S1:1651:8	O
-	LUMIZYME.xml:S1:1659:1	O
Onset	LUMIZYME.xml:S1:1660:5	O
Pompe	LUMIZYME.xml:S1:1666:5	O
Disease	LUMIZYME.xml:S1:1672:7	O

Two	LUMIZYME.xml:S1:1686:3	O
multicenter	LUMIZYME.xml:S1:1690:11	O
,	LUMIZYME.xml:S1:1701:1	O
open	LUMIZYME.xml:S1:1703:4	O
-	LUMIZYME.xml:S1:1707:1	O
label	LUMIZYME.xml:S1:1708:5	O
clinical	LUMIZYME.xml:S1:1714:8	O
trials	LUMIZYME.xml:S1:1723:6	O
were	LUMIZYME.xml:S1:1730:4	O
conducted	LUMIZYME.xml:S1:1735:9	O
in	LUMIZYME.xml:S1:1745:2	O
39	LUMIZYME.xml:S1:1748:2	O
infantile	LUMIZYME.xml:S1:1751:9	O
-	LUMIZYME.xml:S1:1760:1	O
onset	LUMIZYME.xml:S1:1761:5	O
Pompe	LUMIZYME.xml:S1:1767:5	O
disease	LUMIZYME.xml:S1:1773:7	O
patients	LUMIZYME.xml:S1:1781:8	O
,	LUMIZYME.xml:S1:1789:1	O
ages	LUMIZYME.xml:S1:1791:4	O
1	LUMIZYME.xml:S1:1796:1	O
month	LUMIZYME.xml:S1:1798:5	O
to	LUMIZYME.xml:S1:1804:2	O
3.5	LUMIZYME.xml:S1:1807:3	O
years	LUMIZYME.xml:S1:1811:5	O
old	LUMIZYME.xml:S1:1817:3	O
.	LUMIZYME.xml:S1:1820:1	O

Approximately	LUMIZYME.xml:S1:1822:13	O
half	LUMIZYME.xml:S1:1836:4	O
of	LUMIZYME.xml:S1:1841:2	O
the	LUMIZYME.xml:S1:1844:3	O
patients	LUMIZYME.xml:S1:1848:8	O
(	LUMIZYME.xml:S1:1857:1	O
54%	LUMIZYME.xml:S1:1858:3	O
)	LUMIZYME.xml:S1:1861:1	O
were	LUMIZYME.xml:S1:1863:4	O
male	LUMIZYME.xml:S1:1868:4	O
.	LUMIZYME.xml:S1:1872:1	O

Patients	LUMIZYME.xml:S1:1874:8	O
were	LUMIZYME.xml:S1:1883:4	O
treated	LUMIZYME.xml:S1:1888:7	O
with	LUMIZYME.xml:S1:1896:4	O
alglucosidase	LUMIZYME.xml:S1:1901:13	O
alfa	LUMIZYME.xml:S1:1915:4	O
20	LUMIZYME.xml:S1:1920:2	O
or	LUMIZYME.xml:S1:1923:2	O
40	LUMIZYME.xml:S1:1926:2	O
mg	LUMIZYME.xml:S1:1929:2	O
kg	LUMIZYME.xml:S1:1932:2	O
every	LUMIZYME.xml:S1:1935:5	O
other	LUMIZYME.xml:S1:1941:5	O
week	LUMIZYME.xml:S1:1947:4	O
for	LUMIZYME.xml:S1:1952:3	O
periods	LUMIZYME.xml:S1:1956:7	O
ranging	LUMIZYME.xml:S1:1964:7	O
from	LUMIZYME.xml:S1:1972:4	O
1	LUMIZYME.xml:S1:1977:1	O
to	LUMIZYME.xml:S1:1979:2	O
106	LUMIZYME.xml:S1:1982:3	O
weeks	LUMIZYME.xml:S1:1986:5	O
(	LUMIZYME.xml:S1:1992:1	O
mean	LUMIZYME.xml:S1:1993:4	O
:	LUMIZYME.xml:S1:1997:1	O
61	LUMIZYME.xml:S1:1999:2	O
weeks	LUMIZYME.xml:S1:2002:5	O
)	LUMIZYME.xml:S1:2007:1	O
.	LUMIZYME.xml:S1:2008:1	O

The	LUMIZYME.xml:S1:2014:3	O
most	LUMIZYME.xml:S1:2018:4	O
serious	LUMIZYME.xml:S1:2023:7	O
adverse	LUMIZYME.xml:S1:2031:7	O
reactions	LUMIZYME.xml:S1:2039:9	O
reported	LUMIZYME.xml:S1:2049:8	O
with	LUMIZYME.xml:S1:2058:4	O
alglucosidase	LUMIZYME.xml:S1:2063:13	O
alfa	LUMIZYME.xml:S1:2077:4	O
treatment	LUMIZYME.xml:S1:2082:9	O
included	LUMIZYME.xml:S1:2092:8	O
anaphylaxis	LUMIZYME.xml:S1:2101:11	B-AdverseReaction
and	LUMIZYME.xml:S1:2113:3	O
acute	LUMIZYME.xml:S1:2117:5	B-AdverseReaction
cardiorespiratory	LUMIZYME.xml:S1:2123:17	I-AdverseReaction
failure	LUMIZYME.xml:S1:2141:7	I-AdverseReaction
.	LUMIZYME.xml:S1:2148:1	O

The	LUMIZYME.xml:S1:2154:3	O
most	LUMIZYME.xml:S1:2158:4	O
common	LUMIZYME.xml:S1:2163:6	O
adverse	LUMIZYME.xml:S1:2170:7	O
reactions	LUMIZYME.xml:S1:2178:9	O
requiring	LUMIZYME.xml:S1:2188:9	O
intervention	LUMIZYME.xml:S1:2198:12	O
in	LUMIZYME.xml:S1:2211:2	O
clinical	LUMIZYME.xml:S1:2214:8	O
trials	LUMIZYME.xml:S1:2223:6	O
were	LUMIZYME.xml:S1:2230:4	O
hypersensitivity	LUMIZYME.xml:S1:2235:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:2252:9	I-AdverseReaction
,	LUMIZYME.xml:S1:2261:1	O
occurring	LUMIZYME.xml:S1:2263:9	O
in	LUMIZYME.xml:S1:2273:2	O
20	LUMIZYME.xml:S1:2276:2	O
of	LUMIZYME.xml:S1:2279:2	O
39	LUMIZYME.xml:S1:2282:2	O
(	LUMIZYME.xml:S1:2285:1	O
51%	LUMIZYME.xml:S1:2286:3	O
)	LUMIZYME.xml:S1:2289:1	O
patients	LUMIZYME.xml:S1:2291:8	O
treated	LUMIZYME.xml:S1:2300:7	O
with	LUMIZYME.xml:S1:2308:4	O
alglucosidase	LUMIZYME.xml:S1:2313:13	O
alfa	LUMIZYME.xml:S1:2327:4	O
,	LUMIZYME.xml:S1:2331:1	O
and	LUMIZYME.xml:S1:2333:3	O
included	LUMIZYME.xml:S1:2337:8	O
rash	LUMIZYME.xml:S1:2346:4	B-AdverseReaction
,	LUMIZYME.xml:S1:2350:1	O
pyrexia	LUMIZYME.xml:S1:2352:7	B-AdverseReaction
,	LUMIZYME.xml:S1:2359:1	O
urticaria	LUMIZYME.xml:S1:2361:9	B-AdverseReaction
,	LUMIZYME.xml:S1:2370:1	O
flushing	LUMIZYME.xml:S1:2372:8	B-AdverseReaction
,	LUMIZYME.xml:S1:2380:1	O
decreased	LUMIZYME.xml:S1:2382:9	B-AdverseReaction
oxygen	LUMIZYME.xml:S1:2392:6	I-AdverseReaction
saturation	LUMIZYME.xml:S1:2399:10	I-AdverseReaction
,	LUMIZYME.xml:S1:2409:1	O
cough	LUMIZYME.xml:S1:2411:5	B-AdverseReaction
,	LUMIZYME.xml:S1:2416:1	O
tachypnea	LUMIZYME.xml:S1:2418:9	B-AdverseReaction
,	LUMIZYME.xml:S1:2427:1	O
tachycardia	LUMIZYME.xml:S1:2429:11	B-AdverseReaction
,	LUMIZYME.xml:S1:2440:1	O
hypertension	LUMIZYME.xml:S1:2442:12	B-AdverseReaction
increased	LUMIZYME.xml:S1:2455:9	B-AdverseReaction
blood	LUMIZYME.xml:S1:2465:5	I-AdverseReaction
pressure	LUMIZYME.xml:S1:2471:8	I-AdverseReaction
,	LUMIZYME.xml:S1:2479:1	O
pallor	LUMIZYME.xml:S1:2481:6	B-AdverseReaction
,	LUMIZYME.xml:S1:2487:1	O
rigors	LUMIZYME.xml:S1:2489:6	B-AdverseReaction
,	LUMIZYME.xml:S1:2495:1	O
vomiting	LUMIZYME.xml:S1:2497:8	B-AdverseReaction
,	LUMIZYME.xml:S1:2505:1	O
cyanosis	LUMIZYME.xml:S1:2507:8	B-AdverseReaction
,	LUMIZYME.xml:S1:2515:1	O
agitation	LUMIZYME.xml:S1:2517:9	B-AdverseReaction
,	LUMIZYME.xml:S1:2526:1	O
and	LUMIZYME.xml:S1:2528:3	O
tremor	LUMIZYME.xml:S1:2532:6	B-AdverseReaction
.	LUMIZYME.xml:S1:2538:1	O

These	LUMIZYME.xml:S1:2540:5	O
reactions	LUMIZYME.xml:S1:2546:9	O
were	LUMIZYME.xml:S1:2556:4	O
more	LUMIZYME.xml:S1:2561:4	O
likely	LUMIZYME.xml:S1:2566:6	O
to	LUMIZYME.xml:S1:2573:2	O
occur	LUMIZYME.xml:S1:2576:5	O
with	LUMIZYME.xml:S1:2582:4	O
higher	LUMIZYME.xml:S1:2587:6	O
infusion	LUMIZYME.xml:S1:2594:8	O
rates	LUMIZYME.xml:S1:2603:5	O
.	LUMIZYME.xml:S1:2608:1	O

Some	LUMIZYME.xml:S1:2610:4	O
patients	LUMIZYME.xml:S1:2615:8	O
who	LUMIZYME.xml:S1:2624:3	O
were	LUMIZYME.xml:S1:2628:4	O
pre	LUMIZYME.xml:S1:2633:3	O
-	LUMIZYME.xml:S1:2636:1	O
treated	LUMIZYME.xml:S1:2637:7	O
with	LUMIZYME.xml:S1:2645:4	O
antihistamines	LUMIZYME.xml:S1:2650:14	O
,	LUMIZYME.xml:S1:2664:1	O
antipyretics	LUMIZYME.xml:S1:2666:12	O
and	LUMIZYME.xml:S1:2679:3	O
or	LUMIZYME.xml:S1:2683:2	O
corticosteroids	LUMIZYME.xml:S1:2686:15	O
still	LUMIZYME.xml:S1:2702:5	O
experienced	LUMIZYME.xml:S1:2708:11	O
hypersensitivity	LUMIZYME.xml:S1:2720:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:2737:9	I-AdverseReaction
.	LUMIZYME.xml:S1:2746:1	O

Table	LUMIZYME.xml:S1:2754:5	O
2	LUMIZYME.xml:S1:2760:1	O
summarizes	LUMIZYME.xml:S1:2763:10	O
all	LUMIZYME.xml:S1:2774:3	O
adverse	LUMIZYME.xml:S1:2778:7	O
reactions	LUMIZYME.xml:S1:2786:9	O
occurring	LUMIZYME.xml:S1:2796:9	O
in	LUMIZYME.xml:S1:2806:2	O
5%	LUMIZYME.xml:S1:2812:2	O
of	LUMIZYME.xml:S1:2815:2	O
patients	LUMIZYME.xml:S1:2818:8	O
(	LUMIZYME.xml:S1:2827:1	O
2	LUMIZYME.xml:S1:2828:1	O
or	LUMIZYME.xml:S1:2830:2	O
more	LUMIZYME.xml:S1:2833:4	O
patients	LUMIZYME.xml:S1:2838:8	O
)	LUMIZYME.xml:S1:2846:1	O
treated	LUMIZYME.xml:S1:2848:7	O
with	LUMIZYME.xml:S1:2856:4	O
alglucosidase	LUMIZYME.xml:S1:2861:13	O
alfa	LUMIZYME.xml:S1:2875:4	O
in	LUMIZYME.xml:S1:2880:2	O
clinical	LUMIZYME.xml:S1:2883:8	O
trials	LUMIZYME.xml:S1:2892:6	O
described	LUMIZYME.xml:S1:2899:9	O
above	LUMIZYME.xml:S1:2909:5	O
.	LUMIZYME.xml:S1:2914:1	O

Table	LUMIZYME.xml:S1:2920:5	O
2	LUMIZYME.xml:S1:2926:1	O
:	LUMIZYME.xml:S1:2927:1	O
Adverse	LUMIZYME.xml:S1:2929:7	O
Reactions	LUMIZYME.xml:S1:2937:9	O
that	LUMIZYME.xml:S1:2947:4	O
Occurred	LUMIZYME.xml:S1:2952:8	O
in	LUMIZYME.xml:S1:2961:2	O
At	LUMIZYME.xml:S1:2964:2	O
Least	LUMIZYME.xml:S1:2967:5	O
5%	LUMIZYME.xml:S1:2973:2	O
of	LUMIZYME.xml:S1:2976:2	O
Infantile	LUMIZYME.xml:S1:2979:9	O
-	LUMIZYME.xml:S1:2988:1	O
Onset	LUMIZYME.xml:S1:2989:5	O
Patients	LUMIZYME.xml:S1:2995:8	O
Treated	LUMIZYME.xml:S1:3004:7	O
with	LUMIZYME.xml:S1:3012:4	O
Alglucosidase	LUMIZYME.xml:S1:3017:13	O
Alfa	LUMIZYME.xml:S1:3031:4	O
in	LUMIZYME.xml:S1:3036:2	O
Clinical	LUMIZYME.xml:S1:3039:8	O
Trials	LUMIZYME.xml:S1:3048:6	O

Number	LUMIZYME.xml:S1:3127:6	O
of	LUMIZYME.xml:S1:3134:2	O
Patients	LUMIZYME.xml:S1:3137:8	O
(	LUMIZYME.xml:S1:3145:1	O
N	LUMIZYME.xml:S1:3146:1	O
39	LUMIZYME.xml:S1:3148:2	O
)	LUMIZYME.xml:S1:3150:1	O
n	LUMIZYME.xml:S1:3151:1	O
(	LUMIZYME.xml:S1:3153:1	O
)	LUMIZYME.xml:S1:3155:1	O

Adverse	LUMIZYME.xml:S1:3164:7	O
Reaction	LUMIZYME.xml:S1:3172:8	O
20	LUMIZYME.xml:S1:3245:2	O
(	LUMIZYME.xml:S1:3248:1	O
51	LUMIZYME.xml:S1:3249:2	O
)	LUMIZYME.xml:S1:3251:1	O

Rash	LUMIZYME.xml:S1:3276:4	B-AdverseReaction

(	LUMIZYME.xml:S1:3281:1	O
including	LUMIZYME.xml:S1:3282:9	O
rash	LUMIZYME.xml:S1:3292:4	B-AdverseReaction
erythematous	LUMIZYME.xml:S1:3297:12	I-AdverseReaction
,	LUMIZYME.xml:S1:3309:1	O
rash	LUMIZYME.xml:S1:3311:4	B-AdverseReaction
macular	LUMIZYME.xml:S1:3316:7	I-AdverseReaction
and	LUMIZYME.xml:S1:3324:3	O
maculo	LUMIZYME.xml:S1:3328:6	I-AdverseReaction
-	LUMIZYME.xml:S1:3334:1	I-AdverseReaction
papular	LUMIZYME.xml:S1:3335:7	I-AdverseReaction
)	LUMIZYME.xml:S1:3342:1	O
7	LUMIZYME.xml:S1:3359:1	O
(	LUMIZYME.xml:S1:3361:1	O
18	LUMIZYME.xml:S1:3362:2	O
)	LUMIZYME.xml:S1:3364:1	O

Pyrexia	LUMIZYME.xml:S1:3387:7	B-AdverseReaction
6	LUMIZYME.xml:S1:3466:1	O
(	LUMIZYME.xml:S1:3468:1	O
15	LUMIZYME.xml:S1:3469:2	O
)	LUMIZYME.xml:S1:3471:1	O

Urticaria	LUMIZYME.xml:S1:3494:9	B-AdverseReaction
5	LUMIZYME.xml:S1:3573:1	O
(	LUMIZYME.xml:S1:3575:1	O
13	LUMIZYME.xml:S1:3576:2	O
)	LUMIZYME.xml:S1:3578:1	O

Flushing	LUMIZYME.xml:S1:3601:8	B-AdverseReaction
5	LUMIZYME.xml:S1:3680:1	O
(	LUMIZYME.xml:S1:3682:1	O
13	LUMIZYME.xml:S1:3683:2	O
)	LUMIZYME.xml:S1:3685:1	O

Hypertension	LUMIZYME.xml:S1:3708:12	B-AdverseReaction
Increased	LUMIZYME.xml:S1:3721:9	B-AdverseReaction
Blood	LUMIZYME.xml:S1:3731:5	I-AdverseReaction
Pressure	LUMIZYME.xml:S1:3737:8	I-AdverseReaction
4	LUMIZYME.xml:S1:3787:1	O
(	LUMIZYME.xml:S1:3789:1	O
10	LUMIZYME.xml:S1:3790:2	O
)	LUMIZYME.xml:S1:3792:1	O

Decreased	LUMIZYME.xml:S1:3815:9	B-AdverseReaction
Oxygen	LUMIZYME.xml:S1:3825:6	I-AdverseReaction
Saturation	LUMIZYME.xml:S1:3832:10	I-AdverseReaction
3	LUMIZYME.xml:S1:3895:1	O
(	LUMIZYME.xml:S1:3897:1	O
8	LUMIZYME.xml:S1:3898:1	O
)	LUMIZYME.xml:S1:3899:1	O

Cough	LUMIZYME.xml:S1:3922:5	B-AdverseReaction
3	LUMIZYME.xml:S1:4002:1	O
(	LUMIZYME.xml:S1:4004:1	O
8	LUMIZYME.xml:S1:4005:1	O
)	LUMIZYME.xml:S1:4006:1	O

Tachypnea	LUMIZYME.xml:S1:4029:9	B-AdverseReaction
3	LUMIZYME.xml:S1:4109:1	O
(	LUMIZYME.xml:S1:4111:1	O
8	LUMIZYME.xml:S1:4112:1	O
)	LUMIZYME.xml:S1:4113:1	O

Tachycardia	LUMIZYME.xml:S1:4136:11	B-AdverseReaction
3	LUMIZYME.xml:S1:4216:1	O
(	LUMIZYME.xml:S1:4218:1	O
8	LUMIZYME.xml:S1:4219:1	O
)	LUMIZYME.xml:S1:4220:1	O

Erythema	LUMIZYME.xml:S1:4243:8	B-AdverseReaction
2	LUMIZYME.xml:S1:4323:1	O
(	LUMIZYME.xml:S1:4325:1	O
5	LUMIZYME.xml:S1:4326:1	O
)	LUMIZYME.xml:S1:4327:1	O

Vomiting	LUMIZYME.xml:S1:4350:8	B-AdverseReaction
2	LUMIZYME.xml:S1:4430:1	O
(	LUMIZYME.xml:S1:4432:1	O
5	LUMIZYME.xml:S1:4433:1	O
)	LUMIZYME.xml:S1:4434:1	O

Rigors	LUMIZYME.xml:S1:4457:6	B-AdverseReaction
2	LUMIZYME.xml:S1:4537:1	O
(	LUMIZYME.xml:S1:4539:1	O
5	LUMIZYME.xml:S1:4540:1	O
)	LUMIZYME.xml:S1:4541:1	O

Pallor	LUMIZYME.xml:S1:4564:6	B-AdverseReaction
2	LUMIZYME.xml:S1:4644:1	O
(	LUMIZYME.xml:S1:4646:1	O
5	LUMIZYME.xml:S1:4647:1	O
)	LUMIZYME.xml:S1:4648:1	O

Cyanosis	LUMIZYME.xml:S1:4671:8	B-AdverseReaction
2	LUMIZYME.xml:S1:4751:1	O
(	LUMIZYME.xml:S1:4753:1	O
5	LUMIZYME.xml:S1:4754:1	O
)	LUMIZYME.xml:S1:4755:1	O

Agitation	LUMIZYME.xml:S1:4778:9	B-AdverseReaction
2	LUMIZYME.xml:S1:4858:1	O
(	LUMIZYME.xml:S1:4860:1	O
5	LUMIZYME.xml:S1:4861:1	O
)	LUMIZYME.xml:S1:4862:1	O

Tremor	LUMIZYME.xml:S1:4885:6	B-AdverseReaction
2	LUMIZYME.xml:S1:4965:1	O
(	LUMIZYME.xml:S1:4967:1	O
5	LUMIZYME.xml:S1:4968:1	O
)	LUMIZYME.xml:S1:4969:1	O

An	LUMIZYME.xml:S1:4997:2	O
open	LUMIZYME.xml:S1:5000:4	O
-	LUMIZYME.xml:S1:5004:1	O
label	LUMIZYME.xml:S1:5005:5	O
,	LUMIZYME.xml:S1:5010:1	O
single	LUMIZYME.xml:S1:5012:6	O
-	LUMIZYME.xml:S1:5018:1	O
center	LUMIZYME.xml:S1:5019:6	O
trial	LUMIZYME.xml:S1:5026:5	O
was	LUMIZYME.xml:S1:5032:3	O
conducted	LUMIZYME.xml:S1:5036:9	O
in	LUMIZYME.xml:S1:5046:2	O
18	LUMIZYME.xml:S1:5049:2	O
treatment	LUMIZYME.xml:S1:5052:9	O
-	LUMIZYME.xml:S1:5061:1	O
naive	LUMIZYME.xml:S1:5062:5	O
infantile	LUMIZYME.xml:S1:5068:9	O
-	LUMIZYME.xml:S1:5077:1	O
onset	LUMIZYME.xml:S1:5078:5	O
Pompe	LUMIZYME.xml:S1:5084:5	O
disease	LUMIZYME.xml:S1:5090:7	O
patients	LUMIZYME.xml:S1:5098:8	O
who	LUMIZYME.xml:S1:5107:3	O
were	LUMIZYME.xml:S1:5111:4	O
treated	LUMIZYME.xml:S1:5116:7	O
exclusively	LUMIZYME.xml:S1:5124:11	O
with	LUMIZYME.xml:S1:5136:4	O
alglucosidase	LUMIZYME.xml:S1:5141:13	O
alfa	LUMIZYME.xml:S1:5155:4	O
.	LUMIZYME.xml:S1:5159:1	O

Adverse	LUMIZYME.xml:S1:5161:7	O
reactions	LUMIZYME.xml:S1:5169:9	O
observed	LUMIZYME.xml:S1:5179:8	O
in	LUMIZYME.xml:S1:5188:2	O
these	LUMIZYME.xml:S1:5191:5	O
patients	LUMIZYME.xml:S1:5197:8	O
were	LUMIZYME.xml:S1:5206:4	O
similar	LUMIZYME.xml:S1:5211:7	O
to	LUMIZYME.xml:S1:5219:2	O
infantile	LUMIZYME.xml:S1:5222:9	O
-	LUMIZYME.xml:S1:5231:1	O
onset	LUMIZYME.xml:S1:5232:5	O
Pompe	LUMIZYME.xml:S1:5238:5	O
disease	LUMIZYME.xml:S1:5244:7	O
patients	LUMIZYME.xml:S1:5252:8	O
who	LUMIZYME.xml:S1:5261:3	O
received	LUMIZYME.xml:S1:5265:8	O
alglucosidase	LUMIZYME.xml:S1:5274:13	O
alfa	LUMIZYME.xml:S1:5288:4	O
in	LUMIZYME.xml:S1:5293:2	O
other	LUMIZYME.xml:S1:5296:5	O
clinical	LUMIZYME.xml:S1:5302:8	O
trials	LUMIZYME.xml:S1:5311:6	O
.	LUMIZYME.xml:S1:5317:1	O

Additional	LUMIZYME.xml:S1:5323:10	O

hypersensitivity	LUMIZYME.xml:S1:5334:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:5351:9	I-AdverseReaction
observed	LUMIZYME.xml:S1:5361:8	O
in	LUMIZYME.xml:S1:5370:2	O
infantile	LUMIZYME.xml:S1:5373:9	O
-	LUMIZYME.xml:S1:5382:1	O
onset	LUMIZYME.xml:S1:5383:5	O
Pompe	LUMIZYME.xml:S1:5389:5	O
disease	LUMIZYME.xml:S1:5395:7	O
patients	LUMIZYME.xml:S1:5403:8	O
treated	LUMIZYME.xml:S1:5412:7	O
in	LUMIZYME.xml:S1:5420:2	O
other	LUMIZYME.xml:S1:5423:5	O
clinical	LUMIZYME.xml:S1:5429:8	O
trials	LUMIZYME.xml:S1:5438:6	O
and	LUMIZYME.xml:S1:5445:3	O
expanded	LUMIZYME.xml:S1:5449:8	O
access	LUMIZYME.xml:S1:5458:6	O
programs	LUMIZYME.xml:S1:5465:8	O
with	LUMIZYME.xml:S1:5474:4	O
alglucosidase	LUMIZYME.xml:S1:5479:13	O
alfa	LUMIZYME.xml:S1:5493:4	O
included	LUMIZYME.xml:S1:5498:8	O
livedo	LUMIZYME.xml:S1:5507:6	B-AdverseReaction
reticularis	LUMIZYME.xml:S1:5514:11	I-AdverseReaction
,	LUMIZYME.xml:S1:5525:1	O
irritability	LUMIZYME.xml:S1:5527:12	B-AdverseReaction
,	LUMIZYME.xml:S1:5539:1	O
retching	LUMIZYME.xml:S1:5541:8	B-AdverseReaction
,	LUMIZYME.xml:S1:5549:1	O
increased	LUMIZYME.xml:S1:5551:9	B-AdverseReaction
lacrimation	LUMIZYME.xml:S1:5561:11	I-AdverseReaction
,	LUMIZYME.xml:S1:5572:1	O
ventricular	LUMIZYME.xml:S1:5574:11	B-AdverseReaction
extrasystoles	LUMIZYME.xml:S1:5586:13	I-AdverseReaction
,	LUMIZYME.xml:S1:5599:1	O
nodal	LUMIZYME.xml:S1:5601:5	B-AdverseReaction
rhythm	LUMIZYME.xml:S1:5607:6	I-AdverseReaction
,	LUMIZYME.xml:S1:5613:1	O
rales	LUMIZYME.xml:S1:5615:5	B-AdverseReaction
,	LUMIZYME.xml:S1:5620:1	O
respiratory	LUMIZYME.xml:S1:5622:11	B-AdverseReaction
tract	LUMIZYME.xml:S1:5634:5	I-AdverseReaction
irritation	LUMIZYME.xml:S1:5640:10	I-AdverseReaction
,	LUMIZYME.xml:S1:5650:1	O
and	LUMIZYME.xml:S1:5652:3	O
cold	LUMIZYME.xml:S1:5656:4	B-AdverseReaction
sweat	LUMIZYME.xml:S1:5661:5	I-AdverseReaction
.	LUMIZYME.xml:S1:5666:1	O

Safety	LUMIZYME.xml:S1:5672:6	O
was	LUMIZYME.xml:S1:5679:3	O
also	LUMIZYME.xml:S1:5683:4	O
evaluated	LUMIZYME.xml:S1:5688:9	O
in	LUMIZYME.xml:S1:5698:2	O
99	LUMIZYME.xml:S1:5701:2	O
patients	LUMIZYME.xml:S1:5704:8	O
(	LUMIZYME.xml:S1:5713:1	O
51	LUMIZYME.xml:S1:5714:2	O
male	LUMIZYME.xml:S1:5717:4	O
,	LUMIZYME.xml:S1:5721:1	O
48	LUMIZYME.xml:S1:5723:2	O
females	LUMIZYME.xml:S1:5726:7	O
)	LUMIZYME.xml:S1:5733:1	O
with	LUMIZYME.xml:S1:5735:4	O
Pompe	LUMIZYME.xml:S1:5740:5	O
disease	LUMIZYME.xml:S1:5746:7	O
in	LUMIZYME.xml:S1:5754:2	O
an	LUMIZYME.xml:S1:5757:2	O
ongoing	LUMIZYME.xml:S1:5760:7	O
,	LUMIZYME.xml:S1:5767:1	O
open	LUMIZYME.xml:S1:5769:4	O
-	LUMIZYME.xml:S1:5773:1	O
label	LUMIZYME.xml:S1:5774:5	O
,	LUMIZYME.xml:S1:5779:1	O
prospective	LUMIZYME.xml:S1:5781:11	O
study	LUMIZYME.xml:S1:5793:5	O
in	LUMIZYME.xml:S1:5799:2	O
patients	LUMIZYME.xml:S1:5802:8	O
12	LUMIZYME.xml:S1:5811:2	O
months	LUMIZYME.xml:S1:5814:6	O
of	LUMIZYME.xml:S1:5821:2	O
age	LUMIZYME.xml:S1:5824:3	O
and	LUMIZYME.xml:S1:5828:3	O
older	LUMIZYME.xml:S1:5832:5	O
who	LUMIZYME.xml:S1:5838:3	O
were	LUMIZYME.xml:S1:5842:4	O
previously	LUMIZYME.xml:S1:5847:10	O
treated	LUMIZYME.xml:S1:5858:7	O
with	LUMIZYME.xml:S1:5866:4	O
the	LUMIZYME.xml:S1:5871:3	O
160	LUMIZYME.xml:S1:5875:3	O
L	LUMIZYME.xml:S1:5879:1	O
scale	LUMIZYME.xml:S1:5881:5	O
of	LUMIZYME.xml:S1:5887:2	O
alglucosidase	LUMIZYME.xml:S1:5890:13	O
alfa	LUMIZYME.xml:S1:5904:4	O
and	LUMIZYME.xml:S1:5909:3	O
switched	LUMIZYME.xml:S1:5913:8	O
to	LUMIZYME.xml:S1:5922:2	O
the	LUMIZYME.xml:S1:5925:3	O
4000	LUMIZYME.xml:S1:5929:4	O
L	LUMIZYME.xml:S1:5934:1	O
scale	LUMIZYME.xml:S1:5936:5	O
of	LUMIZYME.xml:S1:5942:2	O
alglucosidase	LUMIZYME.xml:S1:5945:13	O
alfa	LUMIZYME.xml:S1:5959:4	O
.	LUMIZYME.xml:S1:5963:1	O

Patients	LUMIZYME.xml:S1:5965:8	O
were	LUMIZYME.xml:S1:5974:4	O
aged	LUMIZYME.xml:S1:5979:4	O
1	LUMIZYME.xml:S1:5984:1	O
to	LUMIZYME.xml:S1:5986:2	O
18	LUMIZYME.xml:S1:5989:2	O
years	LUMIZYME.xml:S1:5992:5	O
with	LUMIZYME.xml:S1:5998:4	O
a	LUMIZYME.xml:S1:6003:1	O
median	LUMIZYME.xml:S1:6005:6	O
duration	LUMIZYME.xml:S1:6012:8	O
of	LUMIZYME.xml:S1:6021:2	O
treatment	LUMIZYME.xml:S1:6024:9	O
of	LUMIZYME.xml:S1:6034:2	O
437	LUMIZYME.xml:S1:6037:3	O
days	LUMIZYME.xml:S1:6041:4	O
(	LUMIZYME.xml:S1:6046:1	O
range	LUMIZYME.xml:S1:6047:5	O
13	LUMIZYME.xml:S1:6053:2	O
to	LUMIZYME.xml:S1:6056:2	O
466	LUMIZYME.xml:S1:6059:3	O
days	LUMIZYME.xml:S1:6063:4	O
)	LUMIZYME.xml:S1:6067:1	O
.	LUMIZYME.xml:S1:6068:1	O

No	LUMIZYME.xml:S1:6070:2	O
new	LUMIZYME.xml:S1:6073:3	O
safety	LUMIZYME.xml:S1:6077:6	O
findings	LUMIZYME.xml:S1:6084:8	O
were	LUMIZYME.xml:S1:6093:4	O
observed	LUMIZYME.xml:S1:6098:8	O
following	LUMIZYME.xml:S1:6107:9	O
the	LUMIZYME.xml:S1:6117:3	O
switch	LUMIZYME.xml:S1:6121:6	O
to	LUMIZYME.xml:S1:6128:2	O
4000	LUMIZYME.xml:S1:6131:4	O
L	LUMIZYME.xml:S1:6136:1	O
scale	LUMIZYME.xml:S1:6138:5	O
of	LUMIZYME.xml:S1:6144:2	O
alglucosidase	LUMIZYME.xml:S1:6147:13	O
alfa	LUMIZYME.xml:S1:6161:4	O
.	LUMIZYME.xml:S1:6165:1	O

Clinical	LUMIZYME.xml:S1:6175:8	O
Trials	LUMIZYME.xml:S1:6184:6	O
in	LUMIZYME.xml:S1:6191:2	O
Late	LUMIZYME.xml:S1:6194:4	O
-	LUMIZYME.xml:S1:6198:1	O
Onset	LUMIZYME.xml:S1:6199:5	O
Pompe	LUMIZYME.xml:S1:6205:5	O
Disease	LUMIZYME.xml:S1:6211:7	O

Assessment	LUMIZYME.xml:S1:6225:10	O
of	LUMIZYME.xml:S1:6236:2	O
adverse	LUMIZYME.xml:S1:6239:7	O
reactions	LUMIZYME.xml:S1:6247:9	O
in	LUMIZYME.xml:S1:6257:2	O
patients	LUMIZYME.xml:S1:6260:8	O
with	LUMIZYME.xml:S1:6269:4	O
late	LUMIZYME.xml:S1:6274:4	O
-	LUMIZYME.xml:S1:6278:1	O
onset	LUMIZYME.xml:S1:6279:5	O
Pompe	LUMIZYME.xml:S1:6285:5	O
disease	LUMIZYME.xml:S1:6291:7	O
is	LUMIZYME.xml:S1:6299:2	O
based	LUMIZYME.xml:S1:6302:5	O
on	LUMIZYME.xml:S1:6308:2	O
the	LUMIZYME.xml:S1:6311:3	O
exposure	LUMIZYME.xml:S1:6315:8	O
of	LUMIZYME.xml:S1:6324:2	O
90	LUMIZYME.xml:S1:6327:2	O
patients	LUMIZYME.xml:S1:6330:8	O
(	LUMIZYME.xml:S1:6339:1	O
45	LUMIZYME.xml:S1:6340:2	O
male	LUMIZYME.xml:S1:6343:4	O
,	LUMIZYME.xml:S1:6347:1	O
45	LUMIZYME.xml:S1:6349:2	O
female	LUMIZYME.xml:S1:6352:6	O
)	LUMIZYME.xml:S1:6358:1	O
,	LUMIZYME.xml:S1:6359:1	O
aged	LUMIZYME.xml:S1:6361:4	O
10	LUMIZYME.xml:S1:6366:2	O
to	LUMIZYME.xml:S1:6369:2	O
70	LUMIZYME.xml:S1:6372:2	O
years	LUMIZYME.xml:S1:6375:5	O
,	LUMIZYME.xml:S1:6380:1	O
to	LUMIZYME.xml:S1:6382:2	O
20	LUMIZYME.xml:S1:6385:2	O
mg	LUMIZYME.xml:S1:6388:2	O
kg	LUMIZYME.xml:S1:6391:2	O
alglucosidase	LUMIZYME.xml:S1:6394:13	O
alfa	LUMIZYME.xml:S1:6408:4	O
or	LUMIZYME.xml:S1:6413:2	O
placebo	LUMIZYME.xml:S1:6416:7	O
in	LUMIZYME.xml:S1:6424:2	O
a	LUMIZYME.xml:S1:6427:1	O
randomized	LUMIZYME.xml:S1:6429:10	O
,	LUMIZYME.xml:S1:6439:1	O
double	LUMIZYME.xml:S1:6441:6	O
-	LUMIZYME.xml:S1:6447:1	O
blind	LUMIZYME.xml:S1:6448:5	O
,	LUMIZYME.xml:S1:6453:1	O
placebo	LUMIZYME.xml:S1:6455:7	O
-	LUMIZYME.xml:S1:6462:1	O
controlled	LUMIZYME.xml:S1:6463:10	O
trial	LUMIZYME.xml:S1:6474:5	O
.	LUMIZYME.xml:S1:6479:1	O

The	LUMIZYME.xml:S1:6481:3	O
youngest	LUMIZYME.xml:S1:6485:8	O
alglucosidase	LUMIZYME.xml:S1:6494:13	O
alfa	LUMIZYME.xml:S1:6508:4	O
-	LUMIZYME.xml:S1:6512:1	O
treated	LUMIZYME.xml:S1:6513:7	O
patient	LUMIZYME.xml:S1:6521:7	O
was	LUMIZYME.xml:S1:6529:3	O
16	LUMIZYME.xml:S1:6533:2	O
years	LUMIZYME.xml:S1:6536:5	O
of	LUMIZYME.xml:S1:6542:2	O
age	LUMIZYME.xml:S1:6545:3	O
,	LUMIZYME.xml:S1:6548:1	O
and	LUMIZYME.xml:S1:6550:3	O
the	LUMIZYME.xml:S1:6554:3	O
youngest	LUMIZYME.xml:S1:6558:8	O
placebo	LUMIZYME.xml:S1:6567:7	O
-	LUMIZYME.xml:S1:6574:1	O
treated	LUMIZYME.xml:S1:6575:7	O
patient	LUMIZYME.xml:S1:6583:7	O
was	LUMIZYME.xml:S1:6591:3	O
10	LUMIZYME.xml:S1:6595:2	O
years	LUMIZYME.xml:S1:6598:5	O
of	LUMIZYME.xml:S1:6604:2	O
age	LUMIZYME.xml:S1:6607:3	O
.	LUMIZYME.xml:S1:6610:1	O

All	LUMIZYME.xml:S1:6612:3	O
patients	LUMIZYME.xml:S1:6616:8	O
were	LUMIZYME.xml:S1:6625:4	O
naive	LUMIZYME.xml:S1:6630:5	O
to	LUMIZYME.xml:S1:6636:2	O
enzyme	LUMIZYME.xml:S1:6639:6	O
replacement	LUMIZYME.xml:S1:6646:11	O
therapy	LUMIZYME.xml:S1:6658:7	O
.	LUMIZYME.xml:S1:6665:1	O

Patients	LUMIZYME.xml:S1:6667:8	O
were	LUMIZYME.xml:S1:6676:4	O
randomized	LUMIZYME.xml:S1:6681:10	O
in	LUMIZYME.xml:S1:6692:2	O
a	LUMIZYME.xml:S1:6695:1	O
2	LUMIZYME.xml:S1:6697:1	O
:	LUMIZYME.xml:S1:6698:1	O
1	LUMIZYME.xml:S1:6699:1	O
ratio	LUMIZYME.xml:S1:6701:5	O
and	LUMIZYME.xml:S1:6707:3	O
received	LUMIZYME.xml:S1:6711:8	O
alglucosidase	LUMIZYME.xml:S1:6720:13	O
alfa	LUMIZYME.xml:S1:6734:4	O
or	LUMIZYME.xml:S1:6739:2	O
placebo	LUMIZYME.xml:S1:6742:7	O
every	LUMIZYME.xml:S1:6750:5	O
other	LUMIZYME.xml:S1:6756:5	O
week	LUMIZYME.xml:S1:6762:4	O
for	LUMIZYME.xml:S1:6767:3	O
78	LUMIZYME.xml:S1:6771:2	O
weeks	LUMIZYME.xml:S1:6774:5	O
(	LUMIZYME.xml:S1:6780:1	O
18	LUMIZYME.xml:S1:6781:2	O
months	LUMIZYME.xml:S1:6784:6	O
)	LUMIZYME.xml:S1:6790:1	O
.	LUMIZYME.xml:S1:6791:1	O

The	LUMIZYME.xml:S1:6793:3	O
study	LUMIZYME.xml:S1:6797:5	O
population	LUMIZYME.xml:S1:6803:10	O
included	LUMIZYME.xml:S1:6814:8	O
34	LUMIZYME.xml:S1:6823:2	O
males	LUMIZYME.xml:S1:6826:5	O
and	LUMIZYME.xml:S1:6832:3	O
26	LUMIZYME.xml:S1:6836:2	O
females	LUMIZYME.xml:S1:6839:7	O
(	LUMIZYME.xml:S1:6847:1	O
n	LUMIZYME.xml:S1:6848:1	O
60	LUMIZYME.xml:S1:6850:2	O
)	LUMIZYME.xml:S1:6852:1	O
in	LUMIZYME.xml:S1:6854:2	O
the	LUMIZYME.xml:S1:6857:3	O
alglucosidase	LUMIZYME.xml:S1:6861:13	O
alfa	LUMIZYME.xml:S1:6875:4	O
group	LUMIZYME.xml:S1:6880:5	O
and	LUMIZYME.xml:S1:6886:3	O
11	LUMIZYME.xml:S1:6890:2	O
males	LUMIZYME.xml:S1:6893:5	O
and	LUMIZYME.xml:S1:6899:3	O
19	LUMIZYME.xml:S1:6903:2	O
females	LUMIZYME.xml:S1:6906:7	O
(	LUMIZYME.xml:S1:6914:1	O
n	LUMIZYME.xml:S1:6915:1	O
30	LUMIZYME.xml:S1:6917:2	O
)	LUMIZYME.xml:S1:6919:1	O
in	LUMIZYME.xml:S1:6921:2	O
the	LUMIZYME.xml:S1:6924:3	O
placebo	LUMIZYME.xml:S1:6928:7	O
group	LUMIZYME.xml:S1:6936:5	O
.	LUMIZYME.xml:S1:6941:1	O

Two	LUMIZYME.xml:S1:6943:3	O
patients	LUMIZYME.xml:S1:6947:8	O
receiving	LUMIZYME.xml:S1:6956:9	O
alglucosidase	LUMIZYME.xml:S1:6966:13	O
alfa	LUMIZYME.xml:S1:6980:4	O
discontinued	LUMIZYME.xml:S1:6985:12	O
the	LUMIZYME.xml:S1:6998:3	O
trial	LUMIZYME.xml:S1:7002:5	O
due	LUMIZYME.xml:S1:7008:3	O
to	LUMIZYME.xml:S1:7012:2	O
anaphylactic	LUMIZYME.xml:S1:7015:12	B-AdverseReaction
reactions	LUMIZYME.xml:S1:7028:9	I-AdverseReaction
.	LUMIZYME.xml:S1:7037:1	O

Serious	LUMIZYME.xml:S1:7043:7	O
adverse	LUMIZYME.xml:S1:7051:7	O
reactions	LUMIZYME.xml:S1:7059:9	O
reported	LUMIZYME.xml:S1:7069:8	O
with	LUMIZYME.xml:S1:7078:4	O
alglucosidase	LUMIZYME.xml:S1:7083:13	O
alfa	LUMIZYME.xml:S1:7097:4	O
included	LUMIZYME.xml:S1:7102:8	O
anaphylaxis	LUMIZYME.xml:S1:7111:11	B-AdverseReaction
,	LUMIZYME.xml:S1:7122:1	O
which	LUMIZYME.xml:S1:7124:5	O
presented	LUMIZYME.xml:S1:7130:9	O
as	LUMIZYME.xml:S1:7140:2	O
angioedema	LUMIZYME.xml:S1:7143:10	B-AdverseReaction
,	LUMIZYME.xml:S1:7153:1	O
throat	LUMIZYME.xml:S1:7155:6	B-AdverseReaction
tightness	LUMIZYME.xml:S1:7162:9	I-AdverseReaction
and	LUMIZYME.xml:S1:7172:3	O
chest	LUMIZYME.xml:S1:7176:5	B-AdverseReaction
pain	LUMIZYME.xml:S1:7182:4	I-AdverseReaction
discomfort	LUMIZYME.xml:S1:7187:10	I-AdverseReaction
.	LUMIZYME.xml:S1:7197:1	O

One	LUMIZYME.xml:S1:7199:3	O
patient	LUMIZYME.xml:S1:7203:7	O
with	LUMIZYME.xml:S1:7211:4	O
a	LUMIZYME.xml:S1:7216:1	O
history	LUMIZYME.xml:S1:7218:7	O
of	LUMIZYME.xml:S1:7226:2	O
Wolff	LUMIZYME.xml:S1:7229:5	O
-	LUMIZYME.xml:S1:7234:1	O
Parkinson	LUMIZYME.xml:S1:7235:9	O
-	LUMIZYME.xml:S1:7244:1	O
White	LUMIZYME.xml:S1:7245:5	O
syndrome	LUMIZYME.xml:S1:7251:8	O
experienced	LUMIZYME.xml:S1:7260:11	O
a	LUMIZYME.xml:S1:7272:1	O
serious	LUMIZYME.xml:S1:7274:7	O
adverse	LUMIZYME.xml:S1:7282:7	O
reaction	LUMIZYME.xml:S1:7290:8	O
of	LUMIZYME.xml:S1:7299:2	O
supraventricular	LUMIZYME.xml:S1:7302:16	B-AdverseReaction
tachycardia	LUMIZYME.xml:S1:7319:11	I-AdverseReaction
.	LUMIZYME.xml:S1:7330:1	O

The	LUMIZYME.xml:S1:7336:3	O
most	LUMIZYME.xml:S1:7340:4	O
common	LUMIZYME.xml:S1:7345:6	O
adverse	LUMIZYME.xml:S1:7352:7	O
reactions	LUMIZYME.xml:S1:7360:9	O
(	LUMIZYME.xml:S1:7370:1	O
3%	LUMIZYME.xml:S1:7374:2	O
;	LUMIZYME.xml:S1:7376:1	O
2	LUMIZYME.xml:S1:7378:1	O
or	LUMIZYME.xml:S1:7380:2	O
more	LUMIZYME.xml:S1:7383:4	O
patients	LUMIZYME.xml:S1:7388:8	O
)	LUMIZYME.xml:S1:7396:1	O
observed	LUMIZYME.xml:S1:7398:8	O
in	LUMIZYME.xml:S1:7407:2	O
alglucosidase	LUMIZYME.xml:S1:7410:13	O
alfa	LUMIZYME.xml:S1:7424:4	O
-	LUMIZYME.xml:S1:7428:1	O
treated	LUMIZYME.xml:S1:7429:7	O
patients	LUMIZYME.xml:S1:7437:8	O
were	LUMIZYME.xml:S1:7446:4	O
hypersensitivity	LUMIZYME.xml:S1:7451:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:7468:9	I-AdverseReaction
and	LUMIZYME.xml:S1:7478:3	O
included	LUMIZYME.xml:S1:7482:8	O
anaphylaxis	LUMIZYME.xml:S1:7491:11	B-AdverseReaction
,	LUMIZYME.xml:S1:7502:1	O
headache	LUMIZYME.xml:S1:7504:8	B-AdverseReaction
,	LUMIZYME.xml:S1:7512:1	O
nausea	LUMIZYME.xml:S1:7514:6	B-AdverseReaction
,	LUMIZYME.xml:S1:7520:1	O
urticaria	LUMIZYME.xml:S1:7522:9	B-AdverseReaction
,	LUMIZYME.xml:S1:7531:1	O
dizziness	LUMIZYME.xml:S1:7533:9	B-AdverseReaction
,	LUMIZYME.xml:S1:7542:1	O
chest	LUMIZYME.xml:S1:7544:5	B-AdverseReaction
discomfort	LUMIZYME.xml:S1:7550:10	I-AdverseReaction
,	LUMIZYME.xml:S1:7560:1	O
vomiting	LUMIZYME.xml:S1:7562:8	B-AdverseReaction
,	LUMIZYME.xml:S1:7570:1	O
hyperhidrosis	LUMIZYME.xml:S1:7572:13	B-AdverseReaction
,	LUMIZYME.xml:S1:7585:1	O
flushing	LUMIZYME.xml:S1:7587:8	B-AdverseReaction
feeling	LUMIZYME.xml:S1:7596:7	B-AdverseReaction
hot	LUMIZYME.xml:S1:7604:3	I-AdverseReaction
,	LUMIZYME.xml:S1:7607:1	O
increased	LUMIZYME.xml:S1:7609:9	B-AdverseReaction
blood	LUMIZYME.xml:S1:7619:5	I-AdverseReaction
pressure	LUMIZYME.xml:S1:7625:8	I-AdverseReaction
,	LUMIZYME.xml:S1:7633:1	O
paresthesia	LUMIZYME.xml:S1:7635:11	B-AdverseReaction
,	LUMIZYME.xml:S1:7646:1	O
pyrexia	LUMIZYME.xml:S1:7648:7	B-AdverseReaction
,	LUMIZYME.xml:S1:7655:1	O
local	LUMIZYME.xml:S1:7657:5	B-AdverseReaction
swelling	LUMIZYME.xml:S1:7663:8	I-AdverseReaction
,	LUMIZYME.xml:S1:7671:1	O
diarrhea	LUMIZYME.xml:S1:7673:8	B-AdverseReaction
,	LUMIZYME.xml:S1:7681:1	O
pruritus	LUMIZYME.xml:S1:7683:8	B-AdverseReaction
,	LUMIZYME.xml:S1:7691:1	O
rash	LUMIZYME.xml:S1:7693:4	B-AdverseReaction
,	LUMIZYME.xml:S1:7697:1	O
and	LUMIZYME.xml:S1:7699:3	O
throat	LUMIZYME.xml:S1:7703:6	B-AdverseReaction
tightness	LUMIZYME.xml:S1:7710:9	I-AdverseReaction
.	LUMIZYME.xml:S1:7719:1	O

Delayed	LUMIZYME.xml:S1:7725:7	O
-	LUMIZYME.xml:S1:7732:1	O
onset	LUMIZYME.xml:S1:7733:5	O
reactions	LUMIZYME.xml:S1:7739:9	O
,	LUMIZYME.xml:S1:7748:1	O
defined	LUMIZYME.xml:S1:7750:7	O
as	LUMIZYME.xml:S1:7758:2	O
adverse	LUMIZYME.xml:S1:7761:7	O
reactions	LUMIZYME.xml:S1:7769:9	O
occurring	LUMIZYME.xml:S1:7779:9	O
2	LUMIZYME.xml:S1:7789:1	O
-	LUMIZYME.xml:S1:7791:1	O
48	LUMIZYME.xml:S1:7793:2	O
hours	LUMIZYME.xml:S1:7796:5	O
after	LUMIZYME.xml:S1:7802:5	O
completion	LUMIZYME.xml:S1:7808:10	O
of	LUMIZYME.xml:S1:7819:2	O
alglucosidase	LUMIZYME.xml:S1:7822:13	O
alfa	LUMIZYME.xml:S1:7836:4	O
infusion	LUMIZYME.xml:S1:7841:8	O
,	LUMIZYME.xml:S1:7849:1	O
that	LUMIZYME.xml:S1:7851:4	O
were	LUMIZYME.xml:S1:7856:4	O
observed	LUMIZYME.xml:S1:7861:8	O
in	LUMIZYME.xml:S1:7870:2	O
3%	LUMIZYME.xml:S1:7876:2	O
more	LUMIZYME.xml:S1:7879:4	O
patients	LUMIZYME.xml:S1:7884:8	O
in	LUMIZYME.xml:S1:7893:2	O
the	LUMIZYME.xml:S1:7896:3	O
alglucosidase	LUMIZYME.xml:S1:7900:13	O
alfa	LUMIZYME.xml:S1:7914:4	O
-	LUMIZYME.xml:S1:7918:1	O
treated	LUMIZYME.xml:S1:7919:7	O
group	LUMIZYME.xml:S1:7927:5	O
compared	LUMIZYME.xml:S1:7933:8	O
to	LUMIZYME.xml:S1:7942:2	O
patients	LUMIZYME.xml:S1:7945:8	O
in	LUMIZYME.xml:S1:7954:2	O
the	LUMIZYME.xml:S1:7957:3	O
placebo	LUMIZYME.xml:S1:7961:7	O
-	LUMIZYME.xml:S1:7968:1	O
treated	LUMIZYME.xml:S1:7969:7	O
group	LUMIZYME.xml:S1:7977:5	O
in	LUMIZYME.xml:S1:7983:2	O
the	LUMIZYME.xml:S1:7986:3	O
controlled	LUMIZYME.xml:S1:7990:10	O
trial	LUMIZYME.xml:S1:8001:5	O
,	LUMIZYME.xml:S1:8006:1	O
included	LUMIZYME.xml:S1:8008:8	O
hyperhidrosis	LUMIZYME.xml:S1:8017:13	B-AdverseReaction
.	LUMIZYME.xml:S1:8030:1	O

Additional	LUMIZYME.xml:S1:8032:10	O
delayed	LUMIZYME.xml:S1:8043:7	O
-	LUMIZYME.xml:S1:8050:1	O
onset	LUMIZYME.xml:S1:8051:5	O
reactions	LUMIZYME.xml:S1:8057:9	O
occurring	LUMIZYME.xml:S1:8067:9	O
in	LUMIZYME.xml:S1:8077:2	O
alglucosidase	LUMIZYME.xml:S1:8080:13	O
alfa	LUMIZYME.xml:S1:8094:4	O
-	LUMIZYME.xml:S1:8098:1	O
treated	LUMIZYME.xml:S1:8099:7	O
patients	LUMIZYME.xml:S1:8107:8	O
included	LUMIZYME.xml:S1:8116:8	O
fatigue	LUMIZYME.xml:S1:8125:7	B-AdverseReaction
,	LUMIZYME.xml:S1:8132:1	O
myalgia	LUMIZYME.xml:S1:8134:7	B-AdverseReaction
,	LUMIZYME.xml:S1:8141:1	O
and	LUMIZYME.xml:S1:8143:3	O
nausea	LUMIZYME.xml:S1:8147:6	B-AdverseReaction
.	LUMIZYME.xml:S1:8153:1	O

Patients	LUMIZYME.xml:S1:8155:8	O
should	LUMIZYME.xml:S1:8164:6	O
be	LUMIZYME.xml:S1:8171:2	O
counseled	LUMIZYME.xml:S1:8174:9	O
about	LUMIZYME.xml:S1:8184:5	O
the	LUMIZYME.xml:S1:8190:3	O
possibility	LUMIZYME.xml:S1:8194:11	O
of	LUMIZYME.xml:S1:8206:2	O
delayed	LUMIZYME.xml:S1:8209:7	O
-	LUMIZYME.xml:S1:8216:1	O
onset	LUMIZYME.xml:S1:8217:5	O
hypersensitivity	LUMIZYME.xml:S1:8223:16	O
reactions	LUMIZYME.xml:S1:8240:9	O
and	LUMIZYME.xml:S1:8250:3	O
given	LUMIZYME.xml:S1:8254:5	O
proper	LUMIZYME.xml:S1:8260:6	O
follow	LUMIZYME.xml:S1:8267:6	O
-	LUMIZYME.xml:S1:8273:1	O
up	LUMIZYME.xml:S1:8274:2	O
instructions	LUMIZYME.xml:S1:8277:12	O
.	LUMIZYME.xml:S1:8289:1	O

Table	LUMIZYME.xml:S1:8297:5	O
3	LUMIZYME.xml:S1:8303:1	O
summarizes	LUMIZYME.xml:S1:8306:10	O
the	LUMIZYME.xml:S1:8317:3	O
most	LUMIZYME.xml:S1:8321:4	O
common	LUMIZYME.xml:S1:8326:6	O
adverse	LUMIZYME.xml:S1:8333:7	O
reactions	LUMIZYME.xml:S1:8341:9	O
that	LUMIZYME.xml:S1:8351:4	O
occurred	LUMIZYME.xml:S1:8356:8	O
in	LUMIZYME.xml:S1:8365:2	O
at	LUMIZYME.xml:S1:8368:2	O
least	LUMIZYME.xml:S1:8371:5	O
3%	LUMIZYME.xml:S1:8377:2	O
of	LUMIZYME.xml:S1:8380:2	O
alglucosidase	LUMIZYME.xml:S1:8383:13	O
alfa	LUMIZYME.xml:S1:8397:4	O
-	LUMIZYME.xml:S1:8401:1	O
treated	LUMIZYME.xml:S1:8402:7	O
patients	LUMIZYME.xml:S1:8410:8	O
and	LUMIZYME.xml:S1:8419:3	O
with	LUMIZYME.xml:S1:8423:4	O
a	LUMIZYME.xml:S1:8428:1	O
higher	LUMIZYME.xml:S1:8430:6	O
incidence	LUMIZYME.xml:S1:8437:9	O
than	LUMIZYME.xml:S1:8447:4	O
the	LUMIZYME.xml:S1:8452:3	O
placebo	LUMIZYME.xml:S1:8456:7	O
-	LUMIZYME.xml:S1:8463:1	O
treated	LUMIZYME.xml:S1:8464:7	O
patients	LUMIZYME.xml:S1:8472:8	O
during	LUMIZYME.xml:S1:8481:6	O
the	LUMIZYME.xml:S1:8488:3	O
randomized	LUMIZYME.xml:S1:8492:10	O
,	LUMIZYME.xml:S1:8502:1	O
double	LUMIZYME.xml:S1:8504:6	O
-	LUMIZYME.xml:S1:8510:1	O
blind	LUMIZYME.xml:S1:8511:5	O
,	LUMIZYME.xml:S1:8516:1	O
placebo	LUMIZYME.xml:S1:8518:7	O
-	LUMIZYME.xml:S1:8525:1	O
controlled	LUMIZYME.xml:S1:8526:10	O
study	LUMIZYME.xml:S1:8537:5	O
described	LUMIZYME.xml:S1:8543:9	O
above	LUMIZYME.xml:S1:8553:5	O
.	LUMIZYME.xml:S1:8558:1	O

Table	LUMIZYME.xml:S1:8564:5	O
3	LUMIZYME.xml:S1:8570:1	O
:	LUMIZYME.xml:S1:8571:1	O
Adverse	LUMIZYME.xml:S1:8573:7	O
Reactions	LUMIZYME.xml:S1:8581:9	O
Occurring	LUMIZYME.xml:S1:8591:9	O
in	LUMIZYME.xml:S1:8601:2	O
at	LUMIZYME.xml:S1:8604:2	O
Least	LUMIZYME.xml:S1:8607:5	O
3%	LUMIZYME.xml:S1:8613:2	O
of	LUMIZYME.xml:S1:8616:2	O
Alglucosidase	LUMIZYME.xml:S1:8619:13	O
Alfa	LUMIZYME.xml:S1:8633:4	O
-	LUMIZYME.xml:S1:8637:1	O
Treated	LUMIZYME.xml:S1:8638:7	O
Late	LUMIZYME.xml:S1:8646:4	O
-	LUMIZYME.xml:S1:8650:1	O
Onset	LUMIZYME.xml:S1:8651:5	O
Patients	LUMIZYME.xml:S1:8657:8	O
and	LUMIZYME.xml:S1:8666:3	O
with	LUMIZYME.xml:S1:8670:4	O
a	LUMIZYME.xml:S1:8675:1	O
Higher	LUMIZYME.xml:S1:8677:6	O
Incidence	LUMIZYME.xml:S1:8684:9	O
than	LUMIZYME.xml:S1:8694:4	O
the	LUMIZYME.xml:S1:8699:3	O
Placebo	LUMIZYME.xml:S1:8703:7	O
-	LUMIZYME.xml:S1:8710:1	O
Treated	LUMIZYME.xml:S1:8711:7	O
Patients	LUMIZYME.xml:S1:8719:8	O

Adverse	LUMIZYME.xml:S1:8730:7	O
Reaction	LUMIZYME.xml:S1:8738:8	O
Alglucosidase	LUMIZYME.xml:S1:8767:13	O
Alfan	LUMIZYME.xml:S1:8781:5	O
60	LUMIZYME.xml:S1:8787:2	O
N	LUMIZYME.xml:S1:8789:1	O
(	LUMIZYME.xml:S1:8791:1	O
)	LUMIZYME.xml:S1:8793:1	O
Placebon	LUMIZYME.xml:S1:8804:8	O
30	LUMIZYME.xml:S1:8813:2	O
N	LUMIZYME.xml:S1:8815:1	O
(	LUMIZYME.xml:S1:8817:1	O
)	LUMIZYME.xml:S1:8819:1	O

Hyperhidrosis	LUMIZYME.xml:S1:8842:13	B-AdverseReaction

5	LUMIZYME.xml:S1:8879:1	O
(	LUMIZYME.xml:S1:8881:1	O
8.3	LUMIZYME.xml:S1:8882:3	O
)	LUMIZYME.xml:S1:8885:1	O
0	LUMIZYME.xml:S1:8916:1	O
(	LUMIZYME.xml:S1:8918:1	O
0	LUMIZYME.xml:S1:8919:1	O
)	LUMIZYME.xml:S1:8920:1	O

Urticaria	LUMIZYME.xml:S1:8951:9	B-AdverseReaction
5	LUMIZYME.xml:S1:8988:1	O
(	LUMIZYME.xml:S1:8990:1	O
8.3	LUMIZYME.xml:S1:8991:3	O
)	LUMIZYME.xml:S1:8994:1	O
0	LUMIZYME.xml:S1:9025:1	O
(	LUMIZYME.xml:S1:9027:1	O
0	LUMIZYME.xml:S1:9028:1	O
)	LUMIZYME.xml:S1:9029:1	O

Anaphylaxis	LUMIZYME.xml:S1:9060:11	B-AdverseReaction
4	LUMIZYME.xml:S1:9097:1	O
(	LUMIZYME.xml:S1:9099:1	O
6.7	LUMIZYME.xml:S1:9100:3	O
)	LUMIZYME.xml:S1:9103:1	O
0	LUMIZYME.xml:S1:9134:1	O
(	LUMIZYME.xml:S1:9136:1	O
0	LUMIZYME.xml:S1:9137:1	O
)	LUMIZYME.xml:S1:9138:1	O

Chest	LUMIZYME.xml:S1:9169:5	B-AdverseReaction
Discomfort	LUMIZYME.xml:S1:9175:10	I-AdverseReaction
4	LUMIZYME.xml:S1:9206:1	O
(	LUMIZYME.xml:S1:9208:1	O
6.7	LUMIZYME.xml:S1:9209:3	O
)	LUMIZYME.xml:S1:9212:1	O
1	LUMIZYME.xml:S1:9243:1	O
(	LUMIZYME.xml:S1:9245:1	O
3.3	LUMIZYME.xml:S1:9246:3	O
)	LUMIZYME.xml:S1:9249:1	O

Muscle	LUMIZYME.xml:S1:9278:6	B-AdverseReaction
Twitching	LUMIZYME.xml:S1:9285:9	I-AdverseReaction
4	LUMIZYME.xml:S1:9315:1	O
(	LUMIZYME.xml:S1:9317:1	O
6.7	LUMIZYME.xml:S1:9318:3	O
)	LUMIZYME.xml:S1:9321:1	O
1	LUMIZYME.xml:S1:9352:1	O
(	LUMIZYME.xml:S1:9354:1	O
3.3	LUMIZYME.xml:S1:9355:3	O
)	LUMIZYME.xml:S1:9358:1	O

Myalgia	LUMIZYME.xml:S1:9387:7	B-AdverseReaction
3	LUMIZYME.xml:S1:9424:1	O
(	LUMIZYME.xml:S1:9426:1	O
5.0	LUMIZYME.xml:S1:9427:3	O
)	LUMIZYME.xml:S1:9430:1	O
1	LUMIZYME.xml:S1:9461:1	O
(	LUMIZYME.xml:S1:9463:1	O
3.3	LUMIZYME.xml:S1:9464:3	O
)	LUMIZYME.xml:S1:9467:1	O

Flushing	LUMIZYME.xml:S1:9496:8	B-AdverseReaction
Feeling	LUMIZYME.xml:S1:9505:7	B-AdverseReaction
Hot	LUMIZYME.xml:S1:9513:3	I-AdverseReaction
3	LUMIZYME.xml:S1:9533:1	O
(	LUMIZYME.xml:S1:9535:1	O
5.0	LUMIZYME.xml:S1:9536:3	O
)	LUMIZYME.xml:S1:9539:1	O
0	LUMIZYME.xml:S1:9570:1	O
(	LUMIZYME.xml:S1:9572:1	O
0	LUMIZYME.xml:S1:9573:1	O
)	LUMIZYME.xml:S1:9574:1	O

Increased	LUMIZYME.xml:S1:9605:9	B-AdverseReaction
Blood	LUMIZYME.xml:S1:9615:5	I-AdverseReaction
Pressure	LUMIZYME.xml:S1:9621:8	I-AdverseReaction
3	LUMIZYME.xml:S1:9642:1	O
(	LUMIZYME.xml:S1:9644:1	O
5.0	LUMIZYME.xml:S1:9645:3	O
)	LUMIZYME.xml:S1:9648:1	O
0	LUMIZYME.xml:S1:9679:1	O
(	LUMIZYME.xml:S1:9681:1	O
0	LUMIZYME.xml:S1:9682:1	O
)	LUMIZYME.xml:S1:9683:1	O

Vomiting	LUMIZYME.xml:S1:9714:8	B-AdverseReaction
3	LUMIZYME.xml:S1:9751:1	O
(	LUMIZYME.xml:S1:9753:1	O
5.0	LUMIZYME.xml:S1:9754:3	O
)	LUMIZYME.xml:S1:9757:1	O
0	LUMIZYME.xml:S1:9788:1	O
(	LUMIZYME.xml:S1:9790:1	O
0	LUMIZYME.xml:S1:9791:1	O
)	LUMIZYME.xml:S1:9792:1	O

Edema	LUMIZYME.xml:S1:9823:5	B-AdverseReaction
,	LUMIZYME.xml:S1:9828:1	I-AdverseReaction
Peripheral	LUMIZYME.xml:S1:9830:10	I-AdverseReaction
2	LUMIZYME.xml:S1:9860:1	O
(	LUMIZYME.xml:S1:9862:1	O
3.3	LUMIZYME.xml:S1:9863:3	O
)	LUMIZYME.xml:S1:9866:1	O
0	LUMIZYME.xml:S1:9897:1	O
(	LUMIZYME.xml:S1:9899:1	O
0	LUMIZYME.xml:S1:9900:1	O
)	LUMIZYME.xml:S1:9901:1	O

Pruritus	LUMIZYME.xml:S1:9932:8	B-AdverseReaction
2	LUMIZYME.xml:S1:9969:1	O
(	LUMIZYME.xml:S1:9971:1	O
3.3	LUMIZYME.xml:S1:9972:3	O
)	LUMIZYME.xml:S1:9975:1	O
0	LUMIZYME.xml:S1:10006:1	O
(	LUMIZYME.xml:S1:10008:1	O
0	LUMIZYME.xml:S1:10009:1	O
)	LUMIZYME.xml:S1:10010:1	O

Rash	LUMIZYME.xml:S1:10041:4	B-AdverseReaction
Papular	LUMIZYME.xml:S1:10046:7	I-AdverseReaction
2	LUMIZYME.xml:S1:10078:1	O
(	LUMIZYME.xml:S1:10080:1	O
3.3	LUMIZYME.xml:S1:10081:3	O
)	LUMIZYME.xml:S1:10084:1	O
0	LUMIZYME.xml:S1:10115:1	O
(	LUMIZYME.xml:S1:10117:1	O
0	LUMIZYME.xml:S1:10118:1	O
)	LUMIZYME.xml:S1:10119:1	O

Throat	LUMIZYME.xml:S1:10150:6	B-AdverseReaction
Tightness	LUMIZYME.xml:S1:10157:9	I-AdverseReaction
2	LUMIZYME.xml:S1:10187:1	O
(	LUMIZYME.xml:S1:10189:1	O
3.3	LUMIZYME.xml:S1:10190:3	O
)	LUMIZYME.xml:S1:10193:1	O
0	LUMIZYME.xml:S1:10224:1	O
(	LUMIZYME.xml:S1:10226:1	O
0	LUMIZYME.xml:S1:10227:1	O
)	LUMIZYME.xml:S1:10228:1	O

In	LUMIZYME.xml:S1:10267:2	O
clinical	LUMIZYME.xml:S1:10270:8	O
trials	LUMIZYME.xml:S1:10279:6	O
,	LUMIZYME.xml:S1:10285:1	O
anaphylaxis	LUMIZYME.xml:S1:10287:11	B-AdverseReaction
and	LUMIZYME.xml:S1:10299:3	O
hypersensitivity	LUMIZYME.xml:S1:10303:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:10320:9	I-AdverseReaction
were	LUMIZYME.xml:S1:10330:4	O
managed	LUMIZYME.xml:S1:10335:7	O
with	LUMIZYME.xml:S1:10343:4	O
infusion	LUMIZYME.xml:S1:10348:8	O
interruption	LUMIZYME.xml:S1:10357:12	O
,	LUMIZYME.xml:S1:10369:1	O
decreased	LUMIZYME.xml:S1:10371:9	O
infusion	LUMIZYME.xml:S1:10381:8	O
rate	LUMIZYME.xml:S1:10390:4	O
,	LUMIZYME.xml:S1:10394:1	O
administration	LUMIZYME.xml:S1:10396:14	O
of	LUMIZYME.xml:S1:10411:2	O
antihistamines	LUMIZYME.xml:S1:10414:14	O
,	LUMIZYME.xml:S1:10428:1	O
corticosteroids	LUMIZYME.xml:S1:10430:15	O
,	LUMIZYME.xml:S1:10445:1	O
intravenous	LUMIZYME.xml:S1:10447:11	O
fluids	LUMIZYME.xml:S1:10459:6	O
,	LUMIZYME.xml:S1:10465:1	O
and	LUMIZYME.xml:S1:10467:3	O
or	LUMIZYME.xml:S1:10471:2	O
oxygen	LUMIZYME.xml:S1:10474:6	O
,	LUMIZYME.xml:S1:10480:1	O
when	LUMIZYME.xml:S1:10482:4	O
clinically	LUMIZYME.xml:S1:10487:10	O
indicated	LUMIZYME.xml:S1:10498:9	O
.	LUMIZYME.xml:S1:10507:1	O

In	LUMIZYME.xml:S1:10509:2	O
some	LUMIZYME.xml:S1:10512:4	O
cases	LUMIZYME.xml:S1:10517:5	O
of	LUMIZYME.xml:S1:10523:2	O
anaphylactic	LUMIZYME.xml:S1:10526:12	B-AdverseReaction
reactions	LUMIZYME.xml:S1:10539:9	I-AdverseReaction
,	LUMIZYME.xml:S1:10548:1	O
epinephrine	LUMIZYME.xml:S1:10550:11	O
was	LUMIZYME.xml:S1:10562:3	O
administered	LUMIZYME.xml:S1:10566:12	O
.	LUMIZYME.xml:S1:10578:1	O

Patients	LUMIZYME.xml:S1:10580:8	O
who	LUMIZYME.xml:S1:10589:3	O
have	LUMIZYME.xml:S1:10593:4	O
experienced	LUMIZYME.xml:S1:10598:11	O
anaphylaxis	LUMIZYME.xml:S1:10610:11	O
or	LUMIZYME.xml:S1:10622:2	O
hypersensitivity	LUMIZYME.xml:S1:10625:16	O
reactions	LUMIZYME.xml:S1:10642:9	O
should	LUMIZYME.xml:S1:10652:6	O
be	LUMIZYME.xml:S1:10659:2	O
treated	LUMIZYME.xml:S1:10662:7	O
with	LUMIZYME.xml:S1:10670:4	O
caution	LUMIZYME.xml:S1:10675:7	O
when	LUMIZYME.xml:S1:10683:4	O
they	LUMIZYME.xml:S1:10688:4	O
are	LUMIZYME.xml:S1:10693:3	O
re	LUMIZYME.xml:S1:10697:2	O
-	LUMIZYME.xml:S1:10699:1	O
administered	LUMIZYME.xml:S1:10700:12	O
alglucosidase	LUMIZYME.xml:S1:10713:13	O
alfa	LUMIZYME.xml:S1:10727:4	O
.	LUMIZYME.xml:S1:10731:1	O

6.2	LUMIZYME.xml:S1:10739:3	O

Immunogenicity	LUMIZYME.xml:S1:10743:14	O

As	LUMIZYME.xml:S1:10761:2	O
with	LUMIZYME.xml:S1:10764:4	O
all	LUMIZYME.xml:S1:10769:3	O
therapeutic	LUMIZYME.xml:S1:10773:11	O
proteins	LUMIZYME.xml:S1:10785:8	O
,	LUMIZYME.xml:S1:10793:1	O
there	LUMIZYME.xml:S1:10795:5	O
is	LUMIZYME.xml:S1:10801:2	O
potential	LUMIZYME.xml:S1:10804:9	O
for	LUMIZYME.xml:S1:10814:3	O
immunogenicity	LUMIZYME.xml:S1:10818:14	O
.	LUMIZYME.xml:S1:10832:1	O

The	LUMIZYME.xml:S1:10834:3	O
data	LUMIZYME.xml:S1:10838:4	O
reflect	LUMIZYME.xml:S1:10843:7	O
the	LUMIZYME.xml:S1:10851:3	O
percentage	LUMIZYME.xml:S1:10855:10	O
of	LUMIZYME.xml:S1:10866:2	O
patients	LUMIZYME.xml:S1:10869:8	O
whose	LUMIZYME.xml:S1:10878:5	O
test	LUMIZYME.xml:S1:10884:4	O
results	LUMIZYME.xml:S1:10889:7	O
were	LUMIZYME.xml:S1:10897:4	O
considered	LUMIZYME.xml:S1:10902:10	O
positive	LUMIZYME.xml:S1:10913:8	O
for	LUMIZYME.xml:S1:10922:3	O
antibodies	LUMIZYME.xml:S1:10926:10	O
to	LUMIZYME.xml:S1:10937:2	O
alglucosidase	LUMIZYME.xml:S1:10940:13	O
alfa	LUMIZYME.xml:S1:10954:4	O
using	LUMIZYME.xml:S1:10959:5	O
an	LUMIZYME.xml:S1:10965:2	O
enzyme	LUMIZYME.xml:S1:10968:6	O
-	LUMIZYME.xml:S1:10974:1	O
linked	LUMIZYME.xml:S1:10975:6	O
immunosorbent	LUMIZYME.xml:S1:10982:13	O
assay	LUMIZYME.xml:S1:10996:5	O
(	LUMIZYME.xml:S1:11002:1	O
ELISA	LUMIZYME.xml:S1:11003:5	O
)	LUMIZYME.xml:S1:11008:1	O
and	LUMIZYME.xml:S1:11010:3	O
confirmed	LUMIZYME.xml:S1:11014:9	O
by	LUMIZYME.xml:S1:11024:2	O
a	LUMIZYME.xml:S1:11027:1	O
radioimmunoprecipitation	LUMIZYME.xml:S1:11029:24	O
(	LUMIZYME.xml:S1:11054:1	O
RIP	LUMIZYME.xml:S1:11055:3	O
)	LUMIZYME.xml:S1:11058:1	O
assay	LUMIZYME.xml:S1:11060:5	O
for	LUMIZYME.xml:S1:11066:3	O
alglucosidase	LUMIZYME.xml:S1:11070:13	O
alfa	LUMIZYME.xml:S1:11084:4	O
-	LUMIZYME.xml:S1:11088:1	O
specific	LUMIZYME.xml:S1:11089:8	O
IgG	LUMIZYME.xml:S1:11098:3	O
antibodies	LUMIZYME.xml:S1:11102:10	O
.	LUMIZYME.xml:S1:11112:1	O

In	LUMIZYME.xml:S1:11118:2	O
the	LUMIZYME.xml:S1:11121:3	O
two	LUMIZYME.xml:S1:11125:3	O
clinical	LUMIZYME.xml:S1:11129:8	O
trials	LUMIZYME.xml:S1:11138:6	O
in	LUMIZYME.xml:S1:11145:2	O
infantile	LUMIZYME.xml:S1:11148:9	O
-	LUMIZYME.xml:S1:11157:1	O
onset	LUMIZYME.xml:S1:11158:5	O
patients	LUMIZYME.xml:S1:11164:8	O
,	LUMIZYME.xml:S1:11172:1	O
the	LUMIZYME.xml:S1:11174:3	O
majority	LUMIZYME.xml:S1:11178:8	O
of	LUMIZYME.xml:S1:11187:2	O
patients	LUMIZYME.xml:S1:11190:8	O
(	LUMIZYME.xml:S1:11199:1	O
34	LUMIZYME.xml:S1:11200:2	O
of	LUMIZYME.xml:S1:11203:2	O
38	LUMIZYME.xml:S1:11206:2	O
;	LUMIZYME.xml:S1:11208:1	O
89%	LUMIZYME.xml:S1:11210:3	O
)	LUMIZYME.xml:S1:11213:1	O
tested	LUMIZYME.xml:S1:11215:6	O
positive	LUMIZYME.xml:S1:11222:8	O
for	LUMIZYME.xml:S1:11231:3	O
IgG	LUMIZYME.xml:S1:11235:3	O
antibodies	LUMIZYME.xml:S1:11239:10	O
to	LUMIZYME.xml:S1:11250:2	O
alglucosidase	LUMIZYME.xml:S1:11253:13	O
alfa	LUMIZYME.xml:S1:11267:4	O
.	LUMIZYME.xml:S1:11271:1	O

There	LUMIZYME.xml:S1:11273:5	O
is	LUMIZYME.xml:S1:11279:2	O
evidence	LUMIZYME.xml:S1:11282:8	O
to	LUMIZYME.xml:S1:11291:2	O
suggest	LUMIZYME.xml:S1:11294:7	O
that	LUMIZYME.xml:S1:11302:4	O
some	LUMIZYME.xml:S1:11307:4	O
patients	LUMIZYME.xml:S1:11312:8	O
who	LUMIZYME.xml:S1:11321:3	O
develop	LUMIZYME.xml:S1:11325:7	O
high	LUMIZYME.xml:S1:11333:4	O
sustained	LUMIZYME.xml:S1:11338:9	O
titers	LUMIZYME.xml:S1:11348:6	O
of	LUMIZYME.xml:S1:11355:2	O
anti	LUMIZYME.xml:S1:11358:4	O
-	LUMIZYME.xml:S1:11362:1	O
alglucosidase	LUMIZYME.xml:S1:11363:13	O
alfa	LUMIZYME.xml:S1:11377:4	O
antibodies	LUMIZYME.xml:S1:11382:10	O
may	LUMIZYME.xml:S1:11393:3	O
experience	LUMIZYME.xml:S1:11397:10	O
reduced	LUMIZYME.xml:S1:11408:7	O
clinical	LUMIZYME.xml:S1:11416:8	O
efficacy	LUMIZYME.xml:S1:11425:8	O
to	LUMIZYME.xml:S1:11434:2	O
alglucosidase	LUMIZYME.xml:S1:11437:13	O
alfa	LUMIZYME.xml:S1:11451:4	O
treatment	LUMIZYME.xml:S1:11456:9	O
[	LUMIZYME.xml:S1:11467:1	O
seeWarnings	LUMIZYME.xml:S1:11468:11	O
and	LUMIZYME.xml:S1:11480:3	O
Precautions	LUMIZYME.xml:S1:11484:11	O
(	LUMIZYME.xml:S1:11496:1	O
5.5	LUMIZYME.xml:S1:11497:3	O
)]	LUMIZYME.xml:S1:11500:2	O
.	LUMIZYME.xml:S1:11504:1	O

Some	LUMIZYME.xml:S1:11506:4	O
IgG	LUMIZYME.xml:S1:11511:3	O
-	LUMIZYME.xml:S1:11514:1	O
positive	LUMIZYME.xml:S1:11515:8	O
patients	LUMIZYME.xml:S1:11524:8	O
in	LUMIZYME.xml:S1:11533:2	O
clinical	LUMIZYME.xml:S1:11536:8	O
trials	LUMIZYME.xml:S1:11545:6	O
who	LUMIZYME.xml:S1:11552:3	O
were	LUMIZYME.xml:S1:11556:4	O
retrospectively	LUMIZYME.xml:S1:11561:15	O
evaluated	LUMIZYME.xml:S1:11577:9	O
for	LUMIZYME.xml:S1:11587:3	O
the	LUMIZYME.xml:S1:11591:3	O
presence	LUMIZYME.xml:S1:11595:8	O
of	LUMIZYME.xml:S1:11604:2	O
inhibitory	LUMIZYME.xml:S1:11607:10	O
antibodies	LUMIZYME.xml:S1:11618:10	O
tested	LUMIZYME.xml:S1:11629:6	O
positive	LUMIZYME.xml:S1:11636:8	O
for	LUMIZYME.xml:S1:11645:3	O
inhibition	LUMIZYME.xml:S1:11649:10	O
of	LUMIZYME.xml:S1:11660:2	O
enzyme	LUMIZYME.xml:S1:11663:6	O
activity	LUMIZYME.xml:S1:11670:8	O
and	LUMIZYME.xml:S1:11679:3	O
or	LUMIZYME.xml:S1:11683:2	O
uptake	LUMIZYME.xml:S1:11686:6	O
in	LUMIZYME.xml:S1:11693:2	O
in	LUMIZYME.xml:S1:11697:2	O
vitro	LUMIZYME.xml:S1:11700:5	O
assays	LUMIZYME.xml:S1:11707:6	O
.	LUMIZYME.xml:S1:11713:1	O

Furthermore	LUMIZYME.xml:S1:11715:11	O
,	LUMIZYME.xml:S1:11726:1	O
CRIM	LUMIZYME.xml:S1:11728:4	O
-	LUMIZYME.xml:S1:11732:1	O
negative	LUMIZYME.xml:S1:11733:8	O
infants	LUMIZYME.xml:S1:11742:7	O
have	LUMIZYME.xml:S1:11750:4	O
shown	LUMIZYME.xml:S1:11755:5	O
reduced	LUMIZYME.xml:S1:11761:7	O
clinical	LUMIZYME.xml:S1:11769:8	O
effect	LUMIZYME.xml:S1:11778:6	O
in	LUMIZYME.xml:S1:11785:2	O
the	LUMIZYME.xml:S1:11788:3	O
presence	LUMIZYME.xml:S1:11792:8	O
of	LUMIZYME.xml:S1:11801:2	O
high	LUMIZYME.xml:S1:11804:4	B-Severity
sustained	LUMIZYME.xml:S1:11809:9	I-Severity
IgG	LUMIZYME.xml:S1:11819:3	B-AdverseReaction
antibody	LUMIZYME.xml:S1:11823:8	I-AdverseReaction
titers	LUMIZYME.xml:S1:11832:6	I-AdverseReaction
with	LUMIZYME.xml:S1:11839:4	I-AdverseReaction
inhibitory	LUMIZYME.xml:S1:11844:10	I-AdverseReaction
activity	LUMIZYME.xml:S1:11855:8	I-AdverseReaction
.	LUMIZYME.xml:S1:11863:1	O

Alglucosidase	LUMIZYME.xml:S1:11865:13	O
alfa	LUMIZYME.xml:S1:11879:4	O
-	LUMIZYME.xml:S1:11883:1	O
treated	LUMIZYME.xml:S1:11884:7	O
patients	LUMIZYME.xml:S1:11892:8	O
who	LUMIZYME.xml:S1:11901:3	O
experience	LUMIZYME.xml:S1:11905:10	O
a	LUMIZYME.xml:S1:11916:1	O
decrease	LUMIZYME.xml:S1:11918:8	O
in	LUMIZYME.xml:S1:11927:2	O
motor	LUMIZYME.xml:S1:11930:5	O
function	LUMIZYME.xml:S1:11936:8	O
should	LUMIZYME.xml:S1:11945:6	O
be	LUMIZYME.xml:S1:11952:2	O
tested	LUMIZYME.xml:S1:11955:6	O
for	LUMIZYME.xml:S1:11962:3	O
the	LUMIZYME.xml:S1:11966:3	O
presence	LUMIZYME.xml:S1:11970:8	O
of	LUMIZYME.xml:S1:11979:2	O
inhibitory	LUMIZYME.xml:S1:11982:10	O
antibodies	LUMIZYME.xml:S1:11993:10	O
that	LUMIZYME.xml:S1:12004:4	O
neutralize	LUMIZYME.xml:S1:12009:10	O
enzyme	LUMIZYME.xml:S1:12020:6	O
uptake	LUMIZYME.xml:S1:12027:6	O
or	LUMIZYME.xml:S1:12034:2	O
activity	LUMIZYME.xml:S1:12037:8	O
.	LUMIZYME.xml:S1:12045:1	O

In	LUMIZYME.xml:S1:12051:2	O
the	LUMIZYME.xml:S1:12054:3	O
randomized	LUMIZYME.xml:S1:12058:10	O
,	LUMIZYME.xml:S1:12068:1	O
double	LUMIZYME.xml:S1:12070:6	O
-	LUMIZYME.xml:S1:12076:1	O
blind	LUMIZYME.xml:S1:12077:5	O
,	LUMIZYME.xml:S1:12082:1	O
placebo	LUMIZYME.xml:S1:12084:7	O
-	LUMIZYME.xml:S1:12091:1	O
controlled	LUMIZYME.xml:S1:12092:10	O
trial	LUMIZYME.xml:S1:12103:5	O
in	LUMIZYME.xml:S1:12109:2	O
late	LUMIZYME.xml:S1:12112:4	O
-	LUMIZYME.xml:S1:12116:1	O
onset	LUMIZYME.xml:S1:12117:5	O
patients	LUMIZYME.xml:S1:12123:8	O
,	LUMIZYME.xml:S1:12131:1	O
all	LUMIZYME.xml:S1:12133:3	O
alglucosidase	LUMIZYME.xml:S1:12137:13	O
alfa	LUMIZYME.xml:S1:12151:4	O
-	LUMIZYME.xml:S1:12155:1	O
treated	LUMIZYME.xml:S1:12156:7	O
patients	LUMIZYME.xml:S1:12164:8	O
with	LUMIZYME.xml:S1:12173:4	O
available	LUMIZYME.xml:S1:12178:9	O
samples	LUMIZYME.xml:S1:12188:7	O
(	LUMIZYME.xml:S1:12196:1	O
N	LUMIZYME.xml:S1:12197:1	O
59	LUMIZYME.xml:S1:12199:2	O
,	LUMIZYME.xml:S1:12201:1	O
100%	LUMIZYME.xml:S1:12203:4	O
)	LUMIZYME.xml:S1:12207:1	O
developed	LUMIZYME.xml:S1:12209:9	O
IgG	LUMIZYME.xml:S1:12219:3	O
antibodies	LUMIZYME.xml:S1:12223:10	O
to	LUMIZYME.xml:S1:12234:2	O
alglucosidase	LUMIZYME.xml:S1:12237:13	O
alfa	LUMIZYME.xml:S1:12251:4	O
.	LUMIZYME.xml:S1:12255:1	O

Most	LUMIZYME.xml:S1:12257:4	O
patients	LUMIZYME.xml:S1:12262:8	O
who	LUMIZYME.xml:S1:12271:3	O
developed	LUMIZYME.xml:S1:12275:9	O
IgG	LUMIZYME.xml:S1:12285:3	O
antibodies	LUMIZYME.xml:S1:12289:10	O
did	LUMIZYME.xml:S1:12300:3	O
so	LUMIZYME.xml:S1:12304:2	O
within	LUMIZYME.xml:S1:12307:6	O
the	LUMIZYME.xml:S1:12314:3	O
first	LUMIZYME.xml:S1:12318:5	O
3	LUMIZYME.xml:S1:12324:1	O
months	LUMIZYME.xml:S1:12326:6	O
of	LUMIZYME.xml:S1:12333:2	O
exposure	LUMIZYME.xml:S1:12336:8	O
(	LUMIZYME.xml:S1:12345:1	O
median	LUMIZYME.xml:S1:12346:6	O
time	LUMIZYME.xml:S1:12353:4	O
to	LUMIZYME.xml:S1:12358:2	O
seroconversion	LUMIZYME.xml:S1:12361:14	O
was	LUMIZYME.xml:S1:12376:3	O
4	LUMIZYME.xml:S1:12380:1	O
weeks	LUMIZYME.xml:S1:12382:5	O
)	LUMIZYME.xml:S1:12387:1	O
.	LUMIZYME.xml:S1:12388:1	O

There	LUMIZYME.xml:S1:12390:5	O
was	LUMIZYME.xml:S1:12396:3	O
no	LUMIZYME.xml:S1:12400:2	O
apparent	LUMIZYME.xml:S1:12403:8	O
association	LUMIZYME.xml:S1:12412:11	O
between	LUMIZYME.xml:S1:12424:7	O
mean	LUMIZYME.xml:S1:12432:4	O
or	LUMIZYME.xml:S1:12437:2	O
peak	LUMIZYME.xml:S1:12440:4	O
IgG	LUMIZYME.xml:S1:12445:3	O
antibody	LUMIZYME.xml:S1:12449:8	O
titers	LUMIZYME.xml:S1:12458:6	O
and	LUMIZYME.xml:S1:12465:3	O
the	LUMIZYME.xml:S1:12469:3	O
occurrence	LUMIZYME.xml:S1:12473:10	O
of	LUMIZYME.xml:S1:12484:2	O
adverse	LUMIZYME.xml:S1:12487:7	O
reactions	LUMIZYME.xml:S1:12495:9	O
.	LUMIZYME.xml:S1:12504:1	O

None	LUMIZYME.xml:S1:12510:4	O
of	LUMIZYME.xml:S1:12515:2	O
the	LUMIZYME.xml:S1:12518:3	O
59	LUMIZYME.xml:S1:12522:2	O
evaluable	LUMIZYME.xml:S1:12525:9	O
patients	LUMIZYME.xml:S1:12535:8	O
tested	LUMIZYME.xml:S1:12544:6	O
positive	LUMIZYME.xml:S1:12551:8	O
for	LUMIZYME.xml:S1:12560:3	O
inhibition	LUMIZYME.xml:S1:12564:10	O
of	LUMIZYME.xml:S1:12575:2	O
enzyme	LUMIZYME.xml:S1:12578:6	O
activity	LUMIZYME.xml:S1:12585:8	O
.	LUMIZYME.xml:S1:12593:1	O

Antibody	LUMIZYME.xml:S1:12595:8	O
titers	LUMIZYME.xml:S1:12604:6	O
for	LUMIZYME.xml:S1:12611:3	O
cellular	LUMIZYME.xml:S1:12615:8	O
uptake	LUMIZYME.xml:S1:12624:6	O
inhibition	LUMIZYME.xml:S1:12631:10	O
were	LUMIZYME.xml:S1:12642:4	O
present	LUMIZYME.xml:S1:12647:7	O
in	LUMIZYME.xml:S1:12655:2	O
18	LUMIZYME.xml:S1:12658:2	O
of	LUMIZYME.xml:S1:12661:2	O
59	LUMIZYME.xml:S1:12664:2	O
(	LUMIZYME.xml:S1:12667:1	O
31%	LUMIZYME.xml:S1:12668:3	O
)	LUMIZYME.xml:S1:12671:1	O
patients	LUMIZYME.xml:S1:12673:8	O
by	LUMIZYME.xml:S1:12682:2	O
Week	LUMIZYME.xml:S1:12685:4	O
78	LUMIZYME.xml:S1:12690:2	O
.	LUMIZYME.xml:S1:12692:1	O

All	LUMIZYME.xml:S1:12694:3	O
other	LUMIZYME.xml:S1:12698:5	O
patients	LUMIZYME.xml:S1:12704:8	O
tested	LUMIZYME.xml:S1:12713:6	O
negative	LUMIZYME.xml:S1:12720:8	O
for	LUMIZYME.xml:S1:12729:3	O
inhibition	LUMIZYME.xml:S1:12733:10	O
of	LUMIZYME.xml:S1:12744:2	O
cellular	LUMIZYME.xml:S1:12747:8	O
uptake	LUMIZYME.xml:S1:12756:6	O
.	LUMIZYME.xml:S1:12762:1	O

Patients	LUMIZYME.xml:S1:12764:8	O
who	LUMIZYME.xml:S1:12773:3	O
tested	LUMIZYME.xml:S1:12777:6	O
positive	LUMIZYME.xml:S1:12784:8	O
for	LUMIZYME.xml:S1:12793:3	O
uptake	LUMIZYME.xml:S1:12797:6	O
inhibition	LUMIZYME.xml:S1:12804:10	O
tended	LUMIZYME.xml:S1:12815:6	O
to	LUMIZYME.xml:S1:12822:2	O
have	LUMIZYME.xml:S1:12825:4	O
higher	LUMIZYME.xml:S1:12830:6	O
IgG	LUMIZYME.xml:S1:12837:3	O
titers	LUMIZYME.xml:S1:12841:6	O
than	LUMIZYME.xml:S1:12848:4	O
patients	LUMIZYME.xml:S1:12853:8	O
who	LUMIZYME.xml:S1:12862:3	O
tested	LUMIZYME.xml:S1:12866:6	O
negative	LUMIZYME.xml:S1:12873:8	O
for	LUMIZYME.xml:S1:12882:3	O
uptake	LUMIZYME.xml:S1:12886:6	O
inhibition	LUMIZYME.xml:S1:12893:10	O
.	LUMIZYME.xml:S1:12903:1	O

Among	LUMIZYME.xml:S1:12905:5	O
the	LUMIZYME.xml:S1:12911:3	O
32	LUMIZYME.xml:S1:12915:2	O
patients	LUMIZYME.xml:S1:12918:8	O
with	LUMIZYME.xml:S1:12927:4	O
evaluable	LUMIZYME.xml:S1:12932:9	O
pharmacokinetic	LUMIZYME.xml:S1:12942:15	O
(	LUMIZYME.xml:S1:12958:1	O
PK	LUMIZYME.xml:S1:12959:2	O
)	LUMIZYME.xml:S1:12961:1	O
samples	LUMIZYME.xml:S1:12963:7	O
,	LUMIZYME.xml:S1:12970:1	O
5	LUMIZYME.xml:S1:12972:1	O
patients	LUMIZYME.xml:S1:12974:8	O
tested	LUMIZYME.xml:S1:12983:6	O
positive	LUMIZYME.xml:S1:12990:8	O
for	LUMIZYME.xml:S1:12999:3	O
uptake	LUMIZYME.xml:S1:13003:6	O
inhibition	LUMIZYME.xml:S1:13010:10	O
.	LUMIZYME.xml:S1:13020:1	O

The	LUMIZYME.xml:S1:13022:3	O
clinical	LUMIZYME.xml:S1:13026:8	O
relevance	LUMIZYME.xml:S1:13035:9	O
of	LUMIZYME.xml:S1:13045:2	O
this	LUMIZYME.xml:S1:13048:4	O
in	LUMIZYME.xml:S1:13054:2	O
vitro	LUMIZYME.xml:S1:13057:5	O
inhibition	LUMIZYME.xml:S1:13064:10	O
is	LUMIZYME.xml:S1:13075:2	O
not	LUMIZYME.xml:S1:13078:3	O
fully	LUMIZYME.xml:S1:13082:5	O
understood	LUMIZYME.xml:S1:13088:10	O
.	LUMIZYME.xml:S1:13098:1	O

The	LUMIZYME.xml:S1:13100:3	O
clearance	LUMIZYME.xml:S1:13104:9	O
values	LUMIZYME.xml:S1:13114:6	O
for	LUMIZYME.xml:S1:13121:3	O
4	LUMIZYME.xml:S1:13125:1	O
of	LUMIZYME.xml:S1:13127:2	O
these	LUMIZYME.xml:S1:13130:5	O
5	LUMIZYME.xml:S1:13136:1	O
patients	LUMIZYME.xml:S1:13138:8	O
were	LUMIZYME.xml:S1:13147:4	O
approximately	LUMIZYME.xml:S1:13152:13	O
1.2	LUMIZYME.xml:S1:13166:3	O
-	LUMIZYME.xml:S1:13169:1	O
to	LUMIZYME.xml:S1:13171:2	O
1.8	LUMIZYME.xml:S1:13174:3	O
-	LUMIZYME.xml:S1:13177:1	O
fold	LUMIZYME.xml:S1:13178:4	O
greater	LUMIZYME.xml:S1:13183:7	O
in	LUMIZYME.xml:S1:13191:2	O
the	LUMIZYME.xml:S1:13194:3	O
presence	LUMIZYME.xml:S1:13198:8	O
of	LUMIZYME.xml:S1:13207:2	O
inhibitory	LUMIZYME.xml:S1:13210:10	O
antibodies	LUMIZYME.xml:S1:13221:10	O
(	LUMIZYME.xml:S1:13232:1	O
Week	LUMIZYME.xml:S1:13233:4	O
52	LUMIZYME.xml:S1:13238:2	O
)	LUMIZYME.xml:S1:13240:1	O
as	LUMIZYME.xml:S1:13242:2	O
compared	LUMIZYME.xml:S1:13245:8	O
to	LUMIZYME.xml:S1:13254:2	O
in	LUMIZYME.xml:S1:13257:2	O
the	LUMIZYME.xml:S1:13260:3	O
absence	LUMIZYME.xml:S1:13264:7	O
of	LUMIZYME.xml:S1:13272:2	O
inhibitory	LUMIZYME.xml:S1:13275:10	O
antibodies	LUMIZYME.xml:S1:13286:10	O
(	LUMIZYME.xml:S1:13297:1	O
Week	LUMIZYME.xml:S1:13298:4	O
0	LUMIZYME.xml:S1:13303:1	O
)	LUMIZYME.xml:S1:13304:1	O
[	LUMIZYME.xml:S1:13307:1	O
seeClinical	LUMIZYME.xml:S1:13308:11	O
Pharmacology	LUMIZYME.xml:S1:13320:12	O
(	LUMIZYME.xml:S1:13333:1	O
12.3	LUMIZYME.xml:S1:13334:4	O
)]	LUMIZYME.xml:S1:13338:2	O
.	LUMIZYME.xml:S1:13342:1	O

Some	LUMIZYME.xml:S1:13348:4	O
patients	LUMIZYME.xml:S1:13353:8	O
in	LUMIZYME.xml:S1:13362:2	O
the	LUMIZYME.xml:S1:13365:3	O
clinical	LUMIZYME.xml:S1:13369:8	O
studies	LUMIZYME.xml:S1:13378:7	O
or	LUMIZYME.xml:S1:13386:2	O
in	LUMIZYME.xml:S1:13389:2	O
the	LUMIZYME.xml:S1:13392:3	O
postmarketing	LUMIZYME.xml:S1:13396:13	O
setting	LUMIZYME.xml:S1:13410:7	O
have	LUMIZYME.xml:S1:13418:4	O
undergone	LUMIZYME.xml:S1:13423:9	O
testing	LUMIZYME.xml:S1:13433:7	O
for	LUMIZYME.xml:S1:13441:3	O
alglucosidase	LUMIZYME.xml:S1:13445:13	O
alfa	LUMIZYME.xml:S1:13459:4	O
-	LUMIZYME.xml:S1:13463:1	O
specific	LUMIZYME.xml:S1:13464:8	O
IgE	LUMIZYME.xml:S1:13473:3	O
antibodies	LUMIZYME.xml:S1:13477:10	O
.	LUMIZYME.xml:S1:13487:1	O

Testing	LUMIZYME.xml:S1:13489:7	O
was	LUMIZYME.xml:S1:13497:3	O
performed	LUMIZYME.xml:S1:13501:9	O
in	LUMIZYME.xml:S1:13511:2	O
patients	LUMIZYME.xml:S1:13514:8	O
who	LUMIZYME.xml:S1:13523:3	O
experienced	LUMIZYME.xml:S1:13527:11	O
moderate	LUMIZYME.xml:S1:13539:8	B-Severity
to	LUMIZYME.xml:S1:13548:2	I-Severity
severe	LUMIZYME.xml:S1:13551:6	I-Severity
or	LUMIZYME.xml:S1:13558:2	O
recurrent	LUMIZYME.xml:S1:13561:9	B-AdverseReaction
hypersensitivity	LUMIZYME.xml:S1:13571:16	I-AdverseReaction
reactions	LUMIZYME.xml:S1:13588:9	I-AdverseReaction
,	LUMIZYME.xml:S1:13597:1	O
for	LUMIZYME.xml:S1:13599:3	O
which	LUMIZYME.xml:S1:13603:5	O
mast	LUMIZYME.xml:S1:13609:4	O
-	LUMIZYME.xml:S1:13613:1	O
cell	LUMIZYME.xml:S1:13614:4	O
activation	LUMIZYME.xml:S1:13619:10	O
was	LUMIZYME.xml:S1:13630:3	O
suspected	LUMIZYME.xml:S1:13634:9	O
.	LUMIZYME.xml:S1:13643:1	O

Some	LUMIZYME.xml:S1:13645:4	O
of	LUMIZYME.xml:S1:13650:2	O
the	LUMIZYME.xml:S1:13653:3	O
patients	LUMIZYME.xml:S1:13657:8	O
who	LUMIZYME.xml:S1:13666:3	O
tested	LUMIZYME.xml:S1:13670:6	O
positive	LUMIZYME.xml:S1:13677:8	O
for	LUMIZYME.xml:S1:13686:3	O
alglucosidase	LUMIZYME.xml:S1:13690:13	O
alfa	LUMIZYME.xml:S1:13704:4	O
-	LUMIZYME.xml:S1:13708:1	O
specific	LUMIZYME.xml:S1:13709:8	O
IgE	LUMIZYME.xml:S1:13718:3	O
antibodies	LUMIZYME.xml:S1:13722:10	O
experienced	LUMIZYME.xml:S1:13733:11	O
anaphylactic	LUMIZYME.xml:S1:13745:12	B-AdverseReaction
reactions	LUMIZYME.xml:S1:13758:9	I-AdverseReaction
[	LUMIZYME.xml:S1:13769:1	O
seeBoxed	LUMIZYME.xml:S1:13770:8	O
WarningandWarnings	LUMIZYME.xml:S1:13779:18	O
and	LUMIZYME.xml:S1:13798:3	O
Precautions	LUMIZYME.xml:S1:13802:11	O
(	LUMIZYME.xml:S1:13814:1	O
5.1	LUMIZYME.xml:S1:13815:3	O
)]	LUMIZYME.xml:S1:13818:2	O
.	LUMIZYME.xml:S1:13820:1	O

Some	LUMIZYME.xml:S1:13828:4	O
patients	LUMIZYME.xml:S1:13833:8	O
who	LUMIZYME.xml:S1:13842:3	O
tested	LUMIZYME.xml:S1:13846:6	O
positive	LUMIZYME.xml:S1:13853:8	O
for	LUMIZYME.xml:S1:13862:3	O
alglucosidase	LUMIZYME.xml:S1:13866:13	O
alfa	LUMIZYME.xml:S1:13880:4	O
-	LUMIZYME.xml:S1:13884:1	O
specific	LUMIZYME.xml:S1:13885:8	O
IgE	LUMIZYME.xml:S1:13894:3	O
antibodies	LUMIZYME.xml:S1:13898:10	O
and	LUMIZYME.xml:S1:13909:3	O
experienced	LUMIZYME.xml:S1:13913:11	O
hypersensitivity	LUMIZYME.xml:S1:13925:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:13942:9	I-AdverseReaction
were	LUMIZYME.xml:S1:13952:4	O
able	LUMIZYME.xml:S1:13957:4	O
to	LUMIZYME.xml:S1:13962:2	O
be	LUMIZYME.xml:S1:13965:2	O
rechallenged	LUMIZYME.xml:S1:13968:12	O
with	LUMIZYME.xml:S1:13981:4	O
alglucosidase	LUMIZYME.xml:S1:13986:13	O
alfa	LUMIZYME.xml:S1:14000:4	O
using	LUMIZYME.xml:S1:14005:5	O
a	LUMIZYME.xml:S1:14011:1	O
slower	LUMIZYME.xml:S1:14013:6	O
infusion	LUMIZYME.xml:S1:14020:8	O
rate	LUMIZYME.xml:S1:14029:4	O
at	LUMIZYME.xml:S1:14034:2	O
lower	LUMIZYME.xml:S1:14037:5	O
starting	LUMIZYME.xml:S1:14043:8	O
doses	LUMIZYME.xml:S1:14052:5	O
and	LUMIZYME.xml:S1:14058:3	O
have	LUMIZYME.xml:S1:14062:4	O
continued	LUMIZYME.xml:S1:14067:9	O
to	LUMIZYME.xml:S1:14077:2	O
receive	LUMIZYME.xml:S1:14080:7	O
treatment	LUMIZYME.xml:S1:14088:9	O
under	LUMIZYME.xml:S1:14098:5	O
close	LUMIZYME.xml:S1:14104:5	O
clinical	LUMIZYME.xml:S1:14110:8	O
supervision	LUMIZYME.xml:S1:14119:11	O
[	LUMIZYME.xml:S1:14132:1	O
seeWarnings	LUMIZYME.xml:S1:14133:11	O
and	LUMIZYME.xml:S1:14145:3	O
Precautions	LUMIZYME.xml:S1:14149:11	O
(	LUMIZYME.xml:S1:14161:1	O
5.1	LUMIZYME.xml:S1:14162:3	O
)]	LUMIZYME.xml:S1:14165:2	O
.	LUMIZYME.xml:S1:14169:1	O

Since	LUMIZYME.xml:S1:14171:5	O
patients	LUMIZYME.xml:S1:14177:8	O
who	LUMIZYME.xml:S1:14186:3	O
develop	LUMIZYME.xml:S1:14190:7	O
IgE	LUMIZYME.xml:S1:14198:3	O
antibodies	LUMIZYME.xml:S1:14202:10	O
to	LUMIZYME.xml:S1:14213:2	O
alglucosidase	LUMIZYME.xml:S1:14216:13	O
alfa	LUMIZYME.xml:S1:14230:4	O
appear	LUMIZYME.xml:S1:14235:6	O
to	LUMIZYME.xml:S1:14242:2	O
be	LUMIZYME.xml:S1:14245:2	O
at	LUMIZYME.xml:S1:14248:2	O
a	LUMIZYME.xml:S1:14251:1	O
higher	LUMIZYME.xml:S1:14253:6	O
risk	LUMIZYME.xml:S1:14260:4	O
for	LUMIZYME.xml:S1:14265:3	O
developing	LUMIZYME.xml:S1:14269:10	O
anaphylaxis	LUMIZYME.xml:S1:14280:11	O
and	LUMIZYME.xml:S1:14292:3	O
hypersensitivity	LUMIZYME.xml:S1:14296:16	O
reactions	LUMIZYME.xml:S1:14313:9	O
,	LUMIZYME.xml:S1:14322:1	O
these	LUMIZYME.xml:S1:14324:5	O
patients	LUMIZYME.xml:S1:14330:8	O
should	LUMIZYME.xml:S1:14339:6	O
be	LUMIZYME.xml:S1:14346:2	O
monitored	LUMIZYME.xml:S1:14349:9	O
more	LUMIZYME.xml:S1:14359:4	O
closely	LUMIZYME.xml:S1:14364:7	O
during	LUMIZYME.xml:S1:14372:6	O
administration	LUMIZYME.xml:S1:14379:14	O
of	LUMIZYME.xml:S1:14394:2	O
alglucosidase	LUMIZYME.xml:S1:14397:13	O
alfa	LUMIZYME.xml:S1:14411:4	O
.	LUMIZYME.xml:S1:14415:1	O

The	LUMIZYME.xml:S1:14421:3	O
detection	LUMIZYME.xml:S1:14425:9	O
of	LUMIZYME.xml:S1:14435:2	O
antibody	LUMIZYME.xml:S1:14438:8	O
formation	LUMIZYME.xml:S1:14447:9	O
is	LUMIZYME.xml:S1:14457:2	O
highly	LUMIZYME.xml:S1:14460:6	O
dependent	LUMIZYME.xml:S1:14467:9	O
on	LUMIZYME.xml:S1:14477:2	O
the	LUMIZYME.xml:S1:14480:3	O
sensitivity	LUMIZYME.xml:S1:14484:11	O
and	LUMIZYME.xml:S1:14496:3	O
specificity	LUMIZYME.xml:S1:14500:11	O
of	LUMIZYME.xml:S1:14512:2	O
the	LUMIZYME.xml:S1:14515:3	O
assay	LUMIZYME.xml:S1:14519:5	O
.	LUMIZYME.xml:S1:14524:1	O

Additionally	LUMIZYME.xml:S1:14526:12	O
,	LUMIZYME.xml:S1:14538:1	O
the	LUMIZYME.xml:S1:14540:3	O
observed	LUMIZYME.xml:S1:14544:8	O
incidence	LUMIZYME.xml:S1:14553:9	O
of	LUMIZYME.xml:S1:14563:2	O
antibody	LUMIZYME.xml:S1:14566:8	O
(	LUMIZYME.xml:S1:14575:1	O
including	LUMIZYME.xml:S1:14576:9	O
neutralizing	LUMIZYME.xml:S1:14586:12	O
antibody	LUMIZYME.xml:S1:14599:8	O
)	LUMIZYME.xml:S1:14607:1	O
positivity	LUMIZYME.xml:S1:14609:10	O
in	LUMIZYME.xml:S1:14620:2	O
an	LUMIZYME.xml:S1:14623:2	O
assay	LUMIZYME.xml:S1:14626:5	O
may	LUMIZYME.xml:S1:14632:3	O
be	LUMIZYME.xml:S1:14636:2	O
influenced	LUMIZYME.xml:S1:14639:10	O
by	LUMIZYME.xml:S1:14650:2	O
several	LUMIZYME.xml:S1:14653:7	O
factors	LUMIZYME.xml:S1:14661:7	O
including	LUMIZYME.xml:S1:14669:9	O
assay	LUMIZYME.xml:S1:14679:5	O
methodology	LUMIZYME.xml:S1:14685:11	O
,	LUMIZYME.xml:S1:14696:1	O
sample	LUMIZYME.xml:S1:14698:6	O
handling	LUMIZYME.xml:S1:14705:8	O
,	LUMIZYME.xml:S1:14713:1	O
timing	LUMIZYME.xml:S1:14715:6	O
of	LUMIZYME.xml:S1:14722:2	O
sample	LUMIZYME.xml:S1:14725:6	O
collection	LUMIZYME.xml:S1:14732:10	O
,	LUMIZYME.xml:S1:14742:1	O
concomitant	LUMIZYME.xml:S1:14744:11	O
medications	LUMIZYME.xml:S1:14756:11	O
,	LUMIZYME.xml:S1:14767:1	O
and	LUMIZYME.xml:S1:14769:3	O
underlying	LUMIZYME.xml:S1:14773:10	O
disease	LUMIZYME.xml:S1:14784:7	O
.	LUMIZYME.xml:S1:14791:1	O

For	LUMIZYME.xml:S1:14793:3	O
these	LUMIZYME.xml:S1:14797:5	O
reasons	LUMIZYME.xml:S1:14803:7	O
,	LUMIZYME.xml:S1:14810:1	O
comparison	LUMIZYME.xml:S1:14812:10	O
of	LUMIZYME.xml:S1:14823:2	O
the	LUMIZYME.xml:S1:14826:3	O
incidence	LUMIZYME.xml:S1:14830:9	O
of	LUMIZYME.xml:S1:14840:2	O
antibodies	LUMIZYME.xml:S1:14843:10	O
to	LUMIZYME.xml:S1:14854:2	O
alglucosidase	LUMIZYME.xml:S1:14857:13	O
alfa	LUMIZYME.xml:S1:14871:4	O
with	LUMIZYME.xml:S1:14876:4	O
the	LUMIZYME.xml:S1:14881:3	O
incidence	LUMIZYME.xml:S1:14885:9	O
of	LUMIZYME.xml:S1:14895:2	O
antibodies	LUMIZYME.xml:S1:14898:10	O
to	LUMIZYME.xml:S1:14909:2	O
other	LUMIZYME.xml:S1:14912:5	O
products	LUMIZYME.xml:S1:14918:8	O
may	LUMIZYME.xml:S1:14927:3	O
be	LUMIZYME.xml:S1:14931:2	O
misleading	LUMIZYME.xml:S1:14934:10	O
.	LUMIZYME.xml:S1:14944:1	O

6.3	LUMIZYME.xml:S1:14952:3	O
Postmarketing	LUMIZYME.xml:S1:14956:13	O
Experience	LUMIZYME.xml:S1:14970:10	O

The	LUMIZYME.xml:S1:14984:3	O
following	LUMIZYME.xml:S1:14988:9	O
adverse	LUMIZYME.xml:S1:14998:7	O
reactions	LUMIZYME.xml:S1:15006:9	O
have	LUMIZYME.xml:S1:15016:4	O
been	LUMIZYME.xml:S1:15021:4	O
identified	LUMIZYME.xml:S1:15026:10	O
during	LUMIZYME.xml:S1:15037:6	O
post	LUMIZYME.xml:S1:15044:4	O
approval	LUMIZYME.xml:S1:15049:8	O
use	LUMIZYME.xml:S1:15058:3	O
of	LUMIZYME.xml:S1:15062:2	O
alglucosidase	LUMIZYME.xml:S1:15065:13	O
alfa	LUMIZYME.xml:S1:15079:4	O
.	LUMIZYME.xml:S1:15085:1	O

Because	LUMIZYME.xml:S1:15088:7	O
these	LUMIZYME.xml:S1:15096:5	O
reactions	LUMIZYME.xml:S1:15102:9	O
are	LUMIZYME.xml:S1:15112:3	O
reported	LUMIZYME.xml:S1:15116:8	O
voluntarily	LUMIZYME.xml:S1:15125:11	O
from	LUMIZYME.xml:S1:15137:4	O
a	LUMIZYME.xml:S1:15142:1	O
population	LUMIZYME.xml:S1:15144:10	O
of	LUMIZYME.xml:S1:15155:2	O
uncertain	LUMIZYME.xml:S1:15158:9	O
size	LUMIZYME.xml:S1:15168:4	O
,	LUMIZYME.xml:S1:15172:1	O
it	LUMIZYME.xml:S1:15174:2	O
is	LUMIZYME.xml:S1:15177:2	O
not	LUMIZYME.xml:S1:15180:3	O
always	LUMIZYME.xml:S1:15184:6	O
possible	LUMIZYME.xml:S1:15191:8	O
to	LUMIZYME.xml:S1:15200:2	O
reliably	LUMIZYME.xml:S1:15203:8	O
estimate	LUMIZYME.xml:S1:15212:8	O
their	LUMIZYME.xml:S1:15221:5	O
frequency	LUMIZYME.xml:S1:15227:9	O
or	LUMIZYME.xml:S1:15237:2	O
establish	LUMIZYME.xml:S1:15240:9	O
a	LUMIZYME.xml:S1:15250:1	O
causal	LUMIZYME.xml:S1:15252:6	O
relationship	LUMIZYME.xml:S1:15259:12	O
to	LUMIZYME.xml:S1:15272:2	O
drug	LUMIZYME.xml:S1:15275:4	O
exposure	LUMIZYME.xml:S1:15280:8	O
.	LUMIZYME.xml:S1:15288:1	O

In	LUMIZYME.xml:S1:15290:2	O
postmarketing	LUMIZYME.xml:S1:15293:13	O
experience	LUMIZYME.xml:S1:15307:10	O
with	LUMIZYME.xml:S1:15318:4	O
alglucosidase	LUMIZYME.xml:S1:15323:13	O
alfa	LUMIZYME.xml:S1:15337:4	O
,	LUMIZYME.xml:S1:15341:1	O
serious	LUMIZYME.xml:S1:15343:7	O
adverse	LUMIZYME.xml:S1:15351:7	O
reactions	LUMIZYME.xml:S1:15359:9	O
have	LUMIZYME.xml:S1:15369:4	O
been	LUMIZYME.xml:S1:15374:4	O
reported	LUMIZYME.xml:S1:15379:8	O
,	LUMIZYME.xml:S1:15387:1	O
including	LUMIZYME.xml:S1:15389:9	O
anaphylaxis	LUMIZYME.xml:S1:15399:11	B-AdverseReaction
[	LUMIZYME.xml:S1:15412:1	O
seeBoxed	LUMIZYME.xml:S1:15413:8	O
WarningandWarnings	LUMIZYME.xml:S1:15422:18	O
and	LUMIZYME.xml:S1:15441:3	O
Precautions	LUMIZYME.xml:S1:15445:11	O
(	LUMIZYME.xml:S1:15457:1	O
5.1	LUMIZYME.xml:S1:15458:3	O
)]	LUMIZYME.xml:S1:15461:2	O
.	LUMIZYME.xml:S1:15465:1	O

Acute	LUMIZYME.xml:S1:15467:5	B-AdverseReaction
cardiorespiratory	LUMIZYME.xml:S1:15473:17	I-AdverseReaction
failure	LUMIZYME.xml:S1:15491:7	I-AdverseReaction
,	LUMIZYME.xml:S1:15498:1	O
possibly	LUMIZYME.xml:S1:15500:8	O
associated	LUMIZYME.xml:S1:15509:10	O
with	LUMIZYME.xml:S1:15520:4	O
fluid	LUMIZYME.xml:S1:15525:5	B-AdverseReaction
overload	LUMIZYME.xml:S1:15531:8	I-AdverseReaction
,	LUMIZYME.xml:S1:15539:1	O
has	LUMIZYME.xml:S1:15541:3	O
been	LUMIZYME.xml:S1:15545:4	O
reported	LUMIZYME.xml:S1:15550:8	O
in	LUMIZYME.xml:S1:15559:2	O
infantile	LUMIZYME.xml:S1:15562:9	O
-	LUMIZYME.xml:S1:15571:1	O
onset	LUMIZYME.xml:S1:15572:5	O
Pompe	LUMIZYME.xml:S1:15578:5	O
disease	LUMIZYME.xml:S1:15584:7	O
patients	LUMIZYME.xml:S1:15592:8	O
with	LUMIZYME.xml:S1:15601:4	O
pre	LUMIZYME.xml:S1:15606:3	O
-	LUMIZYME.xml:S1:15609:1	O
existing	LUMIZYME.xml:S1:15610:8	O
hypertrophic	LUMIZYME.xml:S1:15619:12	O
cardiomyopathy	LUMIZYME.xml:S1:15632:14	O
[	LUMIZYME.xml:S1:15648:1	O
seeBoxed	LUMIZYME.xml:S1:15649:8	O
WarningandWarning	LUMIZYME.xml:S1:15658:17	O
and	LUMIZYME.xml:S1:15676:3	O
Precautions	LUMIZYME.xml:S1:15680:11	O
(	LUMIZYME.xml:S1:15692:1	O
5.3	LUMIZYME.xml:S1:15693:3	O
)]	LUMIZYME.xml:S1:15696:2	O
.	LUMIZYME.xml:S1:15698:1	O

Recurrent	LUMIZYME.xml:S1:15706:9	O
reactions	LUMIZYME.xml:S1:15716:9	O
consisting	LUMIZYME.xml:S1:15726:10	O
of	LUMIZYME.xml:S1:15737:2	O
flu	LUMIZYME.xml:S1:15740:3	B-AdverseReaction
-	LUMIZYME.xml:S1:15743:1	I-AdverseReaction
like	LUMIZYME.xml:S1:15744:4	I-AdverseReaction
illness	LUMIZYME.xml:S1:15749:7	I-AdverseReaction
or	LUMIZYME.xml:S1:15757:2	O
a	LUMIZYME.xml:S1:15760:1	O
combination	LUMIZYME.xml:S1:15762:11	O
of	LUMIZYME.xml:S1:15774:2	O
events	LUMIZYME.xml:S1:15777:6	O
such	LUMIZYME.xml:S1:15784:4	O
as	LUMIZYME.xml:S1:15789:2	O
pyrexia	LUMIZYME.xml:S1:15792:7	B-AdverseReaction
,	LUMIZYME.xml:S1:15799:1	O
chills	LUMIZYME.xml:S1:15801:6	B-AdverseReaction
,	LUMIZYME.xml:S1:15807:1	O
myalgia	LUMIZYME.xml:S1:15809:7	B-AdverseReaction
,	LUMIZYME.xml:S1:15816:1	O
arthralgia	LUMIZYME.xml:S1:15818:10	B-AdverseReaction
,	LUMIZYME.xml:S1:15828:1	O
pain	LUMIZYME.xml:S1:15830:4	B-AdverseReaction
,	LUMIZYME.xml:S1:15834:1	O
or	LUMIZYME.xml:S1:15836:2	O
fatigue	LUMIZYME.xml:S1:15839:7	B-AdverseReaction
occurring	LUMIZYME.xml:S1:15847:9	O
after	LUMIZYME.xml:S1:15857:5	O
completion	LUMIZYME.xml:S1:15863:10	O
of	LUMIZYME.xml:S1:15874:2	O
infusions	LUMIZYME.xml:S1:15877:9	O
and	LUMIZYME.xml:S1:15887:3	O
lasting	LUMIZYME.xml:S1:15891:7	O
usually	LUMIZYME.xml:S1:15899:7	O
for	LUMIZYME.xml:S1:15907:3	O
1	LUMIZYME.xml:S1:15911:1	O
-	LUMIZYME.xml:S1:15913:1	O
3	LUMIZYME.xml:S1:15915:1	O
days	LUMIZYME.xml:S1:15917:4	O
have	LUMIZYME.xml:S1:15922:4	O
been	LUMIZYME.xml:S1:15927:4	O
observed	LUMIZYME.xml:S1:15932:8	O
in	LUMIZYME.xml:S1:15941:2	O
some	LUMIZYME.xml:S1:15944:4	O
patients	LUMIZYME.xml:S1:15949:8	O
treated	LUMIZYME.xml:S1:15958:7	O
with	LUMIZYME.xml:S1:15966:4	O
alglucosidase	LUMIZYME.xml:S1:15971:13	O
alfa	LUMIZYME.xml:S1:15985:4	O
.	LUMIZYME.xml:S1:15989:1	O

The	LUMIZYME.xml:S1:15991:3	O
majority	LUMIZYME.xml:S1:15995:8	O
of	LUMIZYME.xml:S1:16004:2	O
patients	LUMIZYME.xml:S1:16007:8	O
were	LUMIZYME.xml:S1:16016:4	O
able	LUMIZYME.xml:S1:16021:4	O
to	LUMIZYME.xml:S1:16026:2	O
be	LUMIZYME.xml:S1:16029:2	O
rechallenged	LUMIZYME.xml:S1:16032:12	O
with	LUMIZYME.xml:S1:16045:4	O
alglucosidase	LUMIZYME.xml:S1:16050:13	O
alfa	LUMIZYME.xml:S1:16064:4	O
using	LUMIZYME.xml:S1:16069:5	O
lower	LUMIZYME.xml:S1:16075:5	O
doses	LUMIZYME.xml:S1:16081:5	O
and	LUMIZYME.xml:S1:16087:3	O
or	LUMIZYME.xml:S1:16091:2	O
pretreatment	LUMIZYME.xml:S1:16094:12	O
with	LUMIZYME.xml:S1:16107:4	O
anti	LUMIZYME.xml:S1:16112:4	O
-	LUMIZYME.xml:S1:16116:1	O
inflammatory	LUMIZYME.xml:S1:16117:12	O
drugs	LUMIZYME.xml:S1:16130:5	O
and	LUMIZYME.xml:S1:16136:3	O
or	LUMIZYME.xml:S1:16140:2	O
corticosteroids	LUMIZYME.xml:S1:16143:15	O
and	LUMIZYME.xml:S1:16159:3	O
were	LUMIZYME.xml:S1:16163:4	O
able	LUMIZYME.xml:S1:16168:4	O
to	LUMIZYME.xml:S1:16173:2	O
continue	LUMIZYME.xml:S1:16176:8	O
treatment	LUMIZYME.xml:S1:16185:9	O
under	LUMIZYME.xml:S1:16195:5	O
close	LUMIZYME.xml:S1:16201:5	O
clinical	LUMIZYME.xml:S1:16207:8	O
supervision	LUMIZYME.xml:S1:16216:11	O
.	LUMIZYME.xml:S1:16227:1	O

In	LUMIZYME.xml:S1:16233:2	O
addition	LUMIZYME.xml:S1:16236:8	O
to	LUMIZYME.xml:S1:16245:2	O
the	LUMIZYME.xml:S1:16248:3	O
hypersensitivity	LUMIZYME.xml:S1:16252:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:16269:9	I-AdverseReaction
reported	LUMIZYME.xml:S1:16279:8	O
in	LUMIZYME.xml:S1:16288:2	O
clinical	LUMIZYME.xml:S1:16291:8	O
trials	LUMIZYME.xml:S1:16300:6	O
[	LUMIZYME.xml:S1:16308:1	O
seeAdverse	LUMIZYME.xml:S1:16309:10	O
Reactions	LUMIZYME.xml:S1:16320:9	O
(	LUMIZYME.xml:S1:16330:1	O
6.1	LUMIZYME.xml:S1:16331:3	O
)]	LUMIZYME.xml:S1:16334:2	O
,	LUMIZYME.xml:S1:16338:1	O
the	LUMIZYME.xml:S1:16340:3	O
following	LUMIZYME.xml:S1:16344:9	O
hypersensitivity	LUMIZYME.xml:S1:16354:16	B-AdverseReaction
reactions	LUMIZYME.xml:S1:16371:9	I-AdverseReaction
have	LUMIZYME.xml:S1:16381:4	O
been	LUMIZYME.xml:S1:16386:4	O
reported	LUMIZYME.xml:S1:16391:8	O
in	LUMIZYME.xml:S1:16400:2	O
at	LUMIZYME.xml:S1:16403:2	O
least	LUMIZYME.xml:S1:16406:5	O
2	LUMIZYME.xml:S1:16412:1	O
patients	LUMIZYME.xml:S1:16414:8	O
and	LUMIZYME.xml:S1:16423:3	O
included	LUMIZYME.xml:S1:16427:8	O
:	LUMIZYME.xml:S1:16435:1	O
anaphylactic	LUMIZYME.xml:S1:16437:12	B-AdverseReaction
shock	LUMIZYME.xml:S1:16450:5	I-AdverseReaction
,	LUMIZYME.xml:S1:16455:1	O
respiratory	LUMIZYME.xml:S1:16457:11	B-AdverseReaction
failure	LUMIZYME.xml:S1:16469:7	I-AdverseReaction
,	LUMIZYME.xml:S1:16476:1	O
respiratory	LUMIZYME.xml:S1:16478:11	B-AdverseReaction
arrest	LUMIZYME.xml:S1:16490:6	I-AdverseReaction
,	LUMIZYME.xml:S1:16496:1	O
cardiac	LUMIZYME.xml:S1:16498:7	B-AdverseReaction
arrest	LUMIZYME.xml:S1:16506:6	I-AdverseReaction
,	LUMIZYME.xml:S1:16512:1	O
hypoxia	LUMIZYME.xml:S1:16514:7	B-AdverseReaction
,	LUMIZYME.xml:S1:16521:1	O
dyspnea	LUMIZYME.xml:S1:16523:7	B-AdverseReaction
,	LUMIZYME.xml:S1:16530:1	O
wheezing	LUMIZYME.xml:S1:16532:8	B-AdverseReaction
,	LUMIZYME.xml:S1:16540:1	O
convulsions	LUMIZYME.xml:S1:16542:11	B-AdverseReaction
,	LUMIZYME.xml:S1:16553:1	O
peripheral	LUMIZYME.xml:S1:16555:10	B-AdverseReaction
coldness	LUMIZYME.xml:S1:16566:8	I-AdverseReaction
,	LUMIZYME.xml:S1:16574:1	O
restlessness	LUMIZYME.xml:S1:16576:12	B-AdverseReaction
,	LUMIZYME.xml:S1:16588:1	O
nervousness	LUMIZYME.xml:S1:16590:11	B-AdverseReaction
,	LUMIZYME.xml:S1:16601:1	O
back	LUMIZYME.xml:S1:16603:4	B-AdverseReaction
pain	LUMIZYME.xml:S1:16608:4	I-AdverseReaction
,	LUMIZYME.xml:S1:16612:1	O
stridor	LUMIZYME.xml:S1:16614:7	B-AdverseReaction
,	LUMIZYME.xml:S1:16621:1	O
pharyngeal	LUMIZYME.xml:S1:16623:10	B-AdverseReaction
edema	LUMIZYME.xml:S1:16634:5	I-AdverseReaction
,	LUMIZYME.xml:S1:16639:1	O
abdominal	LUMIZYME.xml:S1:16641:9	B-AdverseReaction
pain	LUMIZYME.xml:S1:16651:4	I-AdverseReaction
,	LUMIZYME.xml:S1:16655:1	O
apnea	LUMIZYME.xml:S1:16657:5	B-AdverseReaction
,	LUMIZYME.xml:S1:16662:1	O
muscle	LUMIZYME.xml:S1:16664:6	B-AdverseReaction
spasm	LUMIZYME.xml:S1:16671:5	I-AdverseReaction
,	LUMIZYME.xml:S1:16676:1	O
and	LUMIZYME.xml:S1:16678:3	O
conjunctivitis	LUMIZYME.xml:S1:16682:14	B-AdverseReaction
.	LUMIZYME.xml:S1:16696:1	O

In	LUMIZYME.xml:S1:16698:2	O
addition	LUMIZYME.xml:S1:16701:8	O
,	LUMIZYME.xml:S1:16709:1	O
one	LUMIZYME.xml:S1:16711:3	O
case	LUMIZYME.xml:S1:16715:4	O
of	LUMIZYME.xml:S1:16720:2	O
hyperparathyroidism	LUMIZYME.xml:S1:16723:19	B-AdverseReaction
has	LUMIZYME.xml:S1:16743:3	O
been	LUMIZYME.xml:S1:16747:4	O
reported	LUMIZYME.xml:S1:16752:8	O
.	LUMIZYME.xml:S1:16760:1	O

Systemic	LUMIZYME.xml:S1:16766:8	B-AdverseReaction
and	LUMIZYME.xml:S1:16775:3	O
cutaneous	LUMIZYME.xml:S1:16779:9	B-AdverseReaction
immune	LUMIZYME.xml:S1:16789:6	I-AdverseReaction
-	LUMIZYME.xml:S1:16795:1	I-AdverseReaction
mediated	LUMIZYME.xml:S1:16796:8	I-AdverseReaction
reactions	LUMIZYME.xml:S1:16805:9	I-AdverseReaction
,	LUMIZYME.xml:S1:16814:1	O
including	LUMIZYME.xml:S1:16816:9	O
proteinuria	LUMIZYME.xml:S1:16826:11	B-AdverseReaction
and	LUMIZYME.xml:S1:16838:3	O
nephrotic	LUMIZYME.xml:S1:16842:9	B-AdverseReaction
syndrome	LUMIZYME.xml:S1:16852:8	I-AdverseReaction
secondary	LUMIZYME.xml:S1:16861:9	O
to	LUMIZYME.xml:S1:16871:2	O
membranous	LUMIZYME.xml:S1:16874:10	B-AdverseReaction
glomerulonephritis	LUMIZYME.xml:S1:16885:18	I-AdverseReaction
,	LUMIZYME.xml:S1:16903:1	O
and	LUMIZYME.xml:S1:16905:3	O
necrotizing	LUMIZYME.xml:S1:16909:11	B-AdverseReaction
skin	LUMIZYME.xml:S1:16921:4	I-AdverseReaction
lesions	LUMIZYME.xml:S1:16926:7	I-AdverseReaction
have	LUMIZYME.xml:S1:16934:4	O
been	LUMIZYME.xml:S1:16939:4	O
reported	LUMIZYME.xml:S1:16944:8	O
in	LUMIZYME.xml:S1:16953:2	O
postmarketing	LUMIZYME.xml:S1:16956:13	O
safety	LUMIZYME.xml:S1:16970:6	O
experience	LUMIZYME.xml:S1:16977:10	O
with	LUMIZYME.xml:S1:16988:4	O
alglucosidase	LUMIZYME.xml:S1:16993:13	O
alfa	LUMIZYME.xml:S1:17007:4	O
[	LUMIZYME.xml:S1:17013:1	O
seeWarnings	LUMIZYME.xml:S1:17014:11	O
and	LUMIZYME.xml:S1:17026:3	O
Precautions	LUMIZYME.xml:S1:17030:11	O
(	LUMIZYME.xml:S1:17042:1	O
5.2	LUMIZYME.xml:S1:17043:3	O
)]	LUMIZYME.xml:S1:17046:2	O
.	LUMIZYME.xml:S1:17050:1	O
\n\n	LUMIZYME.xml:S2:0:2	O
BOXED	LUMIZYME.xml:S2:6:5	O
WARNING	LUMIZYME.xml:S2:12:7	O
:	LUMIZYME.xml:S2:19:1	O
WARNING	LUMIZYME.xml:S2:21:7	O
:	LUMIZYME.xml:S2:28:1	O
RISK	LUMIZYME.xml:S2:31:4	B-Factor
OF	LUMIZYME.xml:S2:36:2	O
ANAPHYLAXIS	LUMIZYME.xml:S2:39:11	B-AdverseReaction
,	LUMIZYME.xml:S2:50:1	O
HYPERSENSITIVITY	LUMIZYME.xml:S2:52:16	B-AdverseReaction
AND	LUMIZYME.xml:S2:69:3	O
IMMUNE	LUMIZYME.xml:S2:73:6	B-AdverseReaction
-	LUMIZYME.xml:S2:79:1	I-AdverseReaction
MEDIATED	LUMIZYME.xml:S2:80:8	I-AdverseReaction
REACTIONS	LUMIZYME.xml:S2:89:9	I-AdverseReaction
,	LUMIZYME.xml:S2:98:1	O
AND	LUMIZYME.xml:S2:100:3	O
RISK	LUMIZYME.xml:S2:104:4	B-Factor
OF	LUMIZYME.xml:S2:109:2	O
CARDIORESPIRATORY	LUMIZYME.xml:S2:112:17	B-AdverseReaction
FAILURE	LUMIZYME.xml:S2:130:7	I-AdverseReaction
\n\n	LUMIZYME.xml:S2:137:2	O
WARNING	LUMIZYME.xml:S2:143:7	O
:	LUMIZYME.xml:S2:150:1	O
RISK	LUMIZYME.xml:S2:153:4	B-Factor
OF	LUMIZYME.xml:S2:158:2	O
ANAPHYLAXIS	LUMIZYME.xml:S2:161:11	B-AdverseReaction
,	LUMIZYME.xml:S2:172:1	O
HYPERSENSITIVITY	LUMIZYME.xml:S2:174:16	B-AdverseReaction
AND	LUMIZYME.xml:S2:191:3	O
IMMUNE	LUMIZYME.xml:S2:195:6	B-AdverseReaction
-	LUMIZYME.xml:S2:201:1	I-AdverseReaction
MEDIATED	LUMIZYME.xml:S2:202:8	I-AdverseReaction
REACTIONS	LUMIZYME.xml:S2:211:9	I-AdverseReaction
,	LUMIZYME.xml:S2:220:1	O
AND	LUMIZYME.xml:S2:222:3	O
RISK	LUMIZYME.xml:S2:226:4	B-Factor
OF	LUMIZYME.xml:S2:231:2	O
CARDIORESPIRATORY	LUMIZYME.xml:S2:234:17	B-AdverseReaction
FAILURE	LUMIZYME.xml:S2:252:7	I-AdverseReaction
\n\n	LUMIZYME.xml:S2:261:2	O
Life	LUMIZYME.xml:S2:269:4	B-Severity
-	LUMIZYME.xml:S2:273:1	I-Severity
threatening	LUMIZYME.xml:S2:274:11	I-Severity
anaphylactic	LUMIZYME.xml:S2:286:12	B-AdverseReaction
reactions	LUMIZYME.xml:S2:299:9	I-AdverseReaction
and	LUMIZYME.xml:S2:309:3	O
severe	LUMIZYME.xml:S2:313:6	B-Severity
hypersensitivity	LUMIZYME.xml:S2:320:16	B-AdverseReaction
reactions	LUMIZYME.xml:S2:337:9	I-AdverseReaction
,	LUMIZYME.xml:S2:346:1	O
presenting	LUMIZYME.xml:S2:348:10	O
as	LUMIZYME.xml:S2:359:2	O
respiratory	LUMIZYME.xml:S2:362:11	B-AdverseReaction
distress	LUMIZYME.xml:S2:374:8	I-AdverseReaction
,	LUMIZYME.xml:S2:382:1	O
hypoxia	LUMIZYME.xml:S2:384:7	B-AdverseReaction
,	LUMIZYME.xml:S2:391:1	O
apnea	LUMIZYME.xml:S2:393:5	B-AdverseReaction
,	LUMIZYME.xml:S2:398:1	O
dyspnea	LUMIZYME.xml:S2:400:7	B-AdverseReaction
,	LUMIZYME.xml:S2:407:1	O
bradycardia	LUMIZYME.xml:S2:409:11	B-AdverseReaction
,	LUMIZYME.xml:S2:420:1	O
tachycardia	LUMIZYME.xml:S2:422:11	B-AdverseReaction
,	LUMIZYME.xml:S2:433:1	O
bronchospasm	LUMIZYME.xml:S2:435:12	B-AdverseReaction
,	LUMIZYME.xml:S2:447:1	O
throat	LUMIZYME.xml:S2:449:6	B-AdverseReaction
tightness	LUMIZYME.xml:S2:456:9	I-AdverseReaction
,	LUMIZYME.xml:S2:465:1	O
hypotension	LUMIZYME.xml:S2:467:11	B-AdverseReaction
,	LUMIZYME.xml:S2:478:1	O
angioedema	LUMIZYME.xml:S2:480:10	B-AdverseReaction
(	LUMIZYME.xml:S2:491:1	O
including	LUMIZYME.xml:S2:492:9	O
tongue	LUMIZYME.xml:S2:502:6	B-AdverseReaction
or	LUMIZYME.xml:S2:509:2	O
lip	LUMIZYME.xml:S2:512:3	B-AdverseReaction
swelling	LUMIZYME.xml:S2:516:8	I-AdverseReaction
,	LUMIZYME.xml:S2:524:1	O
periorbital	LUMIZYME.xml:S2:526:11	B-AdverseReaction
edema	LUMIZYME.xml:S2:538:5	I-AdverseReaction
,	LUMIZYME.xml:S2:543:1	O
and	LUMIZYME.xml:S2:545:3	O
face	LUMIZYME.xml:S2:549:4	B-AdverseReaction
edema	LUMIZYME.xml:S2:554:5	I-AdverseReaction
)	LUMIZYME.xml:S2:559:1	O
,	LUMIZYME.xml:S2:560:1	O
and	LUMIZYME.xml:S2:562:3	O
urticaria	LUMIZYME.xml:S2:566:9	B-AdverseReaction
,	LUMIZYME.xml:S2:575:1	O
have	LUMIZYME.xml:S2:577:4	O
occurred	LUMIZYME.xml:S2:582:8	O
in	LUMIZYME.xml:S2:591:2	O
some	LUMIZYME.xml:S2:594:4	O
patients	LUMIZYME.xml:S2:599:8	O
during	LUMIZYME.xml:S2:608:6	O
and	LUMIZYME.xml:S2:615:3	O
after	LUMIZYME.xml:S2:619:5	O
alglucosidase	LUMIZYME.xml:S2:625:13	O
alfa	LUMIZYME.xml:S2:639:4	O
infusions	LUMIZYME.xml:S2:644:9	O
.	LUMIZYME.xml:S2:653:1	O

Immune	LUMIZYME.xml:S2:656:6	B-AdverseReaction
-	LUMIZYME.xml:S2:662:1	I-AdverseReaction
mediated	LUMIZYME.xml:S2:663:8	I-AdverseReaction
reactions	LUMIZYME.xml:S2:672:9	I-AdverseReaction
presenting	LUMIZYME.xml:S2:682:10	O
as	LUMIZYME.xml:S2:693:2	O
proteinuria	LUMIZYME.xml:S2:696:11	B-AdverseReaction
,	LUMIZYME.xml:S2:707:1	O
nephrotic	LUMIZYME.xml:S2:709:9	B-AdverseReaction
syndrome	LUMIZYME.xml:S2:719:8	I-AdverseReaction
,	LUMIZYME.xml:S2:727:1	O
and	LUMIZYME.xml:S2:729:3	O
necrotizing	LUMIZYME.xml:S2:733:11	B-AdverseReaction
skin	LUMIZYME.xml:S2:745:4	I-AdverseReaction
lesions	LUMIZYME.xml:S2:750:7	I-AdverseReaction
have	LUMIZYME.xml:S2:758:4	O
occurred	LUMIZYME.xml:S2:763:8	O
in	LUMIZYME.xml:S2:772:2	O
some	LUMIZYME.xml:S2:775:4	O
patients	LUMIZYME.xml:S2:780:8	O
following	LUMIZYME.xml:S2:789:9	O
alglucosidase	LUMIZYME.xml:S2:799:13	O
alfa	LUMIZYME.xml:S2:813:4	O
treatment	LUMIZYME.xml:S2:818:9	O
.	LUMIZYME.xml:S2:827:1	O

Closely	LUMIZYME.xml:S2:830:7	O
observe	LUMIZYME.xml:S2:838:7	O
patients	LUMIZYME.xml:S2:846:8	O
during	LUMIZYME.xml:S2:855:6	O
and	LUMIZYME.xml:S2:862:3	O
after	LUMIZYME.xml:S2:866:5	O
alglucosidase	LUMIZYME.xml:S2:872:13	O
alfa	LUMIZYME.xml:S2:886:4	O
administration	LUMIZYME.xml:S2:891:14	O
and	LUMIZYME.xml:S2:906:3	O
be	LUMIZYME.xml:S2:910:2	O
prepared	LUMIZYME.xml:S2:913:8	O
to	LUMIZYME.xml:S2:922:2	O
manage	LUMIZYME.xml:S2:925:6	O
anaphylaxis	LUMIZYME.xml:S2:932:11	O
and	LUMIZYME.xml:S2:944:3	O
hypersensitivity	LUMIZYME.xml:S2:948:16	O
reactions	LUMIZYME.xml:S2:965:9	O
.	LUMIZYME.xml:S2:974:1	O

Inform	LUMIZYME.xml:S2:976:6	O
patients	LUMIZYME.xml:S2:983:8	O
of	LUMIZYME.xml:S2:992:2	O
the	LUMIZYME.xml:S2:995:3	O
signs	LUMIZYME.xml:S2:999:5	O
and	LUMIZYME.xml:S2:1005:3	O
symptoms	LUMIZYME.xml:S2:1009:8	O
of	LUMIZYME.xml:S2:1018:2	O
anaphylaxis	LUMIZYME.xml:S2:1021:11	O
,	LUMIZYME.xml:S2:1032:1	O
hypersensitivity	LUMIZYME.xml:S2:1034:16	O
reactions	LUMIZYME.xml:S2:1051:9	O
,	LUMIZYME.xml:S2:1060:1	O
and	LUMIZYME.xml:S2:1062:3	O
immune	LUMIZYME.xml:S2:1066:6	O
-	LUMIZYME.xml:S2:1072:1	O
mediated	LUMIZYME.xml:S2:1073:8	O
reactions	LUMIZYME.xml:S2:1082:9	O
and	LUMIZYME.xml:S2:1092:3	O
have	LUMIZYME.xml:S2:1096:4	O
them	LUMIZYME.xml:S2:1101:4	O
seek	LUMIZYME.xml:S2:1106:4	O
immediate	LUMIZYME.xml:S2:1111:9	O
medical	LUMIZYME.xml:S2:1121:7	O
care	LUMIZYME.xml:S2:1129:4	O
should	LUMIZYME.xml:S2:1134:6	O
signs	LUMIZYME.xml:S2:1141:5	O
and	LUMIZYME.xml:S2:1147:3	O
symptoms	LUMIZYME.xml:S2:1151:8	O
occur	LUMIZYME.xml:S2:1160:5	O
[	LUMIZYME.xml:S2:1168:1	O
see	LUMIZYME.xml:S2:1169:3	O
Warnings	LUMIZYME.xml:S2:1173:8	O
and	LUMIZYME.xml:S2:1182:3	O
Precautions	LUMIZYME.xml:S2:1186:11	O
(	LUMIZYME.xml:S2:1198:1	O
5.1	LUMIZYME.xml:S2:1199:3	O
,	LUMIZYME.xml:S2:1202:1	O
5.2	LUMIZYME.xml:S2:1204:3	O
)]	LUMIZYME.xml:S2:1207:2	O
.	LUMIZYME.xml:S2:1211:1	O

Infantile	LUMIZYME.xml:S2:1225:9	O
-	LUMIZYME.xml:S2:1234:1	O
onset	LUMIZYME.xml:S2:1235:5	O
Pompe	LUMIZYME.xml:S2:1241:5	O
disease	LUMIZYME.xml:S2:1247:7	O
patients	LUMIZYME.xml:S2:1255:8	O
with	LUMIZYME.xml:S2:1264:4	O
compromised	LUMIZYME.xml:S2:1269:11	O
cardiac	LUMIZYME.xml:S2:1281:7	O
or	LUMIZYME.xml:S2:1289:2	O
respiratory	LUMIZYME.xml:S2:1292:11	O
function	LUMIZYME.xml:S2:1304:8	O
may	LUMIZYME.xml:S2:1313:3	B-Factor
be	LUMIZYME.xml:S2:1317:2	O
at	LUMIZYME.xml:S2:1320:2	O
risk	LUMIZYME.xml:S2:1323:4	O
of	LUMIZYME.xml:S2:1328:2	O
serious	LUMIZYME.xml:S2:1331:7	B-Severity
acute	LUMIZYME.xml:S2:1339:5	B-AdverseReaction
exacerbation	LUMIZYME.xml:S2:1345:12	I-AdverseReaction
of	LUMIZYME.xml:S2:1358:2	I-AdverseReaction
their	LUMIZYME.xml:S2:1361:5	O
cardiac	LUMIZYME.xml:S2:1367:7	I-AdverseReaction
or	LUMIZYME.xml:S2:1375:2	O
respiratory	LUMIZYME.xml:S2:1378:11	I-AdverseReaction
compromise	LUMIZYME.xml:S2:1390:10	I-AdverseReaction
due	LUMIZYME.xml:S2:1401:3	O
to	LUMIZYME.xml:S2:1405:2	O
fluid	LUMIZYME.xml:S2:1408:5	B-AdverseReaction
overload	LUMIZYME.xml:S2:1414:8	I-AdverseReaction
,	LUMIZYME.xml:S2:1422:1	O
and	LUMIZYME.xml:S2:1424:3	O
require	LUMIZYME.xml:S2:1428:7	O
additional	LUMIZYME.xml:S2:1436:10	O
monitoring	LUMIZYME.xml:S2:1447:10	O
[	LUMIZYME.xml:S2:1460:1	O
see	LUMIZYME.xml:S2:1461:3	O
Warnings	LUMIZYME.xml:S2:1465:8	O
and	LUMIZYME.xml:S2:1474:3	O
Precautions	LUMIZYME.xml:S2:1478:11	O
(	LUMIZYME.xml:S2:1490:1	O
5.3	LUMIZYME.xml:S2:1491:3	O
)]	LUMIZYME.xml:S2:1494:2	O
.	LUMIZYME.xml:S2:1498:1	O

WARNING	LUMIZYME.xml:S2:1510:7	O
:	LUMIZYME.xml:S2:1517:1	O
RISK	LUMIZYME.xml:S2:1520:4	B-Factor
OF	LUMIZYME.xml:S2:1525:2	O
ANAPHYLAXIS	LUMIZYME.xml:S2:1528:11	B-AdverseReaction
,	LUMIZYME.xml:S2:1539:1	O
HYPERSENSITIVITY	LUMIZYME.xml:S2:1541:16	B-AdverseReaction
AND	LUMIZYME.xml:S2:1558:3	O
IMMUNE	LUMIZYME.xml:S2:1562:6	B-AdverseReaction
-	LUMIZYME.xml:S2:1568:1	I-AdverseReaction
MEDIATED	LUMIZYME.xml:S2:1569:8	I-AdverseReaction
REACTIONS	LUMIZYME.xml:S2:1578:9	I-AdverseReaction
,	LUMIZYME.xml:S2:1587:1	O
and	LUMIZYME.xml:S2:1589:3	O
RISK	LUMIZYME.xml:S2:1593:4	B-Factor
OF	LUMIZYME.xml:S2:1598:2	O
CARDIORESPIRATORY	LUMIZYME.xml:S2:1601:17	B-AdverseReaction
FAILURE	LUMIZYME.xml:S2:1619:7	I-AdverseReaction
\n\n\n\n	LUMIZYME.xml:S2:1626:4	O
See	LUMIZYME.xml:S2:1633:3	O
full	LUMIZYME.xml:S2:1637:4	O
prescribing	LUMIZYME.xml:S2:1642:11	O
information	LUMIZYME.xml:S2:1654:11	O
for	LUMIZYME.xml:S2:1666:3	O
complete	LUMIZYME.xml:S2:1670:8	O
boxed	LUMIZYME.xml:S2:1679:5	O
warning	LUMIZYME.xml:S2:1685:7	O
.	LUMIZYME.xml:S2:1692:1	O

Life	LUMIZYME.xml:S2:1703:4	B-Severity
-	LUMIZYME.xml:S2:1707:1	I-Severity
threatening	LUMIZYME.xml:S2:1708:11	I-Severity
anaphylactic	LUMIZYME.xml:S2:1720:12	B-AdverseReaction
reactions	LUMIZYME.xml:S2:1733:9	I-AdverseReaction
and	LUMIZYME.xml:S2:1743:3	O
severe	LUMIZYME.xml:S2:1747:6	B-Severity
hypersensitivity	LUMIZYME.xml:S2:1754:16	B-AdverseReaction
reactions	LUMIZYME.xml:S2:1771:9	I-AdverseReaction
have	LUMIZYME.xml:S2:1781:4	O
occurred	LUMIZYME.xml:S2:1786:8	O
in	LUMIZYME.xml:S2:1795:2	O
some	LUMIZYME.xml:S2:1798:4	O
patients	LUMIZYME.xml:S2:1803:8	O
during	LUMIZYME.xml:S2:1812:6	O
and	LUMIZYME.xml:S2:1819:3	O
after	LUMIZYME.xml:S2:1823:5	O
alglucosidase	LUMIZYME.xml:S2:1829:13	O
alfa	LUMIZYME.xml:S2:1843:4	O
infusions	LUMIZYME.xml:S2:1848:9	O
.	LUMIZYME.xml:S2:1857:1	O

Immune	LUMIZYME.xml:S2:1859:6	B-AdverseReaction
-	LUMIZYME.xml:S2:1865:1	I-AdverseReaction
mediated	LUMIZYME.xml:S2:1866:8	I-AdverseReaction
reactions	LUMIZYME.xml:S2:1875:9	I-AdverseReaction
presenting	LUMIZYME.xml:S2:1885:10	O
as	LUMIZYME.xml:S2:1896:2	O
proteinuria	LUMIZYME.xml:S2:1899:11	B-AdverseReaction
,	LUMIZYME.xml:S2:1910:1	O
nephrotic	LUMIZYME.xml:S2:1912:9	B-AdverseReaction
syndrome	LUMIZYME.xml:S2:1922:8	I-AdverseReaction
,	LUMIZYME.xml:S2:1930:1	O
and	LUMIZYME.xml:S2:1932:3	O
necrotizing	LUMIZYME.xml:S2:1936:11	B-AdverseReaction
skin	LUMIZYME.xml:S2:1948:4	I-AdverseReaction
lesions	LUMIZYME.xml:S2:1953:7	I-AdverseReaction
have	LUMIZYME.xml:S2:1961:4	O
occurred	LUMIZYME.xml:S2:1966:8	O
in	LUMIZYME.xml:S2:1975:2	O
some	LUMIZYME.xml:S2:1978:4	O
patients	LUMIZYME.xml:S2:1983:8	O
following	LUMIZYME.xml:S2:1992:9	O
alglucosidase	LUMIZYME.xml:S2:2002:13	O
alfa	LUMIZYME.xml:S2:2016:4	O
treatment	LUMIZYME.xml:S2:2021:9	O
.	LUMIZYME.xml:S2:2030:1	O

Closely	LUMIZYME.xml:S2:2032:7	O
observe	LUMIZYME.xml:S2:2040:7	O
patients	LUMIZYME.xml:S2:2048:8	O
during	LUMIZYME.xml:S2:2057:6	O
and	LUMIZYME.xml:S2:2064:3	O
after	LUMIZYME.xml:S2:2068:5	O
alglucosidase	LUMIZYME.xml:S2:2074:13	O
alfa	LUMIZYME.xml:S2:2088:4	O
administration	LUMIZYME.xml:S2:2093:14	O
and	LUMIZYME.xml:S2:2108:3	O
be	LUMIZYME.xml:S2:2112:2	O
prepared	LUMIZYME.xml:S2:2115:8	O
to	LUMIZYME.xml:S2:2124:2	O
manage	LUMIZYME.xml:S2:2127:6	O
anaphylaxis	LUMIZYME.xml:S2:2134:11	O
and	LUMIZYME.xml:S2:2146:3	O
hypersensitivity	LUMIZYME.xml:S2:2150:16	O
reactions	LUMIZYME.xml:S2:2167:9	O
.	LUMIZYME.xml:S2:2176:1	O

Inform	LUMIZYME.xml:S2:2178:6	O
patients	LUMIZYME.xml:S2:2185:8	O
of	LUMIZYME.xml:S2:2194:2	O
the	LUMIZYME.xml:S2:2197:3	O
signs	LUMIZYME.xml:S2:2201:5	O
and	LUMIZYME.xml:S2:2207:3	O
symptoms	LUMIZYME.xml:S2:2211:8	O
of	LUMIZYME.xml:S2:2220:2	O
anaphylaxis	LUMIZYME.xml:S2:2223:11	O
,	LUMIZYME.xml:S2:2234:1	O
hypersensitivity	LUMIZYME.xml:S2:2236:16	O
reactions	LUMIZYME.xml:S2:2253:9	O
,	LUMIZYME.xml:S2:2262:1	O
and	LUMIZYME.xml:S2:2264:3	O
immune	LUMIZYME.xml:S2:2268:6	O
-	LUMIZYME.xml:S2:2274:1	O
mediated	LUMIZYME.xml:S2:2275:8	O
reactions	LUMIZYME.xml:S2:2284:9	O
and	LUMIZYME.xml:S2:2294:3	O
have	LUMIZYME.xml:S2:2298:4	O
them	LUMIZYME.xml:S2:2303:4	O
seek	LUMIZYME.xml:S2:2308:4	O
immediate	LUMIZYME.xml:S2:2313:9	O
medical	LUMIZYME.xml:S2:2323:7	O
care	LUMIZYME.xml:S2:2331:4	O
should	LUMIZYME.xml:S2:2336:6	O
signs	LUMIZYME.xml:S2:2343:5	O
and	LUMIZYME.xml:S2:2349:3	O
symptoms	LUMIZYME.xml:S2:2353:8	O
occur	LUMIZYME.xml:S2:2362:5	O
(	LUMIZYME.xml:S2:2368:1	O
5.1	LUMIZYME.xml:S2:2369:3	O
,	LUMIZYME.xml:S2:2372:1	O
5.2	LUMIZYME.xml:S2:2374:3	O
)	LUMIZYME.xml:S2:2377:1	O
.	LUMIZYME.xml:S2:2378:1	O

Infantile	LUMIZYME.xml:S2:2385:9	O
-	LUMIZYME.xml:S2:2394:1	O
onset	LUMIZYME.xml:S2:2395:5	O
Pompe	LUMIZYME.xml:S2:2401:5	O
disease	LUMIZYME.xml:S2:2407:7	O
patients	LUMIZYME.xml:S2:2415:8	O
with	LUMIZYME.xml:S2:2424:4	O
compromised	LUMIZYME.xml:S2:2429:11	O
cardiac	LUMIZYME.xml:S2:2441:7	O
or	LUMIZYME.xml:S2:2449:2	O
respiratory	LUMIZYME.xml:S2:2452:11	O
function	LUMIZYME.xml:S2:2464:8	O
may	LUMIZYME.xml:S2:2473:3	B-Factor
be	LUMIZYME.xml:S2:2477:2	O
at	LUMIZYME.xml:S2:2480:2	O
risk	LUMIZYME.xml:S2:2483:4	O
of	LUMIZYME.xml:S2:2488:2	O
serious	LUMIZYME.xml:S2:2491:7	B-Severity
acute	LUMIZYME.xml:S2:2499:5	B-AdverseReaction
exacerbation	LUMIZYME.xml:S2:2505:12	I-AdverseReaction
of	LUMIZYME.xml:S2:2518:2	I-AdverseReaction
their	LUMIZYME.xml:S2:2521:5	O
cardiac	LUMIZYME.xml:S2:2527:7	I-AdverseReaction
or	LUMIZYME.xml:S2:2535:2	O
respiratory	LUMIZYME.xml:S2:2538:11	I-AdverseReaction
compromise	LUMIZYME.xml:S2:2550:10	I-AdverseReaction
due	LUMIZYME.xml:S2:2561:3	O
to	LUMIZYME.xml:S2:2565:2	O
fluid	LUMIZYME.xml:S2:2568:5	B-AdverseReaction
overload	LUMIZYME.xml:S2:2574:8	I-AdverseReaction
,	LUMIZYME.xml:S2:2582:1	O
and	LUMIZYME.xml:S2:2584:3	O
require	LUMIZYME.xml:S2:2588:7	O
additional	LUMIZYME.xml:S2:2596:10	O
monitoring	LUMIZYME.xml:S2:2607:10	O
(	LUMIZYME.xml:S2:2618:1	O
5.3	LUMIZYME.xml:S2:2619:3	O
)	LUMIZYME.xml:S2:2622:1	O
.	LUMIZYME.xml:S2:2623:1	O
\n	LUMIZYME.xml:S2:2625:1	O
5	LUMIZYME.xml:S3:4:1	O
WARNINGS	LUMIZYME.xml:S3:6:8	O
AND	LUMIZYME.xml:S3:15:3	O
PRECAUTIONS	LUMIZYME.xml:S3:19:11	O

EXCERPT	LUMIZYME.xml:S3:35:7	O
:	LUMIZYME.xml:S3:42:1	O
Anaphylaxis	LUMIZYME.xml:S3:51:11	B-AdverseReaction
and	LUMIZYME.xml:S3:63:3	O
Hypersensitivity	LUMIZYME.xml:S3:67:16	B-AdverseReaction
Reactions	LUMIZYME.xml:S3:84:9	I-AdverseReaction
:	LUMIZYME.xml:S3:93:1	O
Life	LUMIZYME.xml:S3:95:4	B-Severity
-	LUMIZYME.xml:S3:99:1	I-Severity
threatening	LUMIZYME.xml:S3:100:11	I-Severity
anaphylaxis	LUMIZYME.xml:S3:112:11	B-AdverseReaction
and	LUMIZYME.xml:S3:124:3	O
hypersensitivity	LUMIZYME.xml:S3:128:16	B-AdverseReaction
reactions	LUMIZYME.xml:S3:145:9	I-AdverseReaction
have	LUMIZYME.xml:S3:155:4	O
been	LUMIZYME.xml:S3:160:4	O
observed	LUMIZYME.xml:S3:165:8	O
in	LUMIZYME.xml:S3:174:2	O
some	LUMIZYME.xml:S3:177:4	O
patients	LUMIZYME.xml:S3:182:8	O
during	LUMIZYME.xml:S3:191:6	O
and	LUMIZYME.xml:S3:198:3	O
after	LUMIZYME.xml:S3:202:5	O
treatment	LUMIZYME.xml:S3:208:9	O
with	LUMIZYME.xml:S3:218:4	O
alglucosidase	LUMIZYME.xml:S3:223:13	O
alfa	LUMIZYME.xml:S3:237:4	O
.	LUMIZYME.xml:S3:241:1	O

Ensure	LUMIZYME.xml:S3:243:6	O
that	LUMIZYME.xml:S3:250:4	O
appropriate	LUMIZYME.xml:S3:255:11	O
medical	LUMIZYME.xml:S3:267:7	O
support	LUMIZYME.xml:S3:275:7	O
measures	LUMIZYME.xml:S3:283:8	O
,	LUMIZYME.xml:S3:291:1	O
including	LUMIZYME.xml:S3:293:9	O
cardiopulmonary	LUMIZYME.xml:S3:303:15	O
resuscitation	LUMIZYME.xml:S3:319:13	O
equipment	LUMIZYME.xml:S3:333:9	O
,	LUMIZYME.xml:S3:342:1	O
are	LUMIZYME.xml:S3:344:3	O
readily	LUMIZYME.xml:S3:348:7	O
available	LUMIZYME.xml:S3:356:9	O
.	LUMIZYME.xml:S3:365:1	O

If	LUMIZYME.xml:S3:367:2	O
anaphylaxis	LUMIZYME.xml:S3:370:11	O
or	LUMIZYME.xml:S3:382:2	O
severe	LUMIZYME.xml:S3:385:6	O
hypersensitivity	LUMIZYME.xml:S3:392:16	O
reactions	LUMIZYME.xml:S3:409:9	O
occur	LUMIZYME.xml:S3:419:5	O
,	LUMIZYME.xml:S3:424:1	O
immediately	LUMIZYME.xml:S3:426:11	O
discontinue	LUMIZYME.xml:S3:438:11	O
infusion	LUMIZYME.xml:S3:450:8	O
and	LUMIZYME.xml:S3:459:3	O
initiate	LUMIZYME.xml:S3:463:8	O
appropriate	LUMIZYME.xml:S3:472:11	O
medical	LUMIZYME.xml:S3:484:7	O
treatment	LUMIZYME.xml:S3:492:9	O
(	LUMIZYME.xml:S3:502:1	O
5.1	LUMIZYME.xml:S3:503:3	O
)	LUMIZYME.xml:S3:506:1	O
.	LUMIZYME.xml:S3:507:1	O

Immune	LUMIZYME.xml:S3:515:6	B-AdverseReaction
-	LUMIZYME.xml:S3:521:1	I-AdverseReaction
Mediated	LUMIZYME.xml:S3:522:8	I-AdverseReaction
Reactions	LUMIZYME.xml:S3:531:9	I-AdverseReaction
:	LUMIZYME.xml:S3:540:1	O
Monitor	LUMIZYME.xml:S3:542:7	O
patients	LUMIZYME.xml:S3:550:8	O
for	LUMIZYME.xml:S3:559:3	O
the	LUMIZYME.xml:S3:563:3	O
development	LUMIZYME.xml:S3:567:11	O
of	LUMIZYME.xml:S3:579:2	O
systemic	LUMIZYME.xml:S3:582:8	O
immune	LUMIZYME.xml:S3:591:6	O
-	LUMIZYME.xml:S3:597:1	O
mediated	LUMIZYME.xml:S3:598:8	O
reactions	LUMIZYME.xml:S3:607:9	O
involving	LUMIZYME.xml:S3:617:9	O
skin	LUMIZYME.xml:S3:627:4	O
and	LUMIZYME.xml:S3:632:3	O
other	LUMIZYME.xml:S3:636:5	O
organs	LUMIZYME.xml:S3:642:6	O
(	LUMIZYME.xml:S3:649:1	O
5.2	LUMIZYME.xml:S3:650:3	O
)	LUMIZYME.xml:S3:653:1	O
.	LUMIZYME.xml:S3:654:1	O

Risk	LUMIZYME.xml:S3:662:4	B-Factor
of	LUMIZYME.xml:S3:667:2	O
Acute	LUMIZYME.xml:S3:670:5	B-AdverseReaction
Cardiorespiratory	LUMIZYME.xml:S3:676:17	I-AdverseReaction
Failure	LUMIZYME.xml:S3:694:7	I-AdverseReaction
:	LUMIZYME.xml:S3:701:1	O
Patients	LUMIZYME.xml:S3:703:8	O
with	LUMIZYME.xml:S3:712:4	O
compromised	LUMIZYME.xml:S3:717:11	O
cardiac	LUMIZYME.xml:S3:729:7	O
or	LUMIZYME.xml:S3:737:2	O
respiratory	LUMIZYME.xml:S3:740:11	O
function	LUMIZYME.xml:S3:752:8	O
may	LUMIZYME.xml:S3:761:3	B-Factor
be	LUMIZYME.xml:S3:765:2	O
at	LUMIZYME.xml:S3:768:2	O
risk	LUMIZYME.xml:S3:771:4	O
of	LUMIZYME.xml:S3:776:2	O
acute	LUMIZYME.xml:S3:779:5	B-AdverseReaction
cardiorespiratory	LUMIZYME.xml:S3:785:17	I-AdverseReaction
failure	LUMIZYME.xml:S3:803:7	I-AdverseReaction
.	LUMIZYME.xml:S3:810:1	O

Caution	LUMIZYME.xml:S3:812:7	O
should	LUMIZYME.xml:S3:820:6	O
be	LUMIZYME.xml:S3:827:2	O
exercised	LUMIZYME.xml:S3:830:9	O
when	LUMIZYME.xml:S3:840:4	O
administering	LUMIZYME.xml:S3:845:13	O
alglucosidase	LUMIZYME.xml:S3:859:13	O
alfa	LUMIZYME.xml:S3:873:4	O
to	LUMIZYME.xml:S3:878:2	O
patients	LUMIZYME.xml:S3:881:8	O
susceptible	LUMIZYME.xml:S3:890:11	O
to	LUMIZYME.xml:S3:902:2	O
fluid	LUMIZYME.xml:S3:905:5	O
volume	LUMIZYME.xml:S3:911:6	O
overload	LUMIZYME.xml:S3:918:8	O
.	LUMIZYME.xml:S3:926:1	O

Appropriate	LUMIZYME.xml:S3:928:11	O
medical	LUMIZYME.xml:S3:940:7	O
support	LUMIZYME.xml:S3:948:7	O
and	LUMIZYME.xml:S3:956:3	O
monitoring	LUMIZYME.xml:S3:960:10	O
measures	LUMIZYME.xml:S3:971:8	O
should	LUMIZYME.xml:S3:980:6	O
be	LUMIZYME.xml:S3:987:2	O
available	LUMIZYME.xml:S3:990:9	O
during	LUMIZYME.xml:S3:1000:6	O
infusion	LUMIZYME.xml:S3:1007:8	O
(	LUMIZYME.xml:S3:1016:1	O
5.3	LUMIZYME.xml:S3:1017:3	O
)	LUMIZYME.xml:S3:1020:1	O
.	LUMIZYME.xml:S3:1021:1	O

Risk	LUMIZYME.xml:S3:1029:4	B-Factor
of	LUMIZYME.xml:S3:1034:2	O
Cardiac	LUMIZYME.xml:S3:1037:7	B-AdverseReaction
Arrhythmia	LUMIZYME.xml:S3:1045:10	I-AdverseReaction
and	LUMIZYME.xml:S3:1056:3	O
Sudden	LUMIZYME.xml:S3:1060:6	B-AdverseReaction
Cardiac	LUMIZYME.xml:S3:1067:7	I-AdverseReaction
Death	LUMIZYME.xml:S3:1075:5	I-AdverseReaction
during	LUMIZYME.xml:S3:1081:6	O
General	LUMIZYME.xml:S3:1088:7	O
Anesthesia	LUMIZYME.xml:S3:1096:10	O
for	LUMIZYME.xml:S3:1107:3	O
Central	LUMIZYME.xml:S3:1111:7	O
Venous	LUMIZYME.xml:S3:1119:6	O
Catheter	LUMIZYME.xml:S3:1126:8	O
Placement	LUMIZYME.xml:S3:1135:9	O
:	LUMIZYME.xml:S3:1144:1	O
Caution	LUMIZYME.xml:S3:1146:7	O
should	LUMIZYME.xml:S3:1154:6	O
be	LUMIZYME.xml:S3:1161:2	O
used	LUMIZYME.xml:S3:1164:4	O
when	LUMIZYME.xml:S3:1169:4	O
administering	LUMIZYME.xml:S3:1174:13	O
general	LUMIZYME.xml:S3:1188:7	O
anesthesia	LUMIZYME.xml:S3:1196:10	O
for	LUMIZYME.xml:S3:1207:3	O
the	LUMIZYME.xml:S3:1211:3	O
placement	LUMIZYME.xml:S3:1215:9	O
of	LUMIZYME.xml:S3:1225:2	O
a	LUMIZYME.xml:S3:1228:1	O
central	LUMIZYME.xml:S3:1230:7	O
venous	LUMIZYME.xml:S3:1238:6	O
catheter	LUMIZYME.xml:S3:1245:8	O
intended	LUMIZYME.xml:S3:1254:8	O
for	LUMIZYME.xml:S3:1263:3	O
alglucosidase	LUMIZYME.xml:S3:1267:13	O
alfa	LUMIZYME.xml:S3:1281:4	O
infusion	LUMIZYME.xml:S3:1286:8	O
(	LUMIZYME.xml:S3:1295:1	O
5.4	LUMIZYME.xml:S3:1296:3	O
)	LUMIZYME.xml:S3:1299:1	O
.	LUMIZYME.xml:S3:1300:1	O

5.1	LUMIZYME.xml:S3:1311:3	O

Anaphylaxis	LUMIZYME.xml:S3:1315:11	O
and	LUMIZYME.xml:S3:1327:3	O
Hypersensitivity	LUMIZYME.xml:S3:1331:16	O
Reactions	LUMIZYME.xml:S3:1348:9	O

Anaphylaxis	LUMIZYME.xml:S3:1363:11	B-AdverseReaction
and	LUMIZYME.xml:S3:1375:3	O
hypersensitivity	LUMIZYME.xml:S3:1379:16	B-AdverseReaction
reactions	LUMIZYME.xml:S3:1396:9	I-AdverseReaction
have	LUMIZYME.xml:S3:1406:4	O
been	LUMIZYME.xml:S3:1411:4	O
observed	LUMIZYME.xml:S3:1416:8	O
in	LUMIZYME.xml:S3:1425:2	O
patients	LUMIZYME.xml:S3:1428:8	O
during	LUMIZYME.xml:S3:1437:6	O
and	LUMIZYME.xml:S3:1444:3	O
up	LUMIZYME.xml:S3:1448:2	O
to	LUMIZYME.xml:S3:1451:2	O
3	LUMIZYME.xml:S3:1454:1	O
hours	LUMIZYME.xml:S3:1456:5	O
after	LUMIZYME.xml:S3:1462:5	O
alglucosidase	LUMIZYME.xml:S3:1468:13	O
alfa	LUMIZYME.xml:S3:1482:4	O
infusion	LUMIZYME.xml:S3:1487:8	O
.	LUMIZYME.xml:S3:1495:1	O

Some	LUMIZYME.xml:S3:1497:4	O
of	LUMIZYME.xml:S3:1502:2	O
the	LUMIZYME.xml:S3:1505:3	O
reactions	LUMIZYME.xml:S3:1509:9	O
were	LUMIZYME.xml:S3:1519:4	O
life	LUMIZYME.xml:S3:1524:4	B-Severity
-	LUMIZYME.xml:S3:1528:1	I-Severity
threatening	LUMIZYME.xml:S3:1529:11	I-Severity
and	LUMIZYME.xml:S3:1541:3	O
included	LUMIZYME.xml:S3:1545:8	O
anaphylactic	LUMIZYME.xml:S3:1554:12	B-AdverseReaction
shock	LUMIZYME.xml:S3:1567:5	I-AdverseReaction
,	LUMIZYME.xml:S3:1572:1	O
cardiac	LUMIZYME.xml:S3:1574:7	B-AdverseReaction
arrest	LUMIZYME.xml:S3:1582:6	I-AdverseReaction
,	LUMIZYME.xml:S3:1588:1	O
respiratory	LUMIZYME.xml:S3:1590:11	B-AdverseReaction
arrest	LUMIZYME.xml:S3:1602:6	I-AdverseReaction
,	LUMIZYME.xml:S3:1608:1	O
respiratory	LUMIZYME.xml:S3:1610:11	B-AdverseReaction
distress	LUMIZYME.xml:S3:1622:8	I-AdverseReaction
,	LUMIZYME.xml:S3:1630:1	O
hypoxia	LUMIZYME.xml:S3:1632:7	B-AdverseReaction
,	LUMIZYME.xml:S3:1639:1	O
apnea	LUMIZYME.xml:S3:1641:5	B-AdverseReaction
,	LUMIZYME.xml:S3:1646:1	O
dyspnea	LUMIZYME.xml:S3:1648:7	B-AdverseReaction
,	LUMIZYME.xml:S3:1655:1	O
bradycardia	LUMIZYME.xml:S3:1657:11	B-AdverseReaction
,	LUMIZYME.xml:S3:1668:1	O
tachycardia	LUMIZYME.xml:S3:1670:11	B-AdverseReaction
,	LUMIZYME.xml:S3:1681:1	O
bronchospasm	LUMIZYME.xml:S3:1683:12	B-AdverseReaction
,	LUMIZYME.xml:S3:1695:1	O
throat	LUMIZYME.xml:S3:1697:6	B-AdverseReaction
tightness	LUMIZYME.xml:S3:1704:9	I-AdverseReaction
,	LUMIZYME.xml:S3:1713:1	O
hypotension	LUMIZYME.xml:S3:1715:11	B-AdverseReaction
,	LUMIZYME.xml:S3:1726:1	O
angioedema	LUMIZYME.xml:S3:1728:10	B-AdverseReaction
(	LUMIZYME.xml:S3:1739:1	O
including	LUMIZYME.xml:S3:1740:9	O
tongue	LUMIZYME.xml:S3:1750:6	B-AdverseReaction
or	LUMIZYME.xml:S3:1757:2	O
lip	LUMIZYME.xml:S3:1760:3	B-AdverseReaction
swelling	LUMIZYME.xml:S3:1764:8	I-AdverseReaction
,	LUMIZYME.xml:S3:1772:1	O
periorbital	LUMIZYME.xml:S3:1774:11	B-AdverseReaction
edema	LUMIZYME.xml:S3:1786:5	I-AdverseReaction
,	LUMIZYME.xml:S3:1791:1	O
and	LUMIZYME.xml:S3:1793:3	O
face	LUMIZYME.xml:S3:1797:4	B-AdverseReaction
edema	LUMIZYME.xml:S3:1802:5	I-AdverseReaction
)	LUMIZYME.xml:S3:1807:1	O
,	LUMIZYME.xml:S3:1808:1	O
and	LUMIZYME.xml:S3:1810:3	O
urticaria	LUMIZYME.xml:S3:1814:9	B-AdverseReaction
.	LUMIZYME.xml:S3:1823:1	O

Other	LUMIZYME.xml:S3:1825:5	O
accompanying	LUMIZYME.xml:S3:1831:12	O
reactions	LUMIZYME.xml:S3:1844:9	O
included	LUMIZYME.xml:S3:1854:8	O
chest	LUMIZYME.xml:S3:1863:5	B-AdverseReaction
discomfort	LUMIZYME.xml:S3:1869:10	I-AdverseReaction
pain	LUMIZYME.xml:S3:1880:4	I-AdverseReaction
,	LUMIZYME.xml:S3:1884:1	O
wheezing	LUMIZYME.xml:S3:1886:8	B-AdverseReaction
,	LUMIZYME.xml:S3:1894:1	O
tachypnea	LUMIZYME.xml:S3:1896:9	B-AdverseReaction
,	LUMIZYME.xml:S3:1905:1	O
cyanosis	LUMIZYME.xml:S3:1907:8	B-AdverseReaction
,	LUMIZYME.xml:S3:1915:1	O
decreased	LUMIZYME.xml:S3:1917:9	B-AdverseReaction
oxygen	LUMIZYME.xml:S3:1927:6	I-AdverseReaction
saturation	LUMIZYME.xml:S3:1934:10	I-AdverseReaction
,	LUMIZYME.xml:S3:1944:1	O
convulsions	LUMIZYME.xml:S3:1946:11	B-AdverseReaction
,	LUMIZYME.xml:S3:1957:1	O
pruritus	LUMIZYME.xml:S3:1959:8	B-AdverseReaction
,	LUMIZYME.xml:S3:1967:1	O
rash	LUMIZYME.xml:S3:1969:4	B-AdverseReaction
,	LUMIZYME.xml:S3:1973:1	O
hyperhidrosis	LUMIZYME.xml:S3:1975:13	B-AdverseReaction
,	LUMIZYME.xml:S3:1988:1	O
nausea	LUMIZYME.xml:S3:1990:6	B-AdverseReaction
,	LUMIZYME.xml:S3:1996:1	O
dizziness	LUMIZYME.xml:S3:1998:9	B-AdverseReaction
,	LUMIZYME.xml:S3:2007:1	O
hypertension	LUMIZYME.xml:S3:2009:12	B-AdverseReaction
increased	LUMIZYME.xml:S3:2022:9	B-AdverseReaction
blood	LUMIZYME.xml:S3:2032:5	I-AdverseReaction
pressure	LUMIZYME.xml:S3:2038:8	I-AdverseReaction
,	LUMIZYME.xml:S3:2046:1	O
flushing	LUMIZYME.xml:S3:2048:8	B-AdverseReaction
feeling	LUMIZYME.xml:S3:2057:7	B-AdverseReaction
hot	LUMIZYME.xml:S3:2065:3	I-AdverseReaction
,	LUMIZYME.xml:S3:2068:1	O
erythema	LUMIZYME.xml:S3:2070:8	B-AdverseReaction
,	LUMIZYME.xml:S3:2078:1	O
pyrexia	LUMIZYME.xml:S3:2080:7	B-AdverseReaction
,	LUMIZYME.xml:S3:2087:1	O
pallor	LUMIZYME.xml:S3:2089:6	B-AdverseReaction
,	LUMIZYME.xml:S3:2095:1	O
peripheral	LUMIZYME.xml:S3:2097:10	B-AdverseReaction
coldness	LUMIZYME.xml:S3:2108:8	I-AdverseReaction
,	LUMIZYME.xml:S3:2116:1	O
restlessness	LUMIZYME.xml:S3:2118:12	B-AdverseReaction
,	LUMIZYME.xml:S3:2130:1	O
nervousness	LUMIZYME.xml:S3:2132:11	B-AdverseReaction
,	LUMIZYME.xml:S3:2143:1	O
headache	LUMIZYME.xml:S3:2145:8	B-AdverseReaction
,	LUMIZYME.xml:S3:2153:1	O
back	LUMIZYME.xml:S3:2155:4	B-AdverseReaction
pain	LUMIZYME.xml:S3:2160:4	I-AdverseReaction
,	LUMIZYME.xml:S3:2164:1	O
and	LUMIZYME.xml:S3:2166:3	O
paresthesia	LUMIZYME.xml:S3:2170:11	B-AdverseReaction
.	LUMIZYME.xml:S3:2181:1	O

Some	LUMIZYME.xml:S3:2183:4	O
of	LUMIZYME.xml:S3:2188:2	O
these	LUMIZYME.xml:S3:2191:5	O
reactions	LUMIZYME.xml:S3:2197:9	O
were	LUMIZYME.xml:S3:2207:4	O
IgE	LUMIZYME.xml:S3:2212:3	O
-	LUMIZYME.xml:S3:2215:1	O
mediated	LUMIZYME.xml:S3:2216:8	O
.	LUMIZYME.xml:S3:2224:1	O

If	LUMIZYME.xml:S3:2232:2	O
anaphylaxis	LUMIZYME.xml:S3:2235:11	O
or	LUMIZYME.xml:S3:2247:2	O
severe	LUMIZYME.xml:S3:2250:6	O
hypersensitivity	LUMIZYME.xml:S3:2257:16	O
reactions	LUMIZYME.xml:S3:2274:9	O
occur	LUMIZYME.xml:S3:2284:5	O
,	LUMIZYME.xml:S3:2289:1	O
immediately	LUMIZYME.xml:S3:2291:11	O
discontinue	LUMIZYME.xml:S3:2303:11	O
administration	LUMIZYME.xml:S3:2315:14	O
of	LUMIZYME.xml:S3:2330:2	O
alglucosidase	LUMIZYME.xml:S3:2333:13	O
alfa	LUMIZYME.xml:S3:2347:4	O
,	LUMIZYME.xml:S3:2351:1	O
and	LUMIZYME.xml:S3:2353:3	O
initiate	LUMIZYME.xml:S3:2357:8	O
appropriate	LUMIZYME.xml:S3:2366:11	O
medical	LUMIZYME.xml:S3:2378:7	O
treatment	LUMIZYME.xml:S3:2386:9	O
.	LUMIZYME.xml:S3:2395:1	O

Severe	LUMIZYME.xml:S3:2397:6	O
reactions	LUMIZYME.xml:S3:2404:9	O
are	LUMIZYME.xml:S3:2414:3	O
generally	LUMIZYME.xml:S3:2418:9	O
managed	LUMIZYME.xml:S3:2428:7	O
with	LUMIZYME.xml:S3:2436:4	O
infusion	LUMIZYME.xml:S3:2441:8	O
interruption	LUMIZYME.xml:S3:2450:12	O
,	LUMIZYME.xml:S3:2462:1	O
administration	LUMIZYME.xml:S3:2464:14	O
of	LUMIZYME.xml:S3:2479:2	O
antihistamines	LUMIZYME.xml:S3:2482:14	O
,	LUMIZYME.xml:S3:2496:1	O
corticosteroids	LUMIZYME.xml:S3:2498:15	O
,	LUMIZYME.xml:S3:2513:1	O
intravenous	LUMIZYME.xml:S3:2515:11	O
fluids	LUMIZYME.xml:S3:2527:6	O
,	LUMIZYME.xml:S3:2533:1	O
and	LUMIZYME.xml:S3:2535:3	O
or	LUMIZYME.xml:S3:2539:2	O
oxygen	LUMIZYME.xml:S3:2542:6	O
,	LUMIZYME.xml:S3:2548:1	O
when	LUMIZYME.xml:S3:2550:4	O
clinically	LUMIZYME.xml:S3:2555:10	O
indicated	LUMIZYME.xml:S3:2566:9	O
.	LUMIZYME.xml:S3:2575:1	O

In	LUMIZYME.xml:S3:2577:2	O
some	LUMIZYME.xml:S3:2580:4	O
cases	LUMIZYME.xml:S3:2585:5	O
of	LUMIZYME.xml:S3:2591:2	O
anaphylaxis	LUMIZYME.xml:S3:2594:11	O
,	LUMIZYME.xml:S3:2605:1	O
epinephrine	LUMIZYME.xml:S3:2607:11	O
has	LUMIZYME.xml:S3:2619:3	O
been	LUMIZYME.xml:S3:2623:4	O
administered	LUMIZYME.xml:S3:2628:12	O
.	LUMIZYME.xml:S3:2640:1	O

Appropriate	LUMIZYME.xml:S3:2642:11	O
medical	LUMIZYME.xml:S3:2654:7	O
support	LUMIZYME.xml:S3:2662:7	O
,	LUMIZYME.xml:S3:2669:1	O
including	LUMIZYME.xml:S3:2671:9	O
cardiopulmonary	LUMIZYME.xml:S3:2681:15	O
resuscitation	LUMIZYME.xml:S3:2697:13	O
equipment	LUMIZYME.xml:S3:2711:9	O
,	LUMIZYME.xml:S3:2720:1	O
should	LUMIZYME.xml:S3:2722:6	O
be	LUMIZYME.xml:S3:2729:2	O
readily	LUMIZYME.xml:S3:2732:7	O
available	LUMIZYME.xml:S3:2740:9	O
when	LUMIZYME.xml:S3:2750:4	O
alglucosidase	LUMIZYME.xml:S3:2755:13	O
alfa	LUMIZYME.xml:S3:2769:4	O
is	LUMIZYME.xml:S3:2774:2	O
administered	LUMIZYME.xml:S3:2777:12	O
.	LUMIZYME.xml:S3:2789:1	O

The	LUMIZYME.xml:S3:2795:3	O
risks	LUMIZYME.xml:S3:2799:5	O
and	LUMIZYME.xml:S3:2805:3	O
benefits	LUMIZYME.xml:S3:2809:8	O
of	LUMIZYME.xml:S3:2818:2	O
re	LUMIZYME.xml:S3:2821:2	O
-	LUMIZYME.xml:S3:2823:1	O
administering	LUMIZYME.xml:S3:2824:13	O
alglucosidase	LUMIZYME.xml:S3:2838:13	O
alfa	LUMIZYME.xml:S3:2852:4	O
following	LUMIZYME.xml:S3:2857:9	O
an	LUMIZYME.xml:S3:2867:2	O
anaphylactic	LUMIZYME.xml:S3:2870:12	O
or	LUMIZYME.xml:S3:2883:2	O
hypersensitivity	LUMIZYME.xml:S3:2886:16	O
reaction	LUMIZYME.xml:S3:2903:8	O
should	LUMIZYME.xml:S3:2912:6	O
be	LUMIZYME.xml:S3:2919:2	O
considered	LUMIZYME.xml:S3:2922:10	O
.	LUMIZYME.xml:S3:2932:1	O

Some	LUMIZYME.xml:S3:2934:4	O
patients	LUMIZYME.xml:S3:2939:8	O
have	LUMIZYME.xml:S3:2948:4	O
been	LUMIZYME.xml:S3:2953:4	O
rechallenged	LUMIZYME.xml:S3:2958:12	O
and	LUMIZYME.xml:S3:2971:3	O
have	LUMIZYME.xml:S3:2975:4	O
continued	LUMIZYME.xml:S3:2980:9	O
to	LUMIZYME.xml:S3:2990:2	O
receive	LUMIZYME.xml:S3:2993:7	O
alglucosidase	LUMIZYME.xml:S3:3001:13	O
alfa	LUMIZYME.xml:S3:3015:4	O
under	LUMIZYME.xml:S3:3020:5	O
close	LUMIZYME.xml:S3:3026:5	O
clinical	LUMIZYME.xml:S3:3032:8	O
supervision	LUMIZYME.xml:S3:3041:11	O
.	LUMIZYME.xml:S3:3052:1	O

Extreme	LUMIZYME.xml:S3:3054:7	O
care	LUMIZYME.xml:S3:3062:4	O
should	LUMIZYME.xml:S3:3067:6	O
be	LUMIZYME.xml:S3:3074:2	O
exercised	LUMIZYME.xml:S3:3077:9	O
,	LUMIZYME.xml:S3:3086:1	O
with	LUMIZYME.xml:S3:3088:4	O
appropriate	LUMIZYME.xml:S3:3093:11	O
resuscitation	LUMIZYME.xml:S3:3105:13	O
measures	LUMIZYME.xml:S3:3119:8	O
available	LUMIZYME.xml:S3:3128:9	O
,	LUMIZYME.xml:S3:3137:1	O
if	LUMIZYME.xml:S3:3139:2	O
the	LUMIZYME.xml:S3:3142:3	O
decision	LUMIZYME.xml:S3:3146:8	O
is	LUMIZYME.xml:S3:3155:2	O
made	LUMIZYME.xml:S3:3158:4	O
to	LUMIZYME.xml:S3:3163:2	O
re	LUMIZYME.xml:S3:3166:2	O
-	LUMIZYME.xml:S3:3168:1	O
administer	LUMIZYME.xml:S3:3169:10	O
the	LUMIZYME.xml:S3:3180:3	O
product	LUMIZYME.xml:S3:3184:7	O
[	LUMIZYME.xml:S3:3193:1	O
seeAdverse	LUMIZYME.xml:S3:3194:10	O
Reactions	LUMIZYME.xml:S3:3205:9	O
(	LUMIZYME.xml:S3:3215:1	O
6.2	LUMIZYME.xml:S3:3216:3	O
)]	LUMIZYME.xml:S3:3219:2	O
.	LUMIZYME.xml:S3:3223:1	O

5.2	LUMIZYME.xml:S3:3231:3	O
Immune	LUMIZYME.xml:S3:3235:6	O
-	LUMIZYME.xml:S3:3241:1	O
Mediated	LUMIZYME.xml:S3:3242:8	O
Reactions	LUMIZYME.xml:S3:3251:9	O

Immune	LUMIZYME.xml:S3:3264:6	B-AdverseReaction
-	LUMIZYME.xml:S3:3270:1	I-AdverseReaction
mediated	LUMIZYME.xml:S3:3271:8	I-AdverseReaction
cutaneous	LUMIZYME.xml:S3:3280:9	I-AdverseReaction
reactions	LUMIZYME.xml:S3:3290:9	I-AdverseReaction
have	LUMIZYME.xml:S3:3300:4	O
been	LUMIZYME.xml:S3:3305:4	O
reported	LUMIZYME.xml:S3:3310:8	O
with	LUMIZYME.xml:S3:3319:4	O
alglucosidase	LUMIZYME.xml:S3:3324:13	O
alfa	LUMIZYME.xml:S3:3338:4	O
including	LUMIZYME.xml:S3:3343:9	O
necrotizing	LUMIZYME.xml:S3:3353:11	B-AdverseReaction
skin	LUMIZYME.xml:S3:3365:4	I-AdverseReaction
lesions	LUMIZYME.xml:S3:3370:7	I-AdverseReaction
[	LUMIZYME.xml:S3:3379:1	O
seeAdverse	LUMIZYME.xml:S3:3380:10	O
Reactions	LUMIZYME.xml:S3:3391:9	O
(	LUMIZYME.xml:S3:3401:1	O
6.3	LUMIZYME.xml:S3:3402:3	O
)]	LUMIZYME.xml:S3:3405:2	O
.	LUMIZYME.xml:S3:3409:1	O

Systemic	LUMIZYME.xml:S3:3411:8	B-AdverseReaction
immune	LUMIZYME.xml:S3:3420:6	I-AdverseReaction
-	LUMIZYME.xml:S3:3426:1	I-AdverseReaction
mediated	LUMIZYME.xml:S3:3427:8	I-AdverseReaction
reactions	LUMIZYME.xml:S3:3436:9	I-AdverseReaction
,	LUMIZYME.xml:S3:3445:1	O
including	LUMIZYME.xml:S3:3447:9	O
possible	LUMIZYME.xml:S3:3457:8	B-Factor
type	LUMIZYME.xml:S3:3466:4	B-AdverseReaction
III	LUMIZYME.xml:S3:3471:3	I-AdverseReaction
immune	LUMIZYME.xml:S3:3475:6	I-AdverseReaction
-	LUMIZYME.xml:S3:3481:1	I-AdverseReaction
mediated	LUMIZYME.xml:S3:3482:8	I-AdverseReaction
reactions	LUMIZYME.xml:S3:3491:9	I-AdverseReaction
have	LUMIZYME.xml:S3:3501:4	O
been	LUMIZYME.xml:S3:3506:4	O
observed	LUMIZYME.xml:S3:3511:8	O
with	LUMIZYME.xml:S3:3520:4	O
alglucosidase	LUMIZYME.xml:S3:3525:13	O
alfa	LUMIZYME.xml:S3:3539:4	O
.	LUMIZYME.xml:S3:3543:1	O

These	LUMIZYME.xml:S3:3545:5	O
reactions	LUMIZYME.xml:S3:3551:9	O
occurred	LUMIZYME.xml:S3:3561:8	O
several	LUMIZYME.xml:S3:3570:7	O
weeks	LUMIZYME.xml:S3:3578:5	O
to	LUMIZYME.xml:S3:3584:2	O
3	LUMIZYME.xml:S3:3587:1	O
years	LUMIZYME.xml:S3:3589:5	O
after	LUMIZYME.xml:S3:3595:5	O
initiation	LUMIZYME.xml:S3:3601:10	O
of	LUMIZYME.xml:S3:3612:2	O
alglucosidase	LUMIZYME.xml:S3:3615:13	O
alfa	LUMIZYME.xml:S3:3629:4	O
infusions	LUMIZYME.xml:S3:3634:9	O
.	LUMIZYME.xml:S3:3643:1	O

Skin	LUMIZYME.xml:S3:3645:4	O
biopsy	LUMIZYME.xml:S3:3650:6	O
in	LUMIZYME.xml:S3:3657:2	O
one	LUMIZYME.xml:S3:3660:3	O
patient	LUMIZYME.xml:S3:3664:7	O
demonstrated	LUMIZYME.xml:S3:3672:12	O
deposition	LUMIZYME.xml:S3:3685:10	B-AdverseReaction
of	LUMIZYME.xml:S3:3696:2	I-AdverseReaction
anti	LUMIZYME.xml:S3:3699:4	I-AdverseReaction
-	LUMIZYME.xml:S3:3703:1	I-AdverseReaction
rhGAA	LUMIZYME.xml:S3:3704:5	I-AdverseReaction
antibodies	LUMIZYME.xml:S3:3710:10	I-AdverseReaction
in	LUMIZYME.xml:S3:3721:2	O
the	LUMIZYME.xml:S3:3724:3	O
lesion	LUMIZYME.xml:S3:3728:6	O
.	LUMIZYME.xml:S3:3734:1	O

Another	LUMIZYME.xml:S3:3736:7	O
patient	LUMIZYME.xml:S3:3744:7	O
developed	LUMIZYME.xml:S3:3752:9	O
severe	LUMIZYME.xml:S3:3762:6	B-Severity
inflammatory	LUMIZYME.xml:S3:3769:12	B-AdverseReaction
arthropathy	LUMIZYME.xml:S3:3782:11	I-AdverseReaction
in	LUMIZYME.xml:S3:3794:2	O
association	LUMIZYME.xml:S3:3797:11	O
with	LUMIZYME.xml:S3:3809:4	O
pyrexia	LUMIZYME.xml:S3:3814:7	B-AdverseReaction
and	LUMIZYME.xml:S3:3822:3	O
elevated	LUMIZYME.xml:S3:3826:8	B-AdverseReaction
erythrocyte	LUMIZYME.xml:S3:3835:11	I-AdverseReaction
sedimentation	LUMIZYME.xml:S3:3847:13	I-AdverseReaction
rate	LUMIZYME.xml:S3:3861:4	I-AdverseReaction
.	LUMIZYME.xml:S3:3865:1	O

Nephrotic	LUMIZYME.xml:S3:3867:9	B-AdverseReaction
syndrome	LUMIZYME.xml:S3:3877:8	I-AdverseReaction
secondary	LUMIZYME.xml:S3:3886:9	O
to	LUMIZYME.xml:S3:3896:2	O
membranous	LUMIZYME.xml:S3:3899:10	B-AdverseReaction
glomerulonephritis	LUMIZYME.xml:S3:3910:18	I-AdverseReaction
was	LUMIZYME.xml:S3:3929:3	O
observed	LUMIZYME.xml:S3:3933:8	O
in	LUMIZYME.xml:S3:3942:2	O
some	LUMIZYME.xml:S3:3945:4	O
Pompe	LUMIZYME.xml:S3:3950:5	O
disease	LUMIZYME.xml:S3:3956:7	O
patients	LUMIZYME.xml:S3:3964:8	O
treated	LUMIZYME.xml:S3:3973:7	O
with	LUMIZYME.xml:S3:3981:4	O
alglucosidase	LUMIZYME.xml:S3:3986:13	O
alfa	LUMIZYME.xml:S3:4000:4	O
who	LUMIZYME.xml:S3:4005:3	O
had	LUMIZYME.xml:S3:4009:3	O
persistently	LUMIZYME.xml:S3:4013:12	O
positive	LUMIZYME.xml:S3:4026:8	B-AdverseReaction
anti	LUMIZYME.xml:S3:4035:4	I-AdverseReaction
-	LUMIZYME.xml:S3:4039:1	I-AdverseReaction
rhGAA	LUMIZYME.xml:S3:4040:5	I-AdverseReaction
IgG	LUMIZYME.xml:S3:4046:3	I-AdverseReaction
antibody	LUMIZYME.xml:S3:4050:8	I-AdverseReaction
titers	LUMIZYME.xml:S3:4059:6	I-AdverseReaction
.	LUMIZYME.xml:S3:4065:1	O

In	LUMIZYME.xml:S3:4067:2	O
these	LUMIZYME.xml:S3:4070:5	O
patients	LUMIZYME.xml:S3:4076:8	O
,	LUMIZYME.xml:S3:4084:1	O
renal	LUMIZYME.xml:S3:4086:5	O
biopsy	LUMIZYME.xml:S3:4092:6	O
was	LUMIZYME.xml:S3:4099:3	O
consistent	LUMIZYME.xml:S3:4103:10	O
with	LUMIZYME.xml:S3:4114:4	O
immune	LUMIZYME.xml:S3:4119:6	B-AdverseReaction
complex	LUMIZYME.xml:S3:4126:7	I-AdverseReaction
deposition	LUMIZYME.xml:S3:4134:10	I-AdverseReaction
.	LUMIZYME.xml:S3:4144:1	O

Patients	LUMIZYME.xml:S3:4146:8	O
improved	LUMIZYME.xml:S3:4155:8	O
following	LUMIZYME.xml:S3:4164:9	O
treatment	LUMIZYME.xml:S3:4174:9	O
interruption	LUMIZYME.xml:S3:4184:12	O
.	LUMIZYME.xml:S3:4196:1	O

Therefore	LUMIZYME.xml:S3:4198:9	O
,	LUMIZYME.xml:S3:4207:1	O
patients	LUMIZYME.xml:S3:4209:8	O
receiving	LUMIZYME.xml:S3:4218:9	O
alglucosidase	LUMIZYME.xml:S3:4228:13	O
alfa	LUMIZYME.xml:S3:4242:4	O
should	LUMIZYME.xml:S3:4247:6	O
undergo	LUMIZYME.xml:S3:4254:7	O
periodic	LUMIZYME.xml:S3:4262:8	O
urinalysis	LUMIZYME.xml:S3:4271:10	O
[	LUMIZYME.xml:S3:4283:1	O
seeAdverse	LUMIZYME.xml:S3:4284:10	O
Reactions	LUMIZYME.xml:S3:4295:9	O
(	LUMIZYME.xml:S3:4305:1	O
6.3	LUMIZYME.xml:S3:4306:3	O
)]	LUMIZYME.xml:S3:4309:2	O
.	LUMIZYME.xml:S3:4313:1	O

Patients	LUMIZYME.xml:S3:4319:8	O
should	LUMIZYME.xml:S3:4328:6	O
be	LUMIZYME.xml:S3:4335:2	O
monitored	LUMIZYME.xml:S3:4338:9	O
for	LUMIZYME.xml:S3:4348:3	O
the	LUMIZYME.xml:S3:4352:3	O
development	LUMIZYME.xml:S3:4356:11	O
of	LUMIZYME.xml:S3:4368:2	O
systemic	LUMIZYME.xml:S3:4371:8	O
immune	LUMIZYME.xml:S3:4380:6	O
-	LUMIZYME.xml:S3:4386:1	O
mediated	LUMIZYME.xml:S3:4387:8	O
reactions	LUMIZYME.xml:S3:4396:9	O
involving	LUMIZYME.xml:S3:4406:9	O
skin	LUMIZYME.xml:S3:4416:4	O
and	LUMIZYME.xml:S3:4421:3	O
other	LUMIZYME.xml:S3:4425:5	O
organs	LUMIZYME.xml:S3:4431:6	O
while	LUMIZYME.xml:S3:4438:5	O
receiving	LUMIZYME.xml:S3:4444:9	O
alglucosidase	LUMIZYME.xml:S3:4454:13	O
alfa	LUMIZYME.xml:S3:4468:4	O
.	LUMIZYME.xml:S3:4472:1	O

If	LUMIZYME.xml:S3:4474:2	O
immune	LUMIZYME.xml:S3:4477:6	O
-	LUMIZYME.xml:S3:4483:1	O
mediated	LUMIZYME.xml:S3:4484:8	O
reactions	LUMIZYME.xml:S3:4493:9	O
occur	LUMIZYME.xml:S3:4503:5	O
,	LUMIZYME.xml:S3:4508:1	O
consider	LUMIZYME.xml:S3:4510:8	O
discontinuation	LUMIZYME.xml:S3:4519:15	O
of	LUMIZYME.xml:S3:4535:2	O
the	LUMIZYME.xml:S3:4538:3	O
administration	LUMIZYME.xml:S3:4542:14	O
of	LUMIZYME.xml:S3:4557:2	O
alglucosidase	LUMIZYME.xml:S3:4560:13	O
alfa	LUMIZYME.xml:S3:4574:4	O
,	LUMIZYME.xml:S3:4578:1	O
and	LUMIZYME.xml:S3:4580:3	O
initiate	LUMIZYME.xml:S3:4584:8	O
appropriate	LUMIZYME.xml:S3:4593:11	O
medical	LUMIZYME.xml:S3:4605:7	O
treatment	LUMIZYME.xml:S3:4613:9	O
.	LUMIZYME.xml:S3:4622:1	O

The	LUMIZYME.xml:S3:4624:3	O
risks	LUMIZYME.xml:S3:4628:5	O
and	LUMIZYME.xml:S3:4634:3	O
benefits	LUMIZYME.xml:S3:4638:8	O
of	LUMIZYME.xml:S3:4647:2	O
re	LUMIZYME.xml:S3:4650:2	O
-	LUMIZYME.xml:S3:4652:1	O
administering	LUMIZYME.xml:S3:4653:13	O
alglucosidase	LUMIZYME.xml:S3:4667:13	O
alfa	LUMIZYME.xml:S3:4681:4	O
following	LUMIZYME.xml:S3:4686:9	O
an	LUMIZYME.xml:S3:4696:2	O
immune	LUMIZYME.xml:S3:4699:6	O
-	LUMIZYME.xml:S3:4705:1	O
mediated	LUMIZYME.xml:S3:4706:8	O
reaction	LUMIZYME.xml:S3:4715:8	O
should	LUMIZYME.xml:S3:4724:6	O
be	LUMIZYME.xml:S3:4731:2	O
considered	LUMIZYME.xml:S3:4734:10	O
.	LUMIZYME.xml:S3:4744:1	O

Some	LUMIZYME.xml:S3:4746:4	O
patients	LUMIZYME.xml:S3:4751:8	O
have	LUMIZYME.xml:S3:4760:4	O
been	LUMIZYME.xml:S3:4765:4	O
able	LUMIZYME.xml:S3:4770:4	O
to	LUMIZYME.xml:S3:4775:2	O
be	LUMIZYME.xml:S3:4778:2	O
rechallenged	LUMIZYME.xml:S3:4781:12	O
and	LUMIZYME.xml:S3:4794:3	O
have	LUMIZYME.xml:S3:4798:4	O
continued	LUMIZYME.xml:S3:4803:9	O
to	LUMIZYME.xml:S3:4813:2	O
receive	LUMIZYME.xml:S3:4816:7	O
alglucosidase	LUMIZYME.xml:S3:4824:13	O
alfa	LUMIZYME.xml:S3:4838:4	O
under	LUMIZYME.xml:S3:4843:5	O
close	LUMIZYME.xml:S3:4849:5	O
clinical	LUMIZYME.xml:S3:4855:8	O
supervision	LUMIZYME.xml:S3:4864:11	O
.	LUMIZYME.xml:S3:4875:1	O

5.3	LUMIZYME.xml:S3:4883:3	O
Risk	LUMIZYME.xml:S3:4887:4	O
of	LUMIZYME.xml:S3:4892:2	O
Acute	LUMIZYME.xml:S3:4895:5	O
Cardiorespiratory	LUMIZYME.xml:S3:4901:17	O
Failure	LUMIZYME.xml:S3:4919:7	O

Patients	LUMIZYME.xml:S3:4930:8	O
with	LUMIZYME.xml:S3:4939:4	O
acute	LUMIZYME.xml:S3:4944:5	O
underlying	LUMIZYME.xml:S3:4950:10	O
respiratory	LUMIZYME.xml:S3:4961:11	O
illness	LUMIZYME.xml:S3:4973:7	O
or	LUMIZYME.xml:S3:4981:2	O
compromised	LUMIZYME.xml:S3:4984:11	O
cardiac	LUMIZYME.xml:S3:4996:7	O
and	LUMIZYME.xml:S3:5004:3	O
or	LUMIZYME.xml:S3:5008:2	O
respiratory	LUMIZYME.xml:S3:5011:11	O
function	LUMIZYME.xml:S3:5023:8	O
may	LUMIZYME.xml:S3:5032:3	B-Factor
be	LUMIZYME.xml:S3:5036:2	O
at	LUMIZYME.xml:S3:5039:2	O
risk	LUMIZYME.xml:S3:5042:4	O
of	LUMIZYME.xml:S3:5047:2	O
serious	LUMIZYME.xml:S3:5050:7	B-Severity
exacerbation	LUMIZYME.xml:S3:5058:12	B-AdverseReaction
of	LUMIZYME.xml:S3:5071:2	I-AdverseReaction
their	LUMIZYME.xml:S3:5074:5	O
cardiac	LUMIZYME.xml:S3:5080:7	I-AdverseReaction
or	LUMIZYME.xml:S3:5088:2	O
respiratory	LUMIZYME.xml:S3:5091:11	I-AdverseReaction
compromise	LUMIZYME.xml:S3:5103:10	I-AdverseReaction
during	LUMIZYME.xml:S3:5114:6	O
infusions	LUMIZYME.xml:S3:5121:9	O
.	LUMIZYME.xml:S3:5130:1	O

Appropriate	LUMIZYME.xml:S3:5132:11	O
medical	LUMIZYME.xml:S3:5144:7	O
support	LUMIZYME.xml:S3:5152:7	O
and	LUMIZYME.xml:S3:5160:3	O
monitoring	LUMIZYME.xml:S3:5164:10	O
measures	LUMIZYME.xml:S3:5175:8	O
should	LUMIZYME.xml:S3:5184:6	O
be	LUMIZYME.xml:S3:5191:2	O
readily	LUMIZYME.xml:S3:5194:7	O
available	LUMIZYME.xml:S3:5202:9	O
during	LUMIZYME.xml:S3:5212:6	O
alglucosidase	LUMIZYME.xml:S3:5219:13	O
alfa	LUMIZYME.xml:S3:5233:4	O
infusion	LUMIZYME.xml:S3:5238:8	O
,	LUMIZYME.xml:S3:5246:1	O
and	LUMIZYME.xml:S3:5248:3	O
some	LUMIZYME.xml:S3:5252:4	O
patients	LUMIZYME.xml:S3:5257:8	O
may	LUMIZYME.xml:S3:5266:3	O
require	LUMIZYME.xml:S3:5270:7	O
prolonged	LUMIZYME.xml:S3:5278:9	O
observation	LUMIZYME.xml:S3:5288:11	O
times	LUMIZYME.xml:S3:5300:5	O
that	LUMIZYME.xml:S3:5306:4	O
should	LUMIZYME.xml:S3:5311:6	O
be	LUMIZYME.xml:S3:5318:2	O
individualized	LUMIZYME.xml:S3:5321:14	O
based	LUMIZYME.xml:S3:5336:5	O
on	LUMIZYME.xml:S3:5342:2	O
the	LUMIZYME.xml:S3:5345:3	O
needs	LUMIZYME.xml:S3:5349:5	O
of	LUMIZYME.xml:S3:5355:2	O
the	LUMIZYME.xml:S3:5358:3	O
patient	LUMIZYME.xml:S3:5362:7	O
.	LUMIZYME.xml:S3:5369:1	O

Acute	LUMIZYME.xml:S3:5371:5	B-AdverseReaction
cardiorespiratory	LUMIZYME.xml:S3:5377:17	I-AdverseReaction
failure	LUMIZYME.xml:S3:5395:7	I-AdverseReaction
has	LUMIZYME.xml:S3:5403:3	O
been	LUMIZYME.xml:S3:5407:4	O
observed	LUMIZYME.xml:S3:5412:8	O
in	LUMIZYME.xml:S3:5421:2	O
infantile	LUMIZYME.xml:S3:5424:9	O
-	LUMIZYME.xml:S3:5433:1	O
onset	LUMIZYME.xml:S3:5434:5	O
Pompe	LUMIZYME.xml:S3:5440:5	O
disease	LUMIZYME.xml:S3:5446:7	O
patients	LUMIZYME.xml:S3:5454:8	O
with	LUMIZYME.xml:S3:5463:4	O
underlying	LUMIZYME.xml:S3:5468:10	O
cardiac	LUMIZYME.xml:S3:5479:7	O
hypertrophy	LUMIZYME.xml:S3:5487:11	O
,	LUMIZYME.xml:S3:5498:1	O
possibly	LUMIZYME.xml:S3:5500:8	O
associated	LUMIZYME.xml:S3:5509:10	O
with	LUMIZYME.xml:S3:5520:4	O
fluid	LUMIZYME.xml:S3:5525:5	B-AdverseReaction
overload	LUMIZYME.xml:S3:5531:8	I-AdverseReaction
with	LUMIZYME.xml:S3:5540:4	O
intravenous	LUMIZYME.xml:S3:5545:11	O
administration	LUMIZYME.xml:S3:5557:14	O
of	LUMIZYME.xml:S3:5572:2	O
alglucosidase	LUMIZYME.xml:S3:5575:13	O
alfa	LUMIZYME.xml:S3:5589:4	O
[	LUMIZYME.xml:S3:5595:1	O
seeDosage	LUMIZYME.xml:S3:5596:9	O
and	LUMIZYME.xml:S3:5606:3	O
Administration	LUMIZYME.xml:S3:5610:14	O
(	LUMIZYME.xml:S3:5625:1	O
2.2	LUMIZYME.xml:S3:5626:3	O
)]	LUMIZYME.xml:S3:5629:2	O
.	LUMIZYME.xml:S3:5633:1	O

5.4	LUMIZYME.xml:S3:5641:3	O
Risk	LUMIZYME.xml:S3:5645:4	O
of	LUMIZYME.xml:S3:5650:2	O
Cardiac	LUMIZYME.xml:S3:5653:7	O
Arrhythmia	LUMIZYME.xml:S3:5661:10	O
and	LUMIZYME.xml:S3:5672:3	O
Sudden	LUMIZYME.xml:S3:5676:6	O
Cardiac	LUMIZYME.xml:S3:5683:7	O
Death	LUMIZYME.xml:S3:5691:5	O
During	LUMIZYME.xml:S3:5697:6	O
General	LUMIZYME.xml:S3:5704:7	O
Anesthesia	LUMIZYME.xml:S3:5712:10	O
for	LUMIZYME.xml:S3:5723:3	O
Central	LUMIZYME.xml:S3:5727:7	O
Venous	LUMIZYME.xml:S3:5735:6	O
Catheter	LUMIZYME.xml:S3:5742:8	O
Placement	LUMIZYME.xml:S3:5751:9	O

Administration	LUMIZYME.xml:S3:5766:14	O
of	LUMIZYME.xml:S3:5781:2	O
general	LUMIZYME.xml:S3:5784:7	O
anesthesia	LUMIZYME.xml:S3:5792:10	O
can	LUMIZYME.xml:S3:5803:3	O
be	LUMIZYME.xml:S3:5807:2	O
complicated	LUMIZYME.xml:S3:5810:11	O
by	LUMIZYME.xml:S3:5822:2	O
the	LUMIZYME.xml:S3:5825:3	O
presence	LUMIZYME.xml:S3:5829:8	O
of	LUMIZYME.xml:S3:5838:2	O
severe	LUMIZYME.xml:S3:5841:6	O
cardiac	LUMIZYME.xml:S3:5848:7	O
and	LUMIZYME.xml:S3:5856:3	O
skeletal	LUMIZYME.xml:S3:5860:8	O
(	LUMIZYME.xml:S3:5869:1	O
including	LUMIZYME.xml:S3:5870:9	O
respiratory	LUMIZYME.xml:S3:5880:11	O
)	LUMIZYME.xml:S3:5891:1	O
muscle	LUMIZYME.xml:S3:5893:6	O
weakness	LUMIZYME.xml:S3:5900:8	O
.	LUMIZYME.xml:S3:5908:1	O

Therefore	LUMIZYME.xml:S3:5910:9	O
,	LUMIZYME.xml:S3:5919:1	O
caution	LUMIZYME.xml:S3:5921:7	O
should	LUMIZYME.xml:S3:5929:6	O
be	LUMIZYME.xml:S3:5936:2	O
used	LUMIZYME.xml:S3:5939:4	O
when	LUMIZYME.xml:S3:5944:4	O
administering	LUMIZYME.xml:S3:5949:13	O
general	LUMIZYME.xml:S3:5963:7	O
anesthesia	LUMIZYME.xml:S3:5971:10	O
.	LUMIZYME.xml:S3:5981:1	O

Ventricular	LUMIZYME.xml:S3:5983:11	B-AdverseReaction
arrhythmias	LUMIZYME.xml:S3:5995:11	I-AdverseReaction
and	LUMIZYME.xml:S3:6007:3	O
bradycardia	LUMIZYME.xml:S3:6011:11	B-AdverseReaction
,	LUMIZYME.xml:S3:6022:1	O
resulting	LUMIZYME.xml:S3:6024:9	O
in	LUMIZYME.xml:S3:6034:2	O
cardiac	LUMIZYME.xml:S3:6037:7	B-AdverseReaction
arrest	LUMIZYME.xml:S3:6045:6	I-AdverseReaction
or	LUMIZYME.xml:S3:6052:2	O
death	LUMIZYME.xml:S3:6055:5	B-AdverseReaction
,	LUMIZYME.xml:S3:6060:1	O
or	LUMIZYME.xml:S3:6062:2	O
requiring	LUMIZYME.xml:S3:6065:9	O
cardiac	LUMIZYME.xml:S3:6075:7	O
resuscitation	LUMIZYME.xml:S3:6083:13	O
or	LUMIZYME.xml:S3:6097:2	O
defibrillation	LUMIZYME.xml:S3:6100:14	O
have	LUMIZYME.xml:S3:6115:4	O
been	LUMIZYME.xml:S3:6120:4	O
observed	LUMIZYME.xml:S3:6125:8	O
in	LUMIZYME.xml:S3:6134:2	O
infantile	LUMIZYME.xml:S3:6137:9	O
-	LUMIZYME.xml:S3:6146:1	O
onset	LUMIZYME.xml:S3:6147:5	O
Pompe	LUMIZYME.xml:S3:6153:5	O
disease	LUMIZYME.xml:S3:6159:7	O
patients	LUMIZYME.xml:S3:6167:8	O
with	LUMIZYME.xml:S3:6176:4	O
cardiac	LUMIZYME.xml:S3:6181:7	O
hypertrophy	LUMIZYME.xml:S3:6189:11	O
during	LUMIZYME.xml:S3:6201:6	O
general	LUMIZYME.xml:S3:6208:7	O
anesthesia	LUMIZYME.xml:S3:6216:10	O
for	LUMIZYME.xml:S3:6227:3	O
central	LUMIZYME.xml:S3:6231:7	O
venous	LUMIZYME.xml:S3:6239:6	O
catheter	LUMIZYME.xml:S3:6246:8	O
placement	LUMIZYME.xml:S3:6255:9	O
.	LUMIZYME.xml:S3:6264:1	O

5.5	LUMIZYME.xml:S3:6274:3	O
Risk	LUMIZYME.xml:S3:6278:4	O
of	LUMIZYME.xml:S3:6283:2	O
Antibody	LUMIZYME.xml:S3:6286:8	O
Development	LUMIZYME.xml:S3:6295:11	O

As	LUMIZYME.xml:S3:6312:2	O
with	LUMIZYME.xml:S3:6315:4	O
all	LUMIZYME.xml:S3:6320:3	O
therapeutic	LUMIZYME.xml:S3:6324:11	O
proteins	LUMIZYME.xml:S3:6336:8	O
,	LUMIZYME.xml:S3:6344:1	O
there	LUMIZYME.xml:S3:6346:5	O
is	LUMIZYME.xml:S3:6352:2	O
potential	LUMIZYME.xml:S3:6355:9	O
for	LUMIZYME.xml:S3:6365:3	O
immunogenicity	LUMIZYME.xml:S3:6369:14	O
.	LUMIZYME.xml:S3:6383:1	O

In	LUMIZYME.xml:S3:6385:2	O
clinical	LUMIZYME.xml:S3:6388:8	O
studies	LUMIZYME.xml:S3:6397:7	O
,	LUMIZYME.xml:S3:6404:1	O
the	LUMIZYME.xml:S3:6406:3	O
majority	LUMIZYME.xml:S3:6410:8	O
of	LUMIZYME.xml:S3:6419:2	O
patients	LUMIZYME.xml:S3:6422:8	O
developed	LUMIZYME.xml:S3:6431:9	O
IgG	LUMIZYME.xml:S3:6441:3	O
antibodies	LUMIZYME.xml:S3:6445:10	O
to	LUMIZYME.xml:S3:6456:2	O
alglucosidase	LUMIZYME.xml:S3:6459:13	O
alfa	LUMIZYME.xml:S3:6473:4	O
,	LUMIZYME.xml:S3:6477:1	O
typically	LUMIZYME.xml:S3:6479:9	O
within	LUMIZYME.xml:S3:6489:6	O
3	LUMIZYME.xml:S3:6496:1	O
months	LUMIZYME.xml:S3:6498:6	O
of	LUMIZYME.xml:S3:6505:2	O
treatment	LUMIZYME.xml:S3:6508:9	O
.	LUMIZYME.xml:S3:6517:1	O

There	LUMIZYME.xml:S3:6519:5	O
is	LUMIZYME.xml:S3:6525:2	O
evidence	LUMIZYME.xml:S3:6528:8	O
to	LUMIZYME.xml:S3:6537:2	O
suggest	LUMIZYME.xml:S3:6540:7	O
that	LUMIZYME.xml:S3:6548:4	O
some	LUMIZYME.xml:S3:6553:4	O
patients	LUMIZYME.xml:S3:6558:8	O
who	LUMIZYME.xml:S3:6567:3	O
develop	LUMIZYME.xml:S3:6571:7	O
high	LUMIZYME.xml:S3:6579:4	O
and	LUMIZYME.xml:S3:6584:3	O
sustained	LUMIZYME.xml:S3:6588:9	O
IgG	LUMIZYME.xml:S3:6598:3	O
antibody	LUMIZYME.xml:S3:6602:8	O
titers	LUMIZYME.xml:S3:6611:6	O
may	LUMIZYME.xml:S3:6618:3	B-Factor
experience	LUMIZYME.xml:S3:6622:10	O
reduced	LUMIZYME.xml:S3:6633:7	B-AdverseReaction
clinical	LUMIZYME.xml:S3:6641:8	I-AdverseReaction
efficacy	LUMIZYME.xml:S3:6650:8	I-AdverseReaction
to	LUMIZYME.xml:S3:6659:2	O
alglucosidase	LUMIZYME.xml:S3:6662:13	O
alfa	LUMIZYME.xml:S3:6676:4	O
treatment	LUMIZYME.xml:S3:6681:9	O
,	LUMIZYME.xml:S3:6690:1	O
such	LUMIZYME.xml:S3:6692:4	O
as	LUMIZYME.xml:S3:6697:2	O
loss	LUMIZYME.xml:S3:6700:4	B-AdverseReaction
of	LUMIZYME.xml:S3:6705:2	I-AdverseReaction
motor	LUMIZYME.xml:S3:6708:5	I-AdverseReaction
function	LUMIZYME.xml:S3:6714:8	I-AdverseReaction
,	LUMIZYME.xml:S3:6722:1	O
ventilator	LUMIZYME.xml:S3:6724:10	O
dependence	LUMIZYME.xml:S3:6735:10	O
,	LUMIZYME.xml:S3:6745:1	O
or	LUMIZYME.xml:S3:6747:2	O
death	LUMIZYME.xml:S3:6750:5	B-AdverseReaction
.	LUMIZYME.xml:S3:6755:1	O

The	LUMIZYME.xml:S3:6757:3	O
effect	LUMIZYME.xml:S3:6761:6	O
of	LUMIZYME.xml:S3:6768:2	O
antibody	LUMIZYME.xml:S3:6771:8	O
development	LUMIZYME.xml:S3:6780:11	O
on	LUMIZYME.xml:S3:6792:2	O
the	LUMIZYME.xml:S3:6795:3	O
long	LUMIZYME.xml:S3:6799:4	O
term	LUMIZYME.xml:S3:6804:4	O
efficacy	LUMIZYME.xml:S3:6809:8	O
of	LUMIZYME.xml:S3:6818:2	O
alglucosidase	LUMIZYME.xml:S3:6821:13	O
alfa	LUMIZYME.xml:S3:6835:4	O
is	LUMIZYME.xml:S3:6840:2	O
not	LUMIZYME.xml:S3:6843:3	O
fully	LUMIZYME.xml:S3:6847:5	O
understood	LUMIZYME.xml:S3:6853:10	O
.	LUMIZYME.xml:S3:6863:1	O

Patients	LUMIZYME.xml:S3:6873:8	O
should	LUMIZYME.xml:S3:6882:6	O
be	LUMIZYME.xml:S3:6889:2	O
monitored	LUMIZYME.xml:S3:6892:9	O
for	LUMIZYME.xml:S3:6902:3	O
IgG	LUMIZYME.xml:S3:6906:3	O
antibody	LUMIZYME.xml:S3:6910:8	O
formation	LUMIZYME.xml:S3:6919:9	O
every	LUMIZYME.xml:S3:6929:5	O
3	LUMIZYME.xml:S3:6935:1	O
months	LUMIZYME.xml:S3:6937:6	O
for	LUMIZYME.xml:S3:6944:3	O
2	LUMIZYME.xml:S3:6948:1	O
years	LUMIZYME.xml:S3:6950:5	O
and	LUMIZYME.xml:S3:6956:3	O
then	LUMIZYME.xml:S3:6960:4	O
annually	LUMIZYME.xml:S3:6965:8	O
thereafter	LUMIZYME.xml:S3:6974:10	O
.	LUMIZYME.xml:S3:6984:1	O

Testing	LUMIZYME.xml:S3:6986:7	O
for	LUMIZYME.xml:S3:6994:3	O
IgG	LUMIZYME.xml:S3:6998:3	O
titers	LUMIZYME.xml:S3:7002:6	O
may	LUMIZYME.xml:S3:7009:3	O
also	LUMIZYME.xml:S3:7013:4	O
be	LUMIZYME.xml:S3:7018:2	O
considered	LUMIZYME.xml:S3:7021:10	O
if	LUMIZYME.xml:S3:7032:2	O
patients	LUMIZYME.xml:S3:7035:8	O
develop	LUMIZYME.xml:S3:7044:7	O
hypersensitivity	LUMIZYME.xml:S3:7052:16	O
reactions	LUMIZYME.xml:S3:7069:9	O
,	LUMIZYME.xml:S3:7078:1	O
other	LUMIZYME.xml:S3:7080:5	O
immune	LUMIZYME.xml:S3:7086:6	O
-	LUMIZYME.xml:S3:7092:1	O
mediated	LUMIZYME.xml:S3:7093:8	O
reactions	LUMIZYME.xml:S3:7102:9	O
,	LUMIZYME.xml:S3:7111:1	O
or	LUMIZYME.xml:S3:7113:2	O
lose	LUMIZYME.xml:S3:7116:4	O
clinical	LUMIZYME.xml:S3:7121:8	O
response	LUMIZYME.xml:S3:7130:8	O
.	LUMIZYME.xml:S3:7138:1	O

Patients	LUMIZYME.xml:S3:7140:8	O
who	LUMIZYME.xml:S3:7149:3	O
experience	LUMIZYME.xml:S3:7153:10	O
reduced	LUMIZYME.xml:S3:7164:7	O
clinical	LUMIZYME.xml:S3:7172:8	O
response	LUMIZYME.xml:S3:7181:8	O
may	LUMIZYME.xml:S3:7190:3	O
also	LUMIZYME.xml:S3:7194:4	O
be	LUMIZYME.xml:S3:7199:2	O
tested	LUMIZYME.xml:S3:7202:6	O
for	LUMIZYME.xml:S3:7209:3	O
inhibitory	LUMIZYME.xml:S3:7213:10	O
antibody	LUMIZYME.xml:S3:7224:8	O
activity	LUMIZYME.xml:S3:7233:8	O
.	LUMIZYME.xml:S3:7241:1	O

Patients	LUMIZYME.xml:S3:7243:8	O
who	LUMIZYME.xml:S3:7252:3	O
experience	LUMIZYME.xml:S3:7256:10	O
anaphylactic	LUMIZYME.xml:S3:7267:12	O
or	LUMIZYME.xml:S3:7280:2	O
hypersensitivity	LUMIZYME.xml:S3:7283:16	O
reactions	LUMIZYME.xml:S3:7300:9	O
may	LUMIZYME.xml:S3:7310:3	O
also	LUMIZYME.xml:S3:7314:4	O
be	LUMIZYME.xml:S3:7319:2	O
tested	LUMIZYME.xml:S3:7322:6	O
for	LUMIZYME.xml:S3:7329:3	O
IgE	LUMIZYME.xml:S3:7333:3	O
antibodies	LUMIZYME.xml:S3:7337:10	O
to	LUMIZYME.xml:S3:7348:2	O
alglucosidase	LUMIZYME.xml:S3:7351:13	O
alfa	LUMIZYME.xml:S3:7365:4	O
and	LUMIZYME.xml:S3:7370:3	O
other	LUMIZYME.xml:S3:7374:5	O
mediators	LUMIZYME.xml:S3:7380:9	O
of	LUMIZYME.xml:S3:7390:2	O
anaphylaxis	LUMIZYME.xml:S3:7393:11	O
[	LUMIZYME.xml:S3:7406:1	O
seeAdverse	LUMIZYME.xml:S3:7407:10	O
Reactions	LUMIZYME.xml:S3:7418:9	O
(	LUMIZYME.xml:S3:7428:1	O
6.2	LUMIZYME.xml:S3:7429:3	O
)]	LUMIZYME.xml:S3:7432:2	O
.	LUMIZYME.xml:S3:7436:1	O

There	LUMIZYME.xml:S3:7444:5	O
are	LUMIZYME.xml:S3:7450:3	O
currently	LUMIZYME.xml:S3:7454:9	O
no	LUMIZYME.xml:S3:7464:2	O
marketed	LUMIZYME.xml:S3:7467:8	O
tests	LUMIZYME.xml:S3:7476:5	O
for	LUMIZYME.xml:S3:7482:3	O
antibodies	LUMIZYME.xml:S3:7486:10	O
against	LUMIZYME.xml:S3:7497:7	O
alglucosidase	LUMIZYME.xml:S3:7505:13	O
alfa	LUMIZYME.xml:S3:7519:4	O
;	LUMIZYME.xml:S3:7523:1	O
however	LUMIZYME.xml:S3:7525:7	O
,	LUMIZYME.xml:S3:7532:1	O
a	LUMIZYME.xml:S3:7534:1	O
testing	LUMIZYME.xml:S3:7536:7	O
service	LUMIZYME.xml:S3:7544:7	O
is	LUMIZYME.xml:S3:7552:2	O
provided	LUMIZYME.xml:S3:7555:8	O
by	LUMIZYME.xml:S3:7564:2	O
Genzyme	LUMIZYME.xml:S3:7567:7	O
.	LUMIZYME.xml:S3:7574:1	O

Contact	LUMIZYME.xml:S3:7576:7	O
your	LUMIZYME.xml:S3:7584:4	O
local	LUMIZYME.xml:S3:7589:5	O
Genzyme	LUMIZYME.xml:S3:7595:7	O
representative	LUMIZYME.xml:S3:7603:14	O
or	LUMIZYME.xml:S3:7618:2	O
Genzyme	LUMIZYME.xml:S3:7621:7	O
Corporation	LUMIZYME.xml:S3:7629:11	O
at	LUMIZYME.xml:S3:7641:2	O
1	LUMIZYME.xml:S3:7644:1	O
-	LUMIZYME.xml:S3:7645:1	O
800	LUMIZYME.xml:S3:7646:3	O
-	LUMIZYME.xml:S3:7649:1	O
745	LUMIZYME.xml:S3:7650:3	O
-	LUMIZYME.xml:S3:7653:1	O
4447	LUMIZYME.xml:S3:7654:4	O
for	LUMIZYME.xml:S3:7659:3	O
information	LUMIZYME.xml:S3:7663:11	O
on	LUMIZYME.xml:S3:7675:2	O
testing	LUMIZYME.xml:S3:7678:7	O
and	LUMIZYME.xml:S3:7686:3	O
to	LUMIZYME.xml:S3:7690:2	O
obtain	LUMIZYME.xml:S3:7693:6	O
a	LUMIZYME.xml:S3:7700:1	O
sample	LUMIZYME.xml:S3:7702:6	O
collection	LUMIZYME.xml:S3:7709:10	O
box	LUMIZYME.xml:S3:7720:3	O
.	LUMIZYME.xml:S3:7723:1	O
